Compounds that could be used for HIV therapy
By developing dimeric SMAC mimetics that activate the non-classical NF-κB pathway, the problem that existing HIV treatments cannot completely eliminate viral reservoirs and drug resistance is solved, and HIV RNA induction and induction in resting CD4+ T cells is achieved. The reversal of latent infection significantly reduced viral load and intermittent plasma viremia.
Patent Information
- Application Number
- CN201980090907.2
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Priority Date
- 2018-11-30
- Filing Date
- 2019-11-28
- Publication Date
- 2024-11-08
- Estimated Expiration
- 2039-11-28
AI Technical Summary
Existing HIV treatments such as HAART therapy, although they can inhibit viral replication, cannot completely eliminate viral reservoirs, leading to drug resistance and related inflammation problems, and SMAC mimics have efficiency and tolerance problems in reversing latent HIV cells. .
A class of dimerized SMAC mimics was developed that, by activating the non-classical NF-κB pathway, was able to induce HIV RNA expression in resting CD4+ T cells and significantly reverse latent HIV infection in animal models, with less off-target toxicity and Tolerability.
This dimer SMAC mimic can effectively reverse latent HIV infection, significantly reduce viral load, reduce intermittent plasma viremia, and is clinically measurable, suitable for further development as latent HIV reversal and elimination therapies.
Smart Images

Figure 758236 
Figure FDA0004903165250000011 
Figure FDA0004903165250000012
Abstract
Description
[0001] CROSS-REFERENCE TO RELATED APPLICATIONS
[0002] This application claims priority to U.S. Provisional Serial No. 62 / 773,563, filed on November 30, 2018, the disclosure of which is incorporated herein by reference in its entirety. Field of the Invention
[0003] The present invention relates to compounds, pharmaceutical compositions and methods of use thereof related to individuals infected with HIV, HBV or cancer.
[0004] Sequence Listing
[0005] This application contains the sequences listed in an electronic sequence listing entitled PR66692_Seq_List, which is 2 KB in size and was created using Patent-In 3.5 on November 12, 2010, the contents and sequences of which are hereby incorporated by reference. Background of the Invention
[0007] Human immunodeficiency virus type 1 (HIV-1) infection causes acquired immunodeficiency disease (AIDS). The number of HIV cases continues to grow, and it is currently estimated that more than 35 million individuals worldwide are infected with HIV, such as .
[0008] Currently, long-term suppression of viral replication with antiretroviral drugs is the only option for treating HIV-1 infection. In fact, the U.S. Food and Drug Administration has approved more than 25 drugs from six different inhibitor classes, which have been shown to significantly improve patient survival and quality of life. However, due to many problems, additional therapies are still considered necessary, including but not limited to undesirable drug-drug interactions; drug-food interactions; non-compliance with treatment; drug resistance due to mutations in enzyme targets; and inflammation associated with immune damage caused by HIV infection.
[0009] At present, almost all HIV-positive patients are treated with a combination of antiretroviral drugs called highly active antiretroviral therapy ("HAART"). However, HAART therapy is usually complicated because a combination of different drugs must be often applied to the patient every day to avoid the rapid emergence of drug-resistant HIV-1 variants. Although HAART has a positive impact on patient survival, drug resistance still occurs, and compared with uninfected people, survival and quality of life are not normalized [Lohse Ann Intern Med 2007 146; 87-95]. In fact, in HIV-infected subjects suppressed by HAART, the incidence of several non-AIDS morbidity and mortality, such as cardiovascular disease, frailty and neurocognitive impairment increases [Deeks Annu Rev Med 2011; 62: 141-155]. This increased incidence of non-AIDS morbidity / mortality occurs in the context of, and may be caused by, elevated systemic inflammation associated with immune damage caused by HIV infection and residual HIV infection [Hunt J Infect Dis 2014] [Byakagwa J Infect Dis 2014] [Tenorio J Infect Dis 2014].
[0010] Modern antiretroviral therapy (ART) can effectively suppress HIV replication and improve health outcomes for HIV-infected individuals, but it is believed that it cannot completely eliminate the HIV viral reservoir in individuals. The HIV genome can remain latent in most immune cells of infected individuals and can reactivate at any time, so that viral replication usually resumes within a few weeks after ART is interrupted. In a few individuals, the size of the viral reservoir is significantly reduced, and the rebound of viral replication is delayed after ART is stopped [Henrich TJ J Infect Dis 2013] [Henrich TJ Ann Intern Med 2014]. In one case, the viral reservoir was eliminated during leukemia treatment, and no viral rebound was observed during several years of follow-up [HutterG N Engl J Med 2009]. These examples raise the concept that reducing or eliminating the viral reservoir is possible and can lead to viral remission or cure. Therefore, methods for eliminating the viral reservoir by direct molecular means have been studied, including excision of the viral genome with the CRISPR / Cas9 system, or inducing reactivation of the latent reservoir during ART to eliminate latent cells. It is believed that reversal of latency is required to render latently infected cells vulnerable to clearance.
[0011] SMACm (second mitochondria-derived activator of caspases) mimetics are a class of compounds that have recently entered clinical trials as potential cancer treatments. These drugs deplete and / or inhibit cellular inhibitors of apoptosis proteins (cIAPs), which function as anti-apoptotic proteins, thereby promoting cell death in cancer cells. Antagonism and / or depletion of cIAPs also leads to activation of the non-canonical NF-κB signaling pathway, which can induce HIV expression and enable the elimination of HIV-infected cells. Furthermore, SMAC mimetics can selectively promote cell death in cells infected with HIV [Campbell Cell Host Microbe 2018] or HBV [Ebert Proc Nat Acad Sci 2013] by antagonizing anti-apoptotic proteins.
[0012] Recently, targeting the noncanonical NF-κB (ncNF-κB) pathway to reverse latency in cell line models has been reported. The ncNF-κB pathway is typically activated by ligation of a subset of TNF receptor family members. In the steady state, a multimolecular complex with ubiquitin ligase activity, consisting of TNF receptor-associated factor 2 (TRAF2), TRAF3, and cellular inhibitor of apoptosis protein-1 (cIAP1), binds to the cytoplasmic portion of unligated receptors and constitutively ubiquitinates and degrades NF-κB-inducing kinase (NIK). Following receptor ligation, cIAP1 ubiquitinates TRAF3 and autoubiquitinates, leading to proteasomal degradation of TRAF3 and cIAP1, thereby uninhibiting NIK accumulation. NIK is constitutively active and, upon accumulation, phosphorylates the inhibitor of κB kinase-α (IKKα) homodimer. Activated IKKα / IKKα homodimers then phosphorylate the inactive p100 form of NFκB2, leading to ubiquitination by the Skp1-Cul1-F-box ubiquitin ligase (SCFβTrCP) and proteasomal cleavage of p100, releasing the active p52 subunit. p52 binds to RelB, and this heterodimer translocates into the nucleus to drive transcription from the κB promoter element. In addition to receptor ligation, ncNF-κB can be activated through signaling intermediates in the apoptotic cascade. Cleavage of the second mitochondrial activator of caspases (SMAC) from the mitochondrial membrane exposes the N-terminal motif Ala-Val-Pro-Ile, which specifically binds to the baculoviral intermediate repeat (BIR) domain of IAP proteins. This BIR binding in cIAP1 / 2 activates the ubiquitin ligase activity of the TRAF2:TRAF3:cIAP complex, thereby inducing autoubiquitination and degradation of cIAP1 / 2, NIK accumulation, and activation of the ncNF-κB pathway. Binding of SMAC to the BIR domains of XIAP and ML-IAP antagonizes the caspase-inhibitory activity of these molecules (often overexpressed in tumor cells), leading to enhanced apoptosis. Consequently, the Ala-Val-Pro-Ile motif of SMAC has become a subject of significant interest in oncology, leading to the discovery of a class of peptide mimetics with SMAC-like activity, termed SMAC mimetics (SMACm). SMACm potently activates the ncNF-κB pathway and does not induce apoptosis in non-tumor cells, making it of interest for reversing HIV latency. See, e.g., Richard Dunham et al., The SMAC Mimetic AZD5582 is a Potent HIV Latency Reversing Agent, bioRxiv, May 2, 2018; doi: http: / / dx.doi.org / 10.1101 / 312447 .
[0013] US Patent No. 7,960,372 relates to divalent diazobicyclic SMAC mimetics that inhibit IAP activity. SUMMARY OF THE INVENTION
[0015] In one aspect, the present invention provides a compound having the structure of formula (I):
[0016]
[0017] or a pharmaceutically acceptable salt or stereoisomer thereof, wherein:
[0018] R, R', R'' and R''' are independently selected from H and CH3;
[0019] X1 and X2 are independently selected from O and S; and
[0020] L is a linker selected from the group consisting of:
[0021]
[0022]
[0023]
[0024] in:
[0025] Ar1, Ar2, Ar3, Ar4, Ar5, Ar6, Ar7, Ar8, Ar9, Ar 10 、Ar 11 、Ar 12 、Ar 13 、Ar 14 、Ar 15 、Ar 16 、Ar 17 、Ar 18 、Ar 19 、Ar 21 、Ar 22 、Ar 23 、Ar 24 、Ar 25 and Ar 26 Each independently selected from (C6-C 14 ) aryl;
[0026] Alk, Alk2 and Alk3 are each independently selected from:
[0027] ;
[0028] R1 is a C3-C6 cycloalkyl or a C1-C6 heterocycle;
[0029] R2 is selected from -(CH2) a -、-(CH2)b -O--(CH2) c -、-(CH2) d -(C6-C 14 )aryl-(CH2) e - and -(CH2) f -(C1-C6)heteroaryl-(CH2) g -;
[0030] R3 is selected from -(CH2) h -、-(CH2) i -O--(CH2) j -、-(CH2) k -(C6-C 14 )aryl-(CH2) l - and -(CH2) m' -(C1-C6)heteroaryl-(CH2) m'' -;
[0031] R4 is a C3-C6 cyclic hydrocarbon group, (C6-C 14 )aryl or (CH2) n' -(C6-C 14 )aryl-(CH2) n'' 、(CH2) n''' -Alk-(CH2) n'''' , wherein n', n'', n''' and n'''' are independently selected from 1 to 8;
[0032] R5 is a C3-C6 cycloalkyl group;
[0033] R6 is selected from (CH2) z ,
[0034]
[0035] a, b, c, d, e, f, g, h, i, j, k, l, m, m', m", n, p, q, r, s, t, u, v, x, y and z are each independently selected from 1 to 12.
[0036] In another aspect, the present invention relates to compounds of formula (Ia):
[0037]
[0038] or a pharmaceutically acceptable salt or stereoisomer thereof, wherein:
[0039] R, R', R'' and R''' are independently selected from H and CH3;
[0040] X1 and X2 are independently selected from O and S; and
[0041] L is a linker selected from the group consisting of:
[0042]
[0043]
[0044] in:
[0045] Ar1, Ar2, Ar3, Ar4, Ar5, Ar6, Ar7, Ar8, Ar9, Ar 10 、Ar 11 、Ar 12 、Ar 13 、Ar 14 、Ar 15 、Ar 16 、Ar 17 、Ar 18 、Ar 19 、Ar 21 、Ar 22 、Ar 23 、Ar 24 、Ar 25 and Ar 26 Each independently selected from (C6-C 14 ) aryl;
[0046] Alk, Alk2 and Alk3 are each independently selected from:
[0047] ;
[0048] R1 is a C3-C6 cycloalkyl or a C1-C6 heterocycle;
[0049] R2 is selected from -(CH2) a -、-(CH2) b -O--(CH2) c -、-(CH2) d -(C6-C 14 )aryl-(CH2) e - and -(CH2) f -(C1-C6)heteroaryl-(CH2) g -;
[0050] R3 is selected from -(CH2) h -、-(CH2) i -O--(CH2) j -、-(CH2) k -(C6-C 14 )aryl-(CH2) l - and -(CH2) m'-(C1-C6)heteroaryl-(CH2) m'' -;
[0051] R4 is a C3-C6 cyclic hydrocarbon group, (C6-C 14 )aryl or (CH2) n' -(C6-C 14 )aryl-(CH2) n'' 、(CH2) n''' -Alk-(CH2) n'''' , wherein n', n'', n''' and n'''' are independently selected from 1 to 8;
[0052] R5 is a C3-C6 cycloalkyl group;
[0053] R6 is selected from (CH2) z ,
[0054]
[0055] a, b, c, d, e, f, g, h, i, j, k, l, m, m', m", n, p, q, r, s, t, u, v, x, y and z are each independently selected from 1 to 12.
[0056] In another aspect, the present invention relates to compounds of formula (Ib):
[0057]
[0058] or a pharmaceutically acceptable salt or stereoisomer thereof, wherein:
[0059] R, R', R'' and R''' are independently selected from H and CH3;
[0060] X1 and X2 are independently selected from O and S; and
[0061] L is a linker selected from the group consisting of:
[0062]
[0063]
[0064] in:
[0065] Ar1, Ar2, Ar3, Ar4, Ar5, Ar6, Ar7, Ar8, Ar9, Ar 10 、Ar 11 、Ar 12 、Ar 13 、Ar 14 、Ar 15 、Ar 16 、Ar 17 、Ar18 、Ar 19 、Ar 21 、Ar 22 、Ar 23 、Ar 24 、Ar 25 and Ar 26 Each independently selected from (C6-C 14 ) aryl;
[0066] Alk, Alk2 and Alk3 are each independently selected from:
[0067] ;
[0068] R1 is a C3-C6 cycloalkyl or a C1-C6 heterocycle;
[0069] R2 is selected from -(CH2) a -、-(CH2) b -O--(CH2) c -、-(CH2) d -(C6-C 14 )aryl-(CH2) e - and -(CH2) f -(C1-C6)heteroaryl-(CH2) g -;
[0070] R3 is selected from -(CH2) h -、-(CH2) i -O--(CH2) j -、-(CH2) k -(C6-C 14 )aryl-(CH2) l - and -(CH2) m' -(C1-C6)heteroaryl-(CH2) m'' -;
[0071] R4 is a C3-C6 cyclic hydrocarbon group, (C6-C 14 )aryl or (CH2) n' -(C6-C 14 )aryl-(CH2) n'' 、(CH2) n''' -Alk-(CH2) n'''' , wherein n', n'', n''' and n'''' are independently selected from 1 to 8;
[0072] R5 is a C3-C6 cycloalkyl group;
[0073] R6 is selected from (CH2) z ,
[0074]
[0075] a, b, c, d, e, f, g, h, i, j, k, l, m, m', m", n, p, q, r, s, t, u, v, x, y and z are each independently selected from 1 to 12.
[0076] In another aspect, the present invention relates to a compound represented by formula (II):
[0077]
[0078] in
[0079] R, R', R'' and R''' are independently selected from H and CH3;
[0080] X1 and X2 are independently selected from O and S; and
[0081] L' is a linker of the formula:
[0082]
[0083] in:
[0084] Ar 27 and Ar 28 Each independently selected from C6-C 14 Aryl,
[0085] R7 is selected from
[0086] , C6 aryl and -(CH2) 4-15 -;and
[0087] a' and b' are independently selected from 0 to 6.
[0088] In another aspect, the present invention relates to a compound represented by formula (III):
[0089]
[0090] in
[0091] R, R', R'' and R''' are independently selected from H and CH3;
[0092] X1 and X2 are independently selected from O and S; and
[0093] L'' is a linker of the formula:
[0094]
[0095] Among them, Ar 29 and Ar 30 Independently selected from C6-C10 aryl and R8 is selected from:
[0096] -, -(CH 2)6-15 -, ' - and -(CH 2)d' -(C6-C 10) aryl-(CH2) e' -; where d' and e' are independently selected and range from 1 to 6.
[0097] In another aspect, the present invention provides a pharmaceutical composition comprising a compound according to formula (I), (Ia), (Ib), (II), (III) or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable excipient.
[0098] In another aspect, the present invention provides a method for treating or curing an HIV infection in a subject, which comprises administering to the subject a compound according to formula (I), (Ia), (Ib), (II), (III) or a pharmaceutically acceptable salt thereof.
[0099] In another aspect, the present invention provides a method for depleting HIV-infected cells, which comprises administering to a subject a compound according to formula (I), (Ia), (Ib), (II), (III) or a pharmaceutically acceptable salt thereof.
[0100] In another aspect, the present invention provides a method for depleting HIV-infected cells, which comprises administering to a subject a compound according to formula (I), (Ia), (Ib), (II), (III) or a pharmaceutically acceptable salt thereof and one or more additional agents effective against HIV. In certain aspects, these agents effective against HIV are selected from antiretroviral agents, latency reversing agents, and agents for purge therapy.
[0101] These and other aspects are included in the present invention as described herein. Sequence Listing <110> GlaxoSmithKline Intellectual Property Development Limited The University of North Carolina at Chapel Hill ViiV Healthcare Company De La Rosa, Martha Tai, Vincent Tang, Jun Dunham, Richard Margolis, David <120> Compounds that could be used for HIV therapy <130> PR66692 <150> 62773563 <151> 2018-11-30 <160> 4 <170> PatentIn version 3.5 <210> 1 <211> twenty two <212> DNA <213> Synthetic primers <400> 1 atcaagcagc tatgcaaatg tt 22 <210> 2 <211> 30 <212> DNA <213> Synthetic primers <400> 2 ctgaagggta ctagtagttc ctgctatgtc 30 <210> 3 <211> 29 <212> DNA <213> Synthetic probes <400> 3 accatcaatg aggaagctgc agaatggga 29 <210> 4 <211> 152 <212> DNA <213> Synthetic standard control <400> 4 atcaagcagc catgcaaatg ttaaaagaga ccatcaatga ggaagctgca gaatgggata 60 gattgcatcc agtgcatgca gggcctattg caccaggcca gatgagagaa ccaaggggaa 120 gtgacatagc aggaactact agtacccttc ag 152 BRIEF DESCRIPTION OF THE DRAWINGS
[0103] Figure 1 is a graph of data comparing rodent pharmacokinetic (PK) data for several compounds of Formula I with SMACm AZD5582 PK data.
[0104] Details
[0105] The presently disclosed subject matter will now be described more fully hereinafter. However, those skilled in the art of the presently disclosed subject matter that benefit from the teachings presented in the foregoing description will expect many modifications and other embodiments of the presently disclosed subject matter set forth herein. Therefore, it should be understood that the presently disclosed subject matter is not limited to the disclosed specific embodiments, and modifications and other embodiments are intended to be included within the scope of the appended claims. In other words, the subject matter described herein encompasses all substitutions, modifications, and equivalents. In the event that one or more of the incorporated documents, patents, and similar materials is different from the present application or contradicts the present application, including but not limited to defined terms, term usage, described technology, etc., the present application shall prevail. Unless otherwise defined, all technical and scientific terms used herein have the same meaning as those of ordinary skill in the art are generally understood. All publications, patent applications, patents, and other references mentioned herein are incorporated by reference in their entirety.
[0106] Apoptosis, a form of programmed cell death, plays an important role in maintaining homeostasis and regulating cell number in higher organisms. Abnormal apoptosis is implicated in many diseases, including autoimmune disorders, degenerative diseases of the central nervous system, cancer, and viral infections such as HIV. The inhibitor of apoptosis protein (IAP) family plays a key role in inhibiting pro-apoptotic signaling in mammalian cells. SMACm mimics a key tetrapeptide sequence from a second mitochondrial-derived caspase activator and has been shown to disrupt the binding of IAPs to their functional partners and restore the apoptotic response to pro-apoptotic stimuli in cells. Since the early 2000s, significant efforts have focused on designing and preparing SMAC mimetics that act as IAP antagonists, particularly in promoting cell death in tumor cells and, more recently, in reversing HIV latency. These studies have explored activation of the non-canonical NF-κB pathway (ncNF-κB) as a potential method for SMAC mimetics to selectively deplete latent HIV cells. An example of an early SMAC mimetic is monomeric SBI-0637142, prepared by researchers at the Sanford-Burnham Institute for Medical Research. In HIV depletion experiments, SBI-0637142 was found to be effective in cell line experiments, but did not show activity in primary cells during p100-p52 conversion or HIV caRNA induction. Many studies have also been directed to developing bivalent mimetics, which are covalently linked monomeric SMAC mimetics. AstraZeneca's AZD5582 and Medivir's Birinapant TL32711 are examples of dimeric SMAC mimetics. In HIV latent reversal studies, Birinapant TL32711 was ineffective in Jurkat, p100-p52 conversion or HIV caRNA induction. On the contrary, by Jurkat assays, p100-p52 conversion studies, and HIV and caRNA induction, AZD5582 showed that cell-related HIV RNA expression increased in resting CD4+ T cells (Sampey et al., bioRxiv 312447). However, AZD5582 may also exhibit tolerance issues.
[0107]
[0108] Disclosed herein are dimeric SMACm compounds that are believed to be sufficiently effective and potent as a single agent to activate ncNF-κB and reverse HIV latency in primary, unmodified human cells, and may have less off-target toxicity than other dimeric SMACm compounds, such as AZD5582, making them suitable for further development. In particular, the dimeric SMACm compounds of the present invention are able to induce HIV RNA expression in unstimulated, resting primary CD4+ T cells from HIV-infected donors, whose viremia is completely suppressed by standard therapy. Other SMACm compounds, particularly monomeric or dimeric compounds with unoptimized linkers, are believed to lack this effect in these cells, which serve as the primary latent reservoir for persistent infection. Furthermore, the dimeric SMACm compounds of the present invention are able to clinically measurably reverse latency in two animal models (SIV-infected, antiretroviral-suppressed macaques and HIV-infected ART-suppressed humanized mice), as demonstrated by intermittent plasma viremia that persists despite successful antiviral therapy.
[0109] It should be understood that the terminology used herein is for the purpose of describing particular embodiments only and is not intended to limit the scope of the present invention.In this specification and the claims that follow, reference will be made to a number of terms that are defined to have the following meanings.
[0110] As used herein, unless otherwise indicated, "alkyl" refers to a monovalent saturated aliphatic hydrocarbon group having 1 to 14 carbon atoms, and in some embodiments, 1 to 8 carbon atoms or 1 to 6 carbon atoms. "(Cx-Cy)alkyl" refers to an alkyl group having x to y carbon atoms. For example, the term "alkyl" includes straight and branched chain hydrocarbon groups, such as methyl (CH3), ethyl (CH3CH2), n-propyl (CH3CH2CH2), isopropyl ((CH3)2CH), n-butyl (CH3CH2CH2CH2), isobutyl ((CH3)2CHCH2), sec-butyl ((CH3)(CH3CH2)CH), tert-butyl ((CH3)3C), n-pentyl (CH3CH2CH2CH2CH2), and neopentyl ((CH3)3CCH2). It should be noted that, for example, (C1-Cy)alkyl includes straight and branched chain hydrocarbon groups, such as methyl (CH3), ethyl (CH3CH2), n-propyl (CH3CH2CH2), isopropyl ((CH3)2CH), n-butyl (CH3CH2CH2CH2), isobutyl ((CH3)2CHCH2), sec-butyl ((CH3)(CH3CH2)CH), tert-butyl ((CH3)3C), n-pentyl (CH3CH2CH2CH2CH2), and neopentyl ((CH3)3CCH2). 12 )alkyl is also included within the scope of this group, for example, (C1-C6)alkyl.
[0111] "Alkylene" refers to a divalent saturated aliphatic hydrocarbon group having from 1 to 10 carbon atoms, and in some embodiments, from 1 to 6 carbon atoms. "(C u C v"(C1-C6)alkylene" refers to an alkylene group having u to v carbon atoms. Alkylene includes branched and straight chain hydrocarbon groups. For example, "(C1-C6)alkylene" is intended to include methylene, ethylene, propylene, 2-methylpropylene, dimethylethylene, pentylene, and the like. Thus, the term "propylene" can be exemplified by the following structure: Likewise, the term "dimethylbutylene" may be exemplified by any of the following three structures or more: , p or In addition, the term “(C 1- "C6) alkylene" is intended to include branched hydrocarbon groups such as cyclopropylmethylene, which can be exemplified by the following structure: .
[0112] "Alkynyl" or "alkyne" refers to a straight or branched monovalent hydrocarbon radical containing at least one triple bond. The term "alkynyl" is also intended to include those hydrocarbon radicals having one triple bond and one double bond. For example, (C2-C6)alkynyl is intended to include ethynyl, propynyl, and the like.
[0113] "Aryl" refers to an aromatic group having 6 to 14 carbon atoms and no ring heteroatoms and having a single ring (e.g., phenyl) or multiple fused (condensed) rings (e.g., naphthyl or anthracenyl). For polycyclic ring systems, including fused, bridged, and spirocyclic ring systems having aromatic and non-aromatic rings without ring heteroatoms, the term "aryl" or "Ar" applies when the point of attachment is on an aromatic carbon atom (e.g., 5,6,7,8-tetrahydronaphthalen-2-yl is an aryl group because its point of attachment is at the 2-position of the aromatic phenyl ring). In one embodiment, a preferred bicyclic aryl system can be represented by the following formula:
[0114] .
[0115] For clarity, "aryl" or "Ar" encompasses other points of attachment, for example, where the point of attachment is at a non-aromatic carbon atom.
[0116] "Cycloalkyl" refers to a saturated or partially saturated cyclic group having 3 to 14 carbon atoms and no ring heteroatoms and having monocyclic or polycyclic rings (including fused, bridged, and spirocyclic ring systems). For polycyclic ring systems having aromatic and non-aromatic rings without ring heteroatoms, the term "cycloalkyl" applies when the point of attachment is at a non-aromatic carbon atom (e.g., 5,6,7,8,-tetrahydronaphthalen-5-yl). The term "cycloalkyl" includes cycloalkenyl groups, such as cyclohexenyl. Examples of cycloalkyl groups include, for example, adamantyl, cyclopropyl, cyclobutyl, cyclohexyl, cyclopentyl, cyclooctyl, cyclopentenyl, and cyclohexenyl. Examples of cycloalkyl groups that include multiple bicyclic alkyl ring systems are bicyclohexyl, bicyclopentyl, bicyclooctyl, and the like. Two such bicyclic alkyl polycyclic structures are exemplified and named below:
[0117] Bicyclohexyl, and Biscyclohexyl.
[0118] “(C u- C v ) cycloalkyl" refers to a cycloalkyl group having u to v carbon atoms.
[0119] "Spirocyclic hydrocarbon group" refers to a 3- to 10-membered cyclic substituent formed by replacing two hydrogen atoms on a common carbon atom in a cyclic ring structure or in an alkylene group having 2 to 9 carbon atoms, as exemplified by the following structure, wherein the group shown therein connected to the bond marked with a wavy line is substituted with a spirocyclic hydrocarbon group:
[0120] .
[0121] "Fused cycloalkyl" refers to a 3- to 10-membered cyclic substituent formed by replacing two hydrogen atoms on different carbon atoms in a cycloalkyl ring structure, as exemplified by the following structure, wherein the cycloalkyl shown therein contains bonds marked with wavy lines to the carbon atom being substituted by the fused cycloalkyl:
[0122] .
[0123] "AUC" refers to the area under the plasma drug concentration (not the logarithm of concentration) versus time curve after administration.
[0124] “EC 50 ” refers to the concentration of drug that produces a half-maximal response. Sometimes, it is also converted to pEC 50 Scale (-logIC 50 ), where higher values indicate exponentially greater potency.
[0125] “IC 50 ” refers to the half-maximal inhibitory concentration of a drug. Sometimes, it is also converted to pIC 50 Scale (-log IC 50 ), where higher values indicate exponentially greater potency.
[0126] "Heteroaryl" refers to an aromatic group having, for example and unless otherwise specified, 1 to 14 carbon atoms (preferably 1 to 12 carbon atoms, more preferably 2 to 12 carbon atoms) and 1 to 6 heteroatoms selected from oxygen, nitrogen and sulfur (more preferably 1 to 3 heteroatoms) and including monocyclic (e.g., imidazolyl) and polycyclic systems (e.g., benzimidazol-2-yl and benzimidazol-6-yl). For polycyclic systems, including fused, bridged, and spirocyclic systems having aromatic and non-aromatic rings, the term "heteroaryl" applies if there is at least one ring heteroatom and the point of attachment is on an atom of the aromatic ring (e.g., 1,2,3,4-tetrahydroquinolin-6-yl and 5,6,7,8-tetrahydroquinolin-3-yl). In some embodiments, the nitrogen and / or sulfur ring atoms of the heteroaryl group are optionally oxidized to provide an N-oxide (N→O), sulfinyl, or sulfonyl moiety. The prefix indicating the number of carbon atoms (e.g., C x -C y ) refers to the total number of carbon atoms in the heteroaryl moiety excluding the number of heteroatoms. The group also includes all ranges between x and y, for example, C1-C 14 Including C2-C 14 , C2-C9, etc. More specifically, the term heteroaryl includes, but is not limited to, pyridyl, furyl, thienyl, thiazolyl, isothiazolyl, triazolyl, imidazolyl, imidazolinyl, isoxazolyl, pyrrolyl, pyrazolyl, pyridazinyl, pyrimidinyl, purinyl, phthalazyl, naphthylpyridyl, benzofuranyl, tetrahydrobenzofuranyl, isobenzofuranyl, benzothiazolyl, benzisothiazolyl, benzotriazolyl, indolyl, isoindolyl, indolizinyl, dihydroindole, indole, benzophenone ... In one embodiment, for example, a (C3-C9)heteroaryl spirocyclic fused system is present, more preferably, a (C4-C6)heteroaryl group.
[0127] "Heterocyclic" or "heterocycle" or "heterocycloalkyl" or "heterocyclyl" refers to a saturated or partially saturated cyclic group having, for example and unless otherwise specified, 1 to 14 carbon atoms (preferably 1 to 12 carbon atoms, more preferably 2 to 2 carbon atoms) and 1 to 6 heteroatoms (more preferably 1 to 3 heteroatoms) selected from nitrogen, sulfur, phosphorus or oxygen, and includes monocyclic and polycyclic ring systems (including fused, bridged and spirocyclic ring systems). For polycyclic ring systems having aromatic and / or non-aromatic rings, the terms "heterocyclic", "heterocycle", "heterocycloalkyl" or "heterocyclyl" apply when at least one ring heteroatom is present and the point of attachment is on an atom of the non-aromatic ring (e.g., 1,2,3,4-tetrahydroquinolin-3-yl, 5,6,7,8-tetrahydroquinolin-6-yl and decahydroquinolin-6-yl). In one embodiment, the nitrogen, phosphorus and / or sulfur atoms of the heterocyclic group are optionally oxidized to provide N-oxides, phosphine oxides, sulfinyl, sulfonyl moieties. More specifically, heterocyclic groups include, but are not limited to, tetrahydropyranyl, piperidinyl, piperazinyl, 3-pyrrolidinyl, 2-pyrrolidon-1-yl, morpholinyl, and pyrrolidinyl. Prefixes indicating the number of carbon atoms (e.g., C x -C y ) refers to the total number of carbon atoms in the heterocyclic moiety excluding the number of heteroatoms. The group also includes all ranges between x and y, for example, C1-C 12 Including C2-C 12 , C2-C9, etc. In one embodiment, for example, a (C3-C9) heterocyclic spiro-fused system is present, more preferably a (C4-C6) heterocyclic ring.
[0128] Examples of heterocycles and heteroaryl groups include, but are not limited to, azetidine, pyrrole, imidazole, pyrazole, pyridine, pyrazine, pyrimidine, pyridazine, pyridone, indolizine, isoindole, indole, indoline, indazole, purine, quinolizine, isoquinoline, quinoline, phthalazine, naphthylpyridine, quinoxaline, quinazoline, cinnoline, pteridine, carbazole, carboline, phenanthridine, acridine, phenanthroline, isothiazole, phenazine, isoxazole, phenoxazine, phenothiazine, imidazolidine, imidazoline, piperidine, piperazine, indoline, phthalimide, 1,2,3,4-tetrahydroisoquinoline, 4,5,6,7-tetrahydrobenzo[b]thiophene, thiazole, thiazolidine, thiophene, benzo[b]thiophene, morpholine, thiomorpholine (also known as thiomorpholine), piperidine, pyrrolidine, and tetrahydrofuranyl.
[0129] In addition to the above embodiments described herein, "fused heterocyclic" or "fused heterocycle" refers to a 3- to 9-membered cyclic substituent (more preferably 4- to 6-membered) formed by replacing two hydrogen atoms on different carbon atoms in a cycloalkyl ring structure, as exemplified by the following structures, wherein the cycloalkyl shown therein contains bonds, marked with wavy lines, to the carbon atom being substituted by the fused heterocyclic group:
[0130] .
[0131] The spiro ring system in formula (I), (Ia), (Ib), (II) or (III) (for example, but not limited to, R 2 and R 3 Embodiments of the invention include but are not limited to:
[0132] .
[0133] As used herein, "(a) compound," "(multiple) compounds," "(a) chemical entity," and "(multiple) chemical entities" refer to the compounds encompassed by the formulae disclosed herein, any subgenus of those formulae, and any form of the compounds within the formulae and subformulae, including racemates, stereoisomers, and tautomers of one or more compounds.
[0134] The term "heteroatom" refers to nitrogen, oxygen, or sulfur, including any oxidized form of nitrogen (e.g., N(O) {N + -O -}) and sulfur (e.g., S(O) and S(O)2), as well as the quaternized form of any basic nitrogen.
[0135] "Linker" ("L") refers to a substance (eg, a molecule) that joins two parts of a molecule.
[0136] "Polymorphism" refers to the presence of two or more distinct phenotypes within the same population of a species, where more than one form or morph occurs. To be classified as such, the morphs must simultaneously occupy the same habitat and belong to a promiscuous population (a population that mates randomly).
[0137] "Protein binding" refers to the binding of the drug to proteins in plasma, tissue membranes, red blood cells, and other blood components.
[0138] “Protein turnover” is determined by comparing the EC in the absence and presence of human serum. 50 value to determine the combined conversion.
[0139] "Racemate" refers to a mixture of enantiomers. In one embodiment of the present invention, the compounds of Formulas I, Ia, Ib, II, and III, or pharmaceutically acceptable salts thereof, are enantiomerically enriched in one enantiomer, wherein all chiral carbons are in one configuration. Generally, reference to an enantiomerically enriched compound or salt is intended to indicate that the designated enantiomer will comprise greater than 50% by weight of the total weight of all enantiomers of the compound or salt.
[0140] "Solvate" or "solvate(s)" of a compound refers to those compounds as defined above in combination with a stoichiometric or non-stoichiometric amount of a solvent. Solvates of a compound include all forms of solvates of the compound. In certain embodiments, the solvent is volatile, non-toxic, and / or acceptable for administration to humans in trace amounts. Suitable solvates include water.
[0141] "Stereoisomer" or "stereoisomer(s)" refers to a compound that differs in the chirality of one or more stereocenters. Stereoisomers include enantiomers and diastereomers, including the compounds of Formulas (I), (Ia), (Ib), (II), and (III) described herein and the linker (L) of Formulas (I) to (xiii), as well as the linkers described in Formulas (II) and (III).
[0142] "Tautomer" refers to alternative forms of a compound that differ in the position of a proton, such as enol / keto and imine / enamine tautomers, or tautomeric forms of heteroaryl groups containing ring atoms attached to a ring NH portion and a ring =N portion, such as pyrazole, imidazole, benzimidazole, triazole, and tetrazole.
[0143] The term "atropisomer" refers to a stereoisomer arising from an axis of asymmetry. This may be due to restricted rotation about a single bond, where the barrier to rotation is high enough to allow differentiation of isomeric species, up to and including complete separation of stable non-interconvertible diastereomers or enantiomers. Those skilled in the art will recognize that in the case of an asymmetric R x Once installed into the core, atropisomers may form. Furthermore, once a second chiral center is installed in a given molecule containing an atropisomer, the two chiral elements can be combined to produce diastereomeric and enantiomeric stereochemical species. Depending on the substitution about the Cx axis, interconversion between atropisomers may or may not be possible and may be temperature dependent. In some cases, atropisomers may interconvert rapidly at room temperature and cannot be resolved under ambient conditions. Other cases may allow resolution and separation, but the interconversion may occur over a period of seconds to hours or even days or months, causing a significant decrease in optical purity over time. However, interconversion of other species may be completely restricted at ambient and / or elevated temperatures, allowing resolution and separation and producing stable species. When known, resolved atropisomers are named using helical nomenclature. For this designation, only the two highest priority ligands before and after the axis are considered. When the rotational priority from front ligand 1 to back ligand 1 is clockwise, the configuration is P , counterclockwise M .
[0144] "Pharmaceutically acceptable salt" refers to pharmaceutically acceptable salts derived from a variety of organic and inorganic counterions well known in the art, and include, by way of example only, sodium, potassium, calcium, magnesium, ammonium and tetraalkylammonium, and, when the molecule contains a basic functional group, salts of organic or inorganic acids such as hydrochloride, hydrobromide, tartrate, methanesulfonate, acetate, maleate, and oxalate. Suitable salts include those described in P. Heinrich Stahl, Camille G. Wermuth (Eds.), Handbook of Pharmaceutical Salts Properties, Selection, and Use; 2002.
[0145] "Patient" or "subject" refers to a mammal, including human and non-human mammals.
[0146] To "treat" or "treat" a disease in a patient means 1) preventing the disease from occurring in a patient susceptible to the disease or who is not yet showing symptoms of the disease; 2) inhibiting the disease or arresting its progression; or 3) ameliorating or causing regression of the disease.
[0147] As indicated above, "treating" a condition includes preventing the condition. One of ordinary skill in the art will appreciate that "prevention" is not an absolute term. In medicine, "prevention" is understood to mean the prophylactic administration of a drug to significantly reduce the likelihood or severity of a condition or its biological manifestations, or to delay the onset of such a condition or its biological manifestations.
[0148] As used herein, the terms "intermittent" or "intermittently" mean stopping and starting at regular or irregular intervals. As used herein, the term "viral infection" describes a disease state in which a virus invades healthy cells, uses the cell's reproductive machinery to multiply or replicate, and ultimately lyses the cell, resulting in cell death, release of viral particles, and infection of other cells by newly produced progeny viruses. Latent infection with certain viruses is also a possible outcome of viral infection.
[0149] As used herein, the term "treating a viral infection" refers to inhibiting the replication of a specific virus, inhibiting viral spread, and ameliorating or alleviating the symptoms of a disease caused by a viral infection. Treatment is considered "therapeutic" if viral load is reduced, and mortality and / or morbidity are reduced. "Preventing a viral infection" refers to preventing the virus from establishing itself in the host. Treatment is considered "prophylactic" if a subject is exposed to a virus but does not become infected with the virus as a result of treatment.
[0150] As used herein, "latency" refers to a concept that describes 1) a dormant state of viral activity within a cell population, in which virus production, viral packaging, and host cell lysis do not occur or occur at very low frequencies, or 2) downregulation or absence of gene expression within infected cells.
[0151] As used herein, "reversal of latent HIV infection" refers to treatments that upregulate the expression of the integrated HIV genome within latently infected cells, such as agents that activate the non-canonical NF-κB pathway, which results in susceptibility of infected cells to virus-induced cell death or immune clearance. As used herein, "depletion of latent HIV infection" refers to the elimination of latently HIV-infected cells by agents such as those that activate the non-canonical NF-κB pathway, which may be followed by reversal of HIV latency.
[0152] In certain embodiments, latent HIV-infected cells are resting CD4 + T cells.
[0153] Wherever a dashed line appears adjacent to a single bond represented by a solid line, the dashed line represents an optional double bond at that position. Similarly, wherever a dashed circle appears in a ring structure represented by a solid line or a solid circle, the dashed circle represents one to three optional double bonds, which are arranged according to their appropriate valence states, taking into account whether there are any optional substitutions around the ring, as known to those skilled in the art. For example, the dashed line in the following structure can represent a double bond at that position or a single bond at that position:
[0154] .
[0155] When drawing a particular compound or formula having an aromatic ring (e.g., an aryl or heteroaryl ring), one skilled in the art will understand that the particular aromatic position of any double bond is a blend of equivalent positions, even if they are drawn at different positions from compound to compound or formula to formula. For example, in the following two pyridine rings (A and B), the double bonds are drawn at different positions, but they are known to be the same structure and compound:
[0156] .
[0157] The present invention includes compounds and pharmaceutically acceptable salts thereof. Therefore, the term "or" in the context of "compound or pharmaceutically acceptable salt thereof" should be understood to refer to: 1) the compound alone or the compound and pharmaceutically acceptable salt thereof (alternatively), or 2) the compound and pharmaceutically acceptable salt thereof (combination).
[0158] Unless otherwise indicated, substituents not explicitly defined herein are named by naming the terminal portion of the functional group followed by the adjacent functional group toward the point of attachment. For example, the substituent "arylalkyloxycarbonyl" refers to the group (aryl)(alkyl)OC(O). In a moiety such as "-C(R x )2”, it should be understood that the two R x The groups may be the same, or if R xis defined as having more than one possible identity, they may be different. In addition, certain substituents are drawn as -R x R y , where “-” indicates an adjacent bond to the parent molecule and R y is the terminal portion of the functional group. Similarly, it should be understood that the above definition is not intended to include unacceptable substitution patterns (e.g., a methyl group substituted with 5 fluoro groups). Such unacceptable substitution patterns are well known to those skilled in the art.
[0159] The present invention provides compounds of Formula (I), (Ia), (Ib), (II), and (III), as well as various forms of these compounds as described herein (e.g., pharmaceutically acceptable salts). It should be understood that any reference herein to compounds of Formula (I), (Ia), (Ib), (II), and (III) is expressly intended to also include, but not be limited to, those compounds listed in Table 1.
[0160] In one aspect, the present invention provides compounds having the structure of formula (I):
[0161]
[0162] or a pharmaceutically acceptable salt or stereoisomer thereof, wherein:
[0163] R, R', R'' and R''' are independently selected from H and CH3;
[0164] X1 and X2 are independently selected from O and S; and
[0165] L is a linker selected from the group consisting of:
[0166]
[0167]
[0168] in:
[0169] Ar1, Ar2, Ar3, Ar4, Ar5, Ar6, Ar7, Ar8, Ar9, Ar 10 、Ar 11 、Ar 12 、Ar 13 、Ar 14 、Ar 15 、Ar 16 、Ar 17 、Ar 18 、Ar 19 、Ar 21 、Ar 22 、Ar 23 、Ar 24 、Ar 25 and Ar26 Each independently selected from (C6-C 14 ) aryl;
[0170] Alk, Alk2 and Alk3 are each independently selected from:
[0171] ;
[0172] R1 is a C3-C6 cycloalkyl or a C1-C6 heterocycle;
[0173] R2 is selected from -(CH2) a -、-(CH2) b -O--(CH2) c -、-(CH2) d -(C6-C 14 )aryl-(CH2) e - and -(CH2) f -(C1-C6)heteroaryl-(CH2) g -, more preferably C2 heteroaryl;
[0174] R3 is selected from -(CH2) h -;-(CH2) i -O--(CH2) j -、-(CH2) k -(C6-C 14 )aryl-(CH2) l - and -(CH2) m' -(C1-C6)heteroaryl-(CH2) m'' -;
[0175] R4 is a C3-C6 cyclic hydrocarbon group, (C6-C 14 )aryl or (CH2) n' -(C6-C 14 )aryl-(CH2) n'' 、(CH2) n''' -Alk-(CH2) n'''' , wherein n', n'', n''' and n'''' are independently selected from 1 to 8;
[0176] R5 is a C3-C6 cycloalkyl group;
[0177] R6 is selected from (CH2) z ,
[0178]
[0179] a, b, c, d, e, f, g, h, i, j, k, l, m, m', m", n, p, q, r, s, t, u, v, x, y and z are each independently selected from 1 to 12.
[0180] In another aspect, the present invention relates to compounds of formula (Ia):
[0181]
[0182] or a pharmaceutically acceptable salt or stereoisomer thereof, wherein:
[0183] R, R', R'' and R''' are independently selected from H and CH3;
[0184] X1 and X2 are independently selected from O and S; and
[0185] L is a linker selected from the group consisting of:
[0186]
[0187]
[0188] in:
[0189] Ar1, Ar2, Ar3, Ar4, Ar5, Ar6, Ar7, Ar8, Ar9, Ar 10 、Ar 11 、Ar 12 、Ar 13 、Ar 14 、Ar 15 、Ar 16 、Ar 17 、Ar 18 、Ar 19 、Ar 21 、Ar 22 、Ar 23 、Ar 24 、Ar 25 and Ar 26 Each independently selected from (C6-C 14 ) aryl;
[0190] Alk, Alk2 and Alk3 are each independently selected from:
[0191] ;
[0192] R1 is a C3-C6 cycloalkyl or a C1-C6 heterocycle;
[0193] R2 is selected from -(CH2) a -、-(CH2) b -O--(CH2) c-、-(CH2) d -(C6-C 14 )aryl-(CH2) e - and -(CH2) f -(C1-C6)heteroaryl-(CH2) g -;
[0194] R3 is selected from -(CH2) h -、-(CH2) i -O--(CH2) j -、-(CH2) k -(C6-C 14 )aryl-(CH2) l - and -(CH2) m' -(C1-C6)heteroaryl-(CH2) m'' -;
[0195] R4 is a C3-C6 cyclic hydrocarbon group, (C6-C 14 )aryl or (CH2) n' -(C6-C 14 )aryl-(CH2) n'' 、(CH2) n''' -Alk-(CH2) n'''' , wherein n', n'', n''' and n'''' are independently selected from 1 to 8;
[0196] R5 is a C3-C6 cycloalkyl group;
[0197] R6 is selected from (CH2) z ,
[0198]
[0199] a, b, c, d, e, f, g, h, i, j, k, l, m, m', m", n, p, q, r, s, t, u, v, x, y and z are each independently selected from 1 to 12.
[0200] In another aspect, the present invention relates to compounds of formula (Ib):
[0201]
[0202] or a pharmaceutically acceptable salt or stereoisomer thereof, wherein:
[0203] R, R', R'' and R''' are independently selected from H and CH3;
[0204] X1 and X2 are independently selected from O and S; and
[0205] L is a linker selected from the group consisting of:
[0206]
[0207]
[0208] in:
[0209] Ar1, Ar2, Ar3, Ar4, Ar5, Ar6, Ar7, Ar8, Ar9, Ar 10 、Ar 11 、Ar 12 、Ar 13 、Ar 14 、Ar 15 、Ar 16 、Ar 17 、Ar 18 、Ar 19 、Ar 21 、Ar 22 、Ar 23 、Ar 24 、Ar 25 and Ar 26 Each independently selected from (C6-C 14 ) aryl;
[0210] Alk, Alk2 and Alk3 are each independently selected from:
[0211] ;
[0212] R1 is a C3-C6 cycloalkyl or a C1-C6 heterocycle;
[0213] R2 is selected from -(CH2) a -、-(CH2) b -O--(CH2) c -、-(CH2) d -(C6-C 14 )aryl-(CH2) e - and -(CH2) f -(C1-C6)heteroaryl-(CH2) g -;
[0214] R3 is selected from -(CH2) h -、-(CH2) i -O--(CH2) j -、-(CH2) k -(C6-C 14 )aryl-(CH2) l - and -(CH2) m' -(C1-C6)heteroaryl-(CH2) m'' -;
[0215] R4 is a C3-C6 cyclic hydrocarbon group, (C6-C 14 )aryl or (CH2) n' -(C6-C 14 )aryl-(CH2) n'' 、(CH2) n''' -Alk-(CH2) n'''' , wherein n', n'', n''' and n'''' are independently selected from 1 to 8;
[0216] R5 is a C3-C6 cycloalkyl group;
[0217] R6 is selected from (CH2) z ,
[0218]
[0219] a, b, c, d, e, f, g, h, i, j, k, l, m, m', m", n, p, q, r, s, t, u, v, x, y and z are each independently selected from 1 to 12.
[0220] In various embodiments, in addition to the above, the variables a, b, c, d, e, f, g, h, i, j, k, l, m, m', m'', n, p, q, r, s, t, u, v, x, y and z of Formulas (I), (la), (lb), (II) and (III) may each be independently selected from 1 to 8.
[0221] In various embodiments, at least one of R" and R'" is CH3. Preferably, R" and R' are each CH3.
[0222] Most preferably, R, R', R" and R'" are each CH3.
[0223] In various embodiments, X1 and X2 are both O.
[0224] In various embodiments, X1 and X2 are both S.
[0225] In various embodiments, X1 is O and X2 is S.
[0226] In various embodiments, X1 is S and X2 is O.
[0227] In various embodiments, Alk, Alk2 and Alk3 are each preferably:
[0228] .
[0229] In various embodiments, Ar1, Ar2, Ar3, Ar4, Ar5, Ar6, Ar7, Ar8, Ar9, Ar10 、Ar 11 、Ar 21 、Ar 22 、Ar 23 、Ar 24 、Ar 25 and Ar 26 Each may be a C6 aryl group.
[0230] In various embodiments, Ar 12 、Ar 13 、Ar 14 、Ar 15 、Ar 16 、Ar 17 、Ar 18 and Ar 19 Each may be a C9 aryl group. In a preferred embodiment, the C9 aryl group is represented by
[0231]
[0232] The nitrogen in NH is connected to the bicyclic ring system of the compound through an amide bond, and R represents the connection to the linker.
[0233] In various embodiments, Ar 16 、Ar 17 、Ar 18 and Ar 19 Each is C 10 In a preferred embodiment, C 10 Aryl is represented by
[0234]
[0235] The nitrogen in NH is connected to the bicyclic ring system of the compound through an amide bond, and R represents the connection to the linker.
[0236] In various embodiments, the linker has formula (i):
[0237]
[0238] Ar1 and Ar2 can each be independently selected from C6-C9 aryl groups.
[0239] Preferably, for formula (i), Ar1 is a C6 aryl group. Alk is:
[0240] .
[0241] Ar2 is C6 aryl, m is 1, n is 1, p is 1 and q is 1. In one embodiment, X1 is S and X2 is S. In one embodiment, X1 is S and X2 is O.
[0242] In various embodiments, the linker has formula (ii):
[0243]
[0244] Ar3, Ar2 and Ar5 can each be independently selected from C6-C9 aryl groups.
[0245] Preferably, for formula (ii), Ar3 is C6 aryl, Ar4 is C6 aryl, r is 1, Ar4 is C6 aryl, s is 1 and Ar5 is C6 aryl. In one embodiment, X1 is O and X2 is O. In one embodiment, X1 is S and X2 is S.
[0246] In various embodiments, the linker has formula (iii):
[0247]
[0248] wherein Ar6 and Ar7 are each independently a C6-C9 aryl group, and most preferably each a C6 aryl group;
[0249] Wherein R1 is preferably a C1-C6 heterocycle (e.g., a C4 heterocycle), most preferably:
[0250] .
[0251] In various embodiments, the linker has formula (iv):
[0252] .
[0253] Preferably, for formula (iv), Ar8 is C 6-9 Aryl, more preferably C6 aryl, and Alk2 is:
[0254] ,
[0255] and Ar9 is a C6 aryl group; C 6-9 Aryl, more preferably C6 aryl.
[0256] In various embodiments, the linker has formula (v):
[0257] .
[0258] Preferably, with respect to formula (v), Ar 10 It is C 6-9 Aryl, more preferably C6 aryl, Ar 11 C is preferred 6-9 Aryl, more preferably C6 aryl, and R2 is selected from -(CH2)-C 6-9Aryl-(CH2)-, (more preferably -(CH2)-C6 aryl-(CH2)-), -(CH2) 1-8 -(more preferably -(CH2)4-, -(CH2)3- or -(CH2)6-) and -(CH2) 2-6 -O-(CH2) 2-6 -(more preferably -(CH2) 2-4 -O-(CH2) 2-4 In one embodiment, R2 is -(CH2)2-O-(CH2)2-. When R2 is heteroaryl, it is preferably C2 heteroaryl.
[0259] In various embodiments, the linker has formula (vi):
[0260] .
[0261] Preferably, for formula (vi), Ar 12 It is C 6-9 Aryl, t is 1-4 (more preferably, t is 1), Alk3 is:
[0262] ,
[0263] u is 1-4 (more preferably, u is 1) and Ar 13 It is C 6-9 Most preferably, Ar 12 and Ar 13 Each is a C9 aryl group, and most preferably, the C9 aryl group is represented as follows:
[0264]
[0265] The nitrogen in NH is connected to the bicyclic ring system of the compound through an amide bond, and R represents the connection to the linker.
[0266] In various embodiments, the linker has formula (vii):
[0267] .
[0268] Preferably, for formula (vii), Ar 14 It is C 6-9 Aryl (more preferably, C9 aryl), R3 is selected from (CH2)1- 12 (e.g., (CH2)4-6); -(CH2)1-6-O-(CH2)1-6-(e.g., -(CH2) 2-4 -O-(CH2) 2-4 -), and Ar 15 More preferably, for formula (vii), Ar 14is C9 aryl, R3 is selected from -(CH2) 4-12 -、-(CH2) 2-4 -O-(CH2) 2-4 -.
[0269] In a preferred embodiment, Ar 14 and Ar 15 Each is a C9 aryl group as follows:
[0270]
[0271] The nitrogen in NH is connected to the bicyclic ring system of the compound through an amide bond, and R represents the connection to the linker.
[0272] In various embodiments, the linker has formula (viii):
[0273] .
[0274] Preferably, Ar 16 It is C 6-10 Aryl, more preferably C9 aryl or C 10 Aryl, R4 is selected from C3-C6 cycloalkyl or (C6-C 14 )aryl, and Ar 17 It is C 6-10 Aryl, more preferably C9 aryl or C 10 More preferably, R4 is a C6 cycloalkyl, a C6 aryl, -CH2-C6 aryl-CH2, or
[0275] .
[0276] In various embodiments, the linker has formula (ix):
[0277] .
[0278] Preferably, Ar 18 It is C 6-10 Aryl, more preferably C9 aryl or C 10 Aryl and Ar 19 It is C 6-10 Aryl, more preferably C9 aryl or C 10 Aryl.
[0279] In various embodiments, the linker has formula (x):
[0280] .
[0281] Preferably, A 21 and A 22 Independently selected from C 6-9Aryl, and v ranges from 1 to 6. More preferably, in one embodiment, Ar 21 is a C6 aryl group, v is 1 and Ar 22 More preferably, in one embodiment, Ar 21 is a C6 aryl group, v is 2 and Ar 22 It is a C6 aryl group.
[0282] In various embodiments, the linker has formula (xi):
[0283] .
[0284] Preferably, Ar 23 It is C 6-9 Aryl, more preferably C6 aryl, R5 is C3-C6 cycloalkyl and Ar 24 C is preferred 6-9 Aryl, more preferably C6 aryl. Most preferably, R5 is C6 cycloalkyl.
[0285] In another aspect, the present invention provides a compound of formula (II):
[0286]
[0287] in
[0288] R, R', R'' and R''' are independently selected from H and CH3;
[0289] X1 and X2 are independently selected from O and S; and
[0290] L' is a linker of the formula:
[0291]
[0292] in:
[0293] Ar 27 and Ar 28 Each independently selected from C6-C 14 Aryl,
[0294] R7 is selected from
[0295] , C6 aryl and -(CH2) 4-15 -(more preferably -(CH2) 6-10 -);and
[0296] a' and b' are independently selected from 0 to 6.
[0297] In various embodiments, R, R', R", and R'" are each CH3.
[0298] In various embodiments, X1 and X2 are each O.
[0299] In various embodiments, Ar 27 and Ar 28 Each selected from C6-C 10 In various embodiments, the C9 aryl group can be represented by the formula
[0300]
[0301] wherein the nitrogen in NH is linked to the compound bicyclic system via an amide bond, and R represents the connection to the linker. Most preferably, the C9 aryl group has the formula:
[0302] .
[0303] In one embodiment, R, R', R'' and R''' are each CH3, X1 and X2 are each O;
[0304] a' is 1, b' is 1, and R7 is:
[0305] ;and
[0306] Ar 27 and Ar 28 Each is the following formula:
[0307] .
[0308] In one embodiment, the present invention provides compounds of formula (II), provided that when R, R', R'' and R''' are each CH3, X1 and X2 are each O, Ar 27 and Ar 28 Each is the following formula:
[0309]
[0310] and a' is 1 and b' is 1, then R7 is not:
[0311] .
[0312] In various embodiments, including compounds of formula (II), wherein a' is 0, b' is 0 and R7 is -(CH2) 6-15 -(more preferably -(CH2) 6-10 -), R, R', R'' and R''' are each CH3, X1 and X2 are each O, and Ar 27 and Ar 28 Each is a C9 aryl group. Preferably, the C9 aryl group is represented by the following formula
[0313]
[0314] wherein the nitrogen in NH is linked to the compound bicyclic system via an amide bond, and R represents the connection to the linker. Most preferably, the C9 aryl group has the formula:
[0315] .
[0316] In one embodiment, the present invention provides a compound of formula (II) wherein a' is 0, b' is 0, R7 is -(CH2)6-, R, R', R'' and R''' are CH3, X1 and X2 are each O, Ar 27 and Ar 28 Each is a C9 aryl group represented by the following formula:
[0317] ,
[0318] The nitrogen in NH is connected to the bicyclic ring system of the compound through an amide bond, and R represents the connection to the linker.
[0319] In one aspect, the present invention provides compounds of formula (II), provided that when R, R', R'' and R''' are each CH3, X1 and X2 are each O, Ar 27 and Ar 28 Each is the following formula:
[0320] ,
[0321] When a' is 0 and b' is 0, R7 is not -(CH2)6-.
[0322] In another aspect, the present invention provides a compound having the structure of formula (III):
[0323]
[0324] in
[0325] R, R', R'' and R''' are independently selected from H and CH3;
[0326] X1 and X2 are independently selected from O and S; and
[0327] L'' is a linker of the formula:
[0328]
[0329] Among them, Ar 29 and Ar 30 Independently selected from C6-C 10 Aryl and R8 is selected from:
[0330] 、-(CH2) 6-15 - and -(CH2) d' -(C6-C 10 )aryl-(CH2) e' -; where d' and e' are independently chosen and range from 1 to 6.
[0331] In one embodiment of the compound of formula (III), R, R', R" and R"" are each CH3, X1 and X2 are each O, Ar 29 and Ar 30 Each is a C6 aryl group, and R8 is:
[0332] .
[0333] In one embodiment of the compound of formula (III), R, R', R" and R"" are each CH3, X1 and X2 are each O, Ar 29 and Ar 30 Each is a C6 aryl group, and R8 is -(CH2) ' -(C6)aryl-(CH2) ' -.
[0334] In one embodiment of the compound of formula (III), R, R', R" and R"" are each CH3, X1 and X2 are each O, Ar 29 and Ar 30 Each is a C6 aryl group, and R8 is -(CH2)6-.
[0335] In the above formulas (II) and (III), any aryl group may be optionally substituted by any of the following (but not limited to): (C1-C6) alkyl, (C1-C6) alkoxy, halogen, oxo, haloalkyl, dihaloalkyl, trihaloalkyl, haloalkoxy, dihaloalkoxy, trihaloalkoxy, hydroxy, amino, and amide. In addition, any aryl group in formulas (I), (Ia), and (Ib) may also be optionally substituted by the above.
[0336] Exemplary compounds encompassed by the present invention include, but are not limited to, those in Table 1 below:
[0337] Table 1.
[0338] Compound number Compound structure Compound name 1 #timg# (4S,4'S,7S,7'S,9aS,9a'S)-N,N'-(methylenebis(4,1-phenylene))bis(8,8-dimethyl-4-((S)-2-(methylamino)propionamido)-5-oxooctahydropyrrolo[2,1-b][1,3]thiazepine-7-carboxamide) 2 #timg# (4S,4'S,7S,7'S,9aS,9a'S)-N,N'-(methylenebis(4,1-phenylene))bis(8,8-dimethyl-4-((S)-2-(methylamino)propanethioamido)-5-oxooctahydropyrrolo[2,1-b][1,3]thiazepine-7-carboxamide) 3 #timg# (4S,4'S,7S,7'S,9aS,9a'S)-N,N'-(ethane-1,2-diylbis(2,1-phenylene))bis(8,8-dimethyl-4-((S)-2-(methylamino)propionamido)-5-oxooctahedralpyrrolo[2,1-b][1,3]thiazepine-7-carboxamide) 4 #timg# (4S,4'S,7S,7'S,9aS,9a'S)-N,N'-(ethane-1,2-diylbis(2,1-phenylene))bis(8,8-dimethyl-4-((S)-2-(methylamino)propanethioamido)-5-oxooctahydropyrrolo[2,1-b][1,3]thiazepine-7-carboxamide) 5 #timg# (4S,4'S,7S,7'S,9aS,9a'S)-N,N'-(ethane-1,2-diylbis(4,1-phenylene))bis(8,8-dimethyl-4-((S)-2-(methylamino)propionamido)-5-oxooctahedralpyrrolo[2,1-b][1,3]thiazepine-7-carboxamide) 6 #timg# (4S,4'S,7S,7'S,9aS,9a'S)-N,N'-(ethane-1,2-diylbis(4,1-phenylene))bis(8,8-dimethyl-4-((S)-2-(methylamino)propanethioamido)-5-oxooctahydropyrrolo[2,1-b][1,3]thiazepine-7-carboxamide) 7 #timg# (4S,4'S,7S,7'S,9aS,9a'S)-N,N'-((1R,1'R,2R,2'R)-(piperazine-1,4-dicarbonyl)bis(1,2,3,4-tetrahydronaphthalene-2,1-diyl))bis(8,8-dimethyl-4-((S)-2-(methylamino)propionamido)-5-oxooctahydropyrrolo[2,1-b][1,3]thiazepine-7-carboxamide) 8 #timg# (4S,4'S,7S,7'S,9aS,9a'S)-N,N'-((1R,1'R,2R,2'R)-(piperazine-1,4-dicarbonyl)bis(1,2,3,4-tetrahydronaphthalene-2,1-diyl))bis(8,8-dimethyl-4-((S)-2-(methylamino)propanethioamido)-5-oxooctahydropyrrolo[2,1-b][1,3]thiazepine-7-carboxamide) 9 #timg# (4S,4'S,7S,7'S,9aS,9a'S)-N,N'-((1R,1'R,2R,2'R)-(((1,4-phenylenebis(methylene))bis(azanediyl))bis(carbonyl))bis(1,2,3,4-tetrahydronaphthalene-2,1-diyl))bis(8,8-dimethyl-4-((S)-2-(methylamino)propionamido)-5-oxooctahydropyrrolo[2,1-b][1,3]thiazepine-7-carboxamide) 10 #timg# (4S,4'S,7S,7'S,9aS,9a'S)-N,N'-((1R,1'R,2R,2'R)-(((1,4-phenylenebis(methylene))bis(azanediyl))bis(carbonyl))bis(1,2,3,4-tetrahydronaphthalene-2,1-diyl))bis(8,8-dimethyl-4-((S)-2-(methylamino)propanethioamido)-5-oxooctahydropyrrolo[2,1-b][1,3]thiazepine-7-carboxamide) 11 #timg# (4S,7S,9aS)-8,8-Dimethyl-4-[(2S)-2-(methylamino)propionamido]-5-oxo-N-[(1R,2R)-2-{[(1rs,4rs)-4-[(1R,2R)-1-[(4S,7S,9aS)-8,8-dimethyl-4-[(2S)-2-(methylamino)propionamido]-5-oxo-octahydropyrrolo[2,1-b][1,3]thiazepine-7-amide]-1,2,3,4-tetrahydronaphthalene-2-amide]cyclohexyl]carbamoyl}-1,2,3,4-tetrahydronaphthalene-1-yl]-octahydropyrrolo[2,1-b][1,3]thiazepine-7-carboxamide 12 #timg# (4S,7S,9aS)-8,8-Dimethyl-4-[(2S)-2-(methylamino)propanethioamido]-5-oxo-N-[(1R,2R)-2-{[(1rs,4rs)-4-[(1R,2R)-1-[(4S,7S,9aS)-8,8-dimethyl-4-[(2S)-2-(methylamino)propanethioamido]-5-oxo-octahydropyrrolo[2,1-b][1,3]thiazepine-7-carboxamide]-1,2,3,4-tetrahydronaphthalene-2-carboxamide]cyclohexyl]carbamoyl}-1,2,3,4-tetrahydronaphthalene-1-yl]-octahydropyrrolo[2,1-b][1,3]thiazepine-7-carboxamide 13 #timg# (4S,4'S,7S,7'S,9aS,9a'S)-N,N'-((1S,1'S,2R,2'R)-(hexane-2,4-diyn-1,6-diylbis(oxy))bis(2,3-dihydro-1H-indene-2,1-diyl))bis(8,8-dimethyl-4-((S)-2-(methylamino)propionamido)-5-oxooctahydropyrrolo[2,1-b][1,3]thiazepine-7-carboxamide) 14 #timg# (4S,7S,9aS)-N-((1S,2R)-2-((6-(((1S,2R)-1-((4S,7S,9aS)-8,8-dimethyl-4-((S)-2-(methylamino)propionamido)-5-oxooctahydropyrrolo[2,1-b][1,3]thiazepin-7-carboxamido)-2,3-dihydro-1H-inden-2-yl)oxy)hexa-2,4-diyn-1-yl)oxy)-2,3-dihydro-1H-inden-1-yl)-8,8-dimethyl-4-((S)-2-(methylamino)propanethioamido)-5-oxooctahydropyrrolo[2,1-b][1,3]thiazepin-7-carboxamide 15 #timg# (4S,4'S,7S,7'S,9aS,9a'S)-N,N'-((1S,1'S,2R,2'R)-(hexane-2,4-diyn-1,6-diylbis(oxy))bis(2,3-dihydro-1H-indene-2,1-diyl))bis(8,8-dimethyl-4-((S)-2-(methylamino)propanethioamido)-5-oxooctahydropyrrolo[2,1-b][1,3]thiazepine-7-carboxamide) 16 #timg# (4S,4'S,7S,7'S,9aS,9a'S)-N,N'-((1S,1'S,2R,2'R)-(butane-1,4-diylbis(oxy))bis(2,3-dihydro-1H-indene-2,1-diyl))bis(8,8-dimethyl-4-((S)-2-(methylamino)propionamido)-5-oxooctahydropyrrolo[2,1-b][1,3]thiazepine-7-carboxamide) 17 #timg# (4S,4'S,7S,7'S,9aS,9a'S)-N,N'-((1S,1'S,2R,2'R)-(butane-1,4-diylbis(oxy))bis(2,3-dihydro-1H-indene-2,1-diyl))bis(8,8-dimethyl-4-((S)-2-(methylamino)propanethioamido)-5-oxooctahydropyrrolo[2,1-b][1,3]thiazepine-7-carboxamide) 18 #timg# (4S,4'S,7S,7'S,9aS,9a'S)-N,N'-((1S,1'S,2R,2'R)-((oxybis(ethane-2,1-diyl))bis(oxy))bis(2,3-dihydro-1H-indene-2,1-diyl))bis(8,8-dimethyl-4-((S)-2-(methylamino)propionamido)-5-oxooctahydropyrrolo[2,1-b][1,3]thiazepine-7-carboxamide) 19 #timg# (4S,4'S,7S,7'S,9aS,9a'S)-N,N'-((1S,1'S,2R,2'R)-((oxybis(ethane-2,1-diyl))bis(oxy))bis(2,3-dihydro-1H-indene-2,1-diyl))bis(8,8-dimethyl-4-((S)-2-(methylamino)propanethioamido)-5-oxooctahydropyrrolo[2,1-b][1,3]thiazepine-7-carboxamide) 20 #timg# (4S,4'S,7S,7'S,9aS,9a'S)-N,N'-((1S,1'S,2R,2'R)-(hexane-1,6-diylbis(oxy))bis(2,3-dihydro-1H-indene-2,1-diyl))bis(8,8-dimethyl-4-((S)-2-(methylamino)propionamido)-5-oxooctahydropyrrolo[2,1-b][1,3]thiazepine-7-carboxamide) 21 #timg# (4S,4'S,7S,7'S,9aS,9a'S)-N,N'-((1S,1'S,2R,2'R)-(hexane-1,6-diylbis(oxy))bis(2,3-dihydro-1H-indene-2,1-diyl))bis(8,8-dimethyl-4-((S)-2-(methylamino)propanethioamido)-5-oxooctahydropyrrolo[2,1-b][1,3]thiazepine-7-carboxamide) 22 #timg# (4S,4'S,7S,7'S,9aS,9a'S)-N,N'-((1S,1'S,2R,2'R)-((1,4-phenylenebis(methylene))bis(oxy))bis(2,3-dihydro-1H-indene-2,1-diyl))bis(8,8-dimethyl-4-((S)-2-(methylamino)propionamido)-5-oxooctahydropyrrolo[2,1-b][1,3]thiazepine-7-carboxamide) 23 #timg# (4S,4'S,7S,7'S,9aS,9a'S)-N,N'-((1S,1'S,2R,2'R)-((1,4-phenylenebis(methylene))bis(oxy))bis(2,3-dihydro-1H-indene-2,1-diyl))bis(8,8-dimethyl-4-((S)-2-(methylamino)propanethioamido)-5-oxooctahydropyrrolo[2,1-b][1,3]thiazepine-7-carboxamide) 24 #timg# (4S,4'S,7S,7'S,9aS,9a'S)-N,N'-((1S,1'S)-((1,4-phenylenebis(methylene))bis(azanediyl))bis(2-oxo-1-phenylethane-2,1-diyl))bis(8,8-dimethyl-4-((S)-2-(methylamino)propionamido)-5-oxooctahedralpyrrolo[2,1-b][1,3]thiazepine-7-carboxamide) 25 #timg# (4S,4'S,7S,7'S,9aS,9a'S)-N,N'-((1S,1'S)-((1,4-phenylenebis(methylene))bis(azanediyl))bis(2-oxo-1-phenylethane-2,1-diyl))bis(8,8-dimethyl-4-((S)-2-(methylamino)propanethioamido)-5-oxooctahedralpyrrolo[2,1-b][1,3]thiazepine-7-carboxamide) 26 #timg# (4S,4'S,7S,7'S,9aS,9a'S)-N,N'-((1S,1'S)-piperazine-1,4-diylbis(2-oxo-1-phenylethane-2,1-diyl))bis(8,8-dimethyl-4-((S)-2-(methylamino)propionamido)-5-oxooctahedralpyrrolo[2,1-b][1,3]thiazepine-7-carboxamide) 27 #timg# (4S,4'S,7S,7'S,9aS,9a'S)-N,N'-((1S,1'S)-piperazine-1,4-diylbis(2-oxo-1-phenylethane-2,1-diyl))bis(8,8-dimethyl-4-((S)-2-(methylamino)propanethioamido)-5-oxooctahedralpyrrolo[2,1-b][1,3]thiazepine-7-carboxamide) 28 #timg# (2S)-N-[(4S,7S,9aS)-8,8-dimethyl-5-oxo-7-{[(S)-phenyl({[(1rs,4rs)-4-[(2S)-2-{[(4S,7S,9aS)-8,8-dimethyl-4-[(2S)-2-(methylamino)propionamido]-5-oxo-octahydropyrrolo[2,1-b][1,3]thiazepin-7-yl]formamido}-2-phenylacetamido]cyclohexyl]carbamoyl})methyl]carbamoyl}-octahydropyrrolo[2,1-b][1,3]thiazepin-4-yl]-2-(methylamino)propionamide 29 #timg# (2S)-2-{[(4S,7S,9aS)-8,8-dimethyl-4-[(2S)-2-(methylamino)propanethioamido]-5-oxo-octahydropyrrolo[2,1-b][1,3]thiazepin-7-yl]formamido}-2-phenyl-N-[(1rs,4rs)-4-[(2S)-2-{[(4S,7S,9aS)-8,8-dimethyl-4-[(2S)-2-(methylamino)propanethioamido]-5-oxo-octahydropyrrolo[2,1-b][1,3]thiazepin-7-yl]formamido}-2-phenylacetamido]cyclohexyl]acetamide 30 #timg# (4S,4'S,7S,7'S,9aS,9a'S)-N,N'-((1S,1'S)-(hexane-2,4-diyn-1,6-diylbis(azanediyl))bis(2-oxo-1-phenylethane-2,1-diyl))bis(8,8-dimethyl-4-((S)-2-(methylamino)propionamido)-5-oxooctahedralpyrrolo[2,1-b][1,3]thiazepine-7-carboxamide) 31 #timg# (4S,7S,9aS)-N-((S)-2-((6-((S)-2-((4S,7S,9aS)-8,8-dimethyl-4-((S)-2-(methylamino)propionamido)-5-oxooctahydropyrrolo[2,1-b][1,3]thiazepine-7-carboxamido)-2-phenylacetamido)hexa-2,4-diyn-1-yl)amino)-2-oxo-1-phenylethyl)-8,8-dimethyl-4-((S)-2-(methylamino)propanethioamido)-5-oxooctahydropyrrolo[2,1-b][1,3]thiazepine-7-carboxamide 32 #timg# (4S,4'S,7S,7'S,9aS,9a'S)-N,N'-((1S,1'S)-(hexane-2,4-diyn-1,6-diylbis(azanediyl))bis(2-oxo-1-phenylethane-2,1-diyl))bis(8,8-dimethyl-4-((S)-2-(methylamino)propanethioamido)-5-oxooctahedralpyrrolo[2,1-b][1,3]thiazepine-7-carboxamide) 33 #timg# (4S,4'S,7S,7'S,9aS,9a'S)-N,N'-((1S,1'S)-(hexane-2,4-diyn-1,6-diylbis(oxy))bis(1-phenylethane-2,1-diyl))bis(8,8-dimethyl-4-((S)-2-(methylamino)propionamido)-5-oxooctahydropyrrolo[2,1-b][1,3]thiazepine-7-carboxamide) 34 #timg# (4S,7S,9aS)-N-((S)-2-((6-((S)-2-((4S,7S,9aS)-8,8-dimethyl-4-((S)-2-(methylamino)propionamido)-5-oxooctahydropyrrolo[2,1-b][1,3]thiazepine-7-carboxamido)-2-phenylethoxy)hexa-2,4-diyn-1-yl)oxy)-1-phenylethyl)-8,8-dimethyl-4-((S)-2-(methylamino)propanethioamido)-5-oxooctahydropyrrolo[2,1-b][1,3]thiazepine-7-carboxamide 35 #timg# (4S,4'S,7S,7'S,9aS,9a'S)-N,N'-((1S,1'S)-(hexane-2,4-diyn-1,6-diylbis(oxy))bis(1-phenylethane-2,1-diyl))bis(8,8-dimethyl-4-((S)-2-(methylamino)propanethioamido)-5-oxooctahydropyrrolo[2,1-b][1,3]thiazepine-7-carboxamide) 36 #timg# (4S,4'S,7S,7'S,9aS,9a'S)-N,N'-((1S,1'S)-(butane-1,4-diylbis(oxy))bis(1-phenylethane-2,1-diyl))bis(8,8-dimethyl-4-((S)-2-(methylamino)propionamido)-5-oxooctahydropyrrolo[2,1-b][1,3]thiazepine-7-carboxamide) 37 #timg# (4S,4'S,7S,7'S,9aS,9a'S)-N,N'-((1S,1'S)-(butane-1,4-diylbis(oxy))bis(1-phenylethane-2,1-diyl))bis(8,8-dimethyl-4-((S)-2-(methylamino)propanethioamido)-5-oxooctahydropyrrolo[2,1-b][1,3]thiazepine-7-carboxamide) 38 #timg# (4S,4'S,7S,7'S,9aS,9a'S)-N,N'-((1S,1'S)-((oxybis(ethane-2,1-diyl))bis(oxy))bis(1-phenylethane-2,1-diyl))bis(8,8-dimethyl-4-((S)-2-(methylamino)propionamido)-5-oxooctahedralpyrrolo[2,1-b][1,3]thiazepine-7-carboxamide) 39 #timg# (4S,4'S,7S,7'S,9aS,9a'S)-N,N'-((1S,1'S)-((oxybis(ethane-2,1-diyl))bis(oxy))bis(1-phenylethane-2,1-diyl))bis(8,8-dimethyl-4-((S)-2-(methylamino)propanethioamido)-5-oxooctahydropyrrolo[2,1-b][1,3]thiazepine-7-carboxamide) 40 #timg# (4S,4'S,7S,7'S,9aS,9a'S)-N,N'-((1S,1'S)-(hexane-1,6-diylbis(oxy))bis(1-phenylethane-2,1-diyl))bis(8,8-dimethyl-4-((S)-2-(methylamino)propionamido)-5-oxooctahedralpyrrolo[2,1-b][1,3]thiazepine-7-carboxamide) 41 #timg# (4S,4'S,7S,7'S,9aS,9a'S)-N,N'-((1S,1'S)-(hexane-1,6-diylbis(oxy))bis(1-phenylethane-2,1-diyl))bis(8,8-dimethyl-4-((S)-2-(methylamino)propanethioamido)-5-oxooctahydropyrrolo[2,1-b][1,3]thiazepine-7-carboxamide) 42 #timg# (4S,4'S,7S,7'S,9aS,9a'S)-N,N'-((1S,1'S)-((1,4-phenylenebis(methylene))bis(oxy))bis(1-phenylethane-2,1-diyl))bis(8,8-dimethyl-4-((S)-2-(methylamino)propionamido)-5-oxooctahydropyrrolo[2,1-b][1,3]thiazepine-7-carboxamide) 43 #timg# (4S,4'S,7S,7'S,9aS,9a'S)-N,N'-((1S,1'S)-((1,4-phenylenebis(methylene))bis(oxy))bis(1-phenylethane-2,1-diyl))bis(8,8-dimethyl-4-((S)-2-(methylamino)propanethioamido)-5-oxooctahydropyrrolo[2,1-b][1,3]thiazepine-7-carboxamide) 44 #timg# (4S,7S,9aS)-N-[(1R,2R)-2-({[4-({[(1R,2R)-1-[(4S,7S,9aS)-8,8-dimethyl-4-[(2S)-2-(methylamino)propanethioamido]-5-oxo-octahydropyrrolo[2,1-b][1,3]thiazepine-7-carboxamide]-2,3-dihydro-1H-inden-2-yl]formamido}methyl)phenyl]methyl}carbamoyl)-2,3-dihydro-1H-inden-1-yl]-8,8-dimethyl-4-[(2S)-2-(methylamino)propanethioamido]-5-oxo-octahydropyrrolo[2,1-b][1,3]thiazepine-7-carboxamide 45 #timg# (4S,7S,9aS)-N-[(1R,2R)-2-({[4-({[(1R,2R)-1-[(4S,7S,9aS)-8,8-dimethyl-4-[(2S)-2-(methylamino)propionamido]-5-oxo-octahydropyrrolo[2,1-b][1,3]thiazepine-7-carboxamide]-2,3-dihydro-1H-inden-2-yl]formamido}methyl)phenyl]methyl}carbamoyl)-2,3-dihydro-1H-inden-1-yl]-8,8-dimethyl-4-[(2S)-2-(methylamino)propionamido]-5-oxo-octahydropyrrolo[2,1-b][1,3]thiazepine-7-carboxamide 46 #timg# (4S,7S,9aS)-N-[(1R,2R)-2-{4-[(1R,2R)-1-[(4S,7S,9aS)-8,8-dimethyl-4-[(2S)-2-(methylamino)propionamido]-5-oxo-octahydropyrrolo[2,1-b][1,3]thiazepine-7-carboxamide]-2,3-dihydro-1H-indene-2-carbonyl]piperazine-1-carbonyl}-2,3-dihydro-1H-indene-1-yl]-8,8-dimethyl-4-[(2S)-2-(methylamino)propionamido]-5-oxo-octahydropyrrolo[2,1-b][1,3]thiazepine-7-carboxamide 47 #timg# (4S,7S,9aS)-N-[(1R,2R)-2-{4-[(1R,2R)-1-[(4S,7S,9aS)-8,8-dimethyl-4-[(2S)-2-(methylamino)propanethioamido]-5-oxo-octahydropyrrolo[2,1-b][1,3]thiazepine-7-carboxamide]-2,3-dihydro-1H-indene-2-carbonyl]piperazine-1-carbonyl}-2,3-dihydro-1H-indene-1-yl]-8,8-dimethyl-4-[(2S)-2-(methylamino)propanethioamido]-5-oxo-octahydropyrrolo[2,1-b][1,3]thiazepine-7-carboxamide 48 #timg# (4S,7S,9aS)-N-[(1S,2R)-2-[(8-{[(1S,2R)-1-[(4S,7S,9aS)-8,8-dimethyl-4-[(2S)-2-(methylamino)propionamido]-5-oxo-octahydropyrrolo[2,1-b][1,3]thiazepine-7-carboxamide]-2,3-dihydro-1H-inden-2-yl]oxy}octyl)oxy]-2,3-dihydro-1H-inden-1-yl]-8,8-dimethyl-4-[(2S)-2-(methylamino)propionamido]-5-oxo-octahydropyrrolo[2,1-b][1,3]thiazepine-7-carboxamide 49 #timg# (4S,7S,9aS)-N-[(1R,2R)-2-[(6-{[(1R,2R)-1-[(4S,7S,9aS)-8,8-dimethyl-4-[(2S)-2-(methylamino)propionamido]-5-oxo-octahydropyrrolo[2,1-b][1,3]thiazepine-7-carboxamide]-2,3-dihydro-1H-inden-2-yl]formamido}hexa-2,4-diyn-1-yl)carbamoyl]-2,3-dihydro-1H-inden-1-yl]-8,8-dimethyl-4-[(2S)-2-(methylamino)propionamido]-5-oxo-octahydropyrrolo[2,1-b][1,3]thiazepine-7-carboxamide 50 #timg# (4S,7S,9aS)-N-[(1S)-2-[2-(4-{[(2S)-2-{[(4S,7S,9aS)-8,8-dimethyl-4-[(2S)-2-(methylamino)propionamido]-5-oxo-octahydropyrrolo[2,1-b][1,3]thiazepin-7-yl]carboxamido}-2-phenylethoxy]methyl}-1H-1,2,3-triazol-1-yl)ethoxy]-1-phenylethyl]-8,8-dimethyl-4-[(2S)-2-(methylamino)propionamido]-5-oxo-octahydropyrrolo[2,1-b][1,3]thiazepin-7-carboxamide 51 #timg# (4S,7S,9aS)-N-[(1S,2R)-2-[3-(3-{[(1S,2R)-1-[(4S,7S,9aS)-8,8-dimethyl-4-[(2S)-2-(methylamino)propionamido]-5-oxo-octahydropyrrolo[2,1-b][1,3]thiazepine-7-carboxamide]-2,3-dihydro-1H-inden-2-yl]oxy}propoxy)propoxy]-2,3-dihydro-1H-inden-1-yl]-8,8-dimethyl-4-[(2S)-2-(methylamino)propionamido]-5-oxo-octahydropyrrolo[2,1-b][1,3]thiazepine-7-carboxamide 52 #timg# (4S,7S,9aS)-N-[(1S)-2-[2-(4-{[(2S)-2-{[(4S,7S,9aS)-8,8-dimethyl-4-[(2S)-2-(methylamino)propanethioamido]-5-oxo-octahydropyrrolo[2,1-b][1,3]thiazepin-7-yl]carboxamido}-2-phenylethoxy]methyl}-1H-1,2,3-triazol-1-yl)ethoxy]-1-phenylethyl]-8,8-dimethyl-4-[(2S)-2-(methylamino)propanethioamido]-5-oxo-octahydropyrrolo[2,1-b][1,3]thiazepin-7-carboxamide 53 #timg# (4S,7S,9aS)-N-[(1S)-2-[3-(4-{[(2S)-2-{[(4S,7S,9aS)-8,8-dimethyl-4-[(2S)-2-(methylamino)propanethioamido]-5-oxo-octahydropyrrolo[2,1-b][1,3]thiazepin-7-yl]carboxamido}-2-phenylethoxy]methyl}-1H-1,2,3-triazol-1-yl)propoxy]-1-phenylethyl]-8,8-dimethyl-4-[(2S)-2-(methylamino)propanethioamido]-5-oxo-octahydropyrrolo[2,1-b][1,3]thiazepin-7-carboxamide 54 #timg# (4S,7S,9aS)-8,8-Dimethyl-4-[(2S)-2-(methylamino)propanethioamido]-5-oxo-N-[(1R,2R)-2-{[(1rs,4rs)-4-[(1R,2R)-1-[(4S,7S,9aS)-8,8-dimethyl-4-[(2S)-2-(methylamino)propanethioamido]-5-oxo-octahydropyrrolo[2,1-b][1,3]thiazepine-7-carboxamide]-2,3-dihydro-1H-inden-2-carboxamide]cyclohexyl]carbamoyl}-2,3-dihydro-1H-inden-1-yl]-octahydropyrrolo[2,1-b][1,3]thiazepine-7-carboxamide 55 #timg# (4S,7S,9aS)-8,8-Dimethyl-4-[(2S)-2-(methylamino)propionamido]-5-oxo-N-[(1R,2R)-2-{[(1rs,4rs)-4-[(1R,2R)-1-[(4S,7S,9aS)-8,8-dimethyl-4-[(2S)-2-(methylamino)propionamido]-5-oxo-octahydropyrrolo[2,1-b][1,3]thiazepine-7-carboxamide]-2,3-dihydro-1H-inden-2-carboxamide]cyclohexyl]carbamoyl}-2,3-dihydro-1H-inden-1-yl]-octahydropyrrolo[2,1-b][1,3]thiazepine-7-carboxamide 56 #timg# (4S,4'S,7S,7'S,9aS,9a'S)-N,N'-((1S,1'S)-((naphthalene-2,7-diylbis(methylene))bis(oxy))bis(1-phenylethane-2,1-diyl))bis(8,8-dimethyl-4-((S)-2-(methylamino)propionamido)-5-oxooctahydropyrrolo[2,1-b][1,3]thiazepine-7-carboxamide 57 #timg# (4S,4'S,7S,7'S,9aS,9a'S)-N,N'-((1S,1'S,2R,2'R)-(decane-1,10-diylbis(oxy))bis(2,3-dihydro-1H-indene-2,1-diyl))bis(8,8-dimethyl-4-((S)-2-(methylamino)propionamido)-5-oxooctahydropyrrolo[2,1-b][1,3]thiazepine-7-carboxamide) 58 #timg# (4S,4'S,7S,7'S,9aS,9a'S)-N,N'-((1S,1'S)-(octane-1,8-diylbis(oxy))bis(1-phenylethane-2,1-diyl))bis(8,8-dimethyl-4-((S)-2-(methylamino)propionamido)-5-oxooctahydropyrrolo[2,1-b][1,3]thiazepine-7-carboxamide) 59 #timg# (4S,4'S,7S,7'S,9aS,9a'S)-N,N'-((1S,1'S,2R,2'R)-(Dodecane-1,12-diylbis(oxy))bis(2,3-dihydro-1H-indene-2,1-diyl))bis(8,8-dimethyl-4-((S)-2-(methylamino)propionamido)-5-oxooctahydropyrrolo[2,1-b][1,3]thiazepine-7-carboxamide) 60 #timg# (4S,4'S,7S,7'S,9aS,9a'S)-N,N'-((1S,1'S)-(decane-1,10-diylbis(oxy))bis(1-phenylethane-2,1-diyl))bis(8,8-dimethyl-4-((S)-2-(methylamino)propionamido)-5-oxooctahydropyrrolo[2,1-b][1,3]thiazepine-7-carboxamide) 61 #timg# (4S,4'S,7S,7'S,9aS,9a'S)-N,N'-((1S,1'S)-(dodecane-1,12-diylbis(oxy))bis(1-phenylethane-2,1-diyl))bis(8,8-dimethyl-4-((S)-2-(methylamino)propionamido)-5-oxooctahedralpyrrolo[2,1-b][1,3]thiazepine-7-carboxamide) 62 #timg# 4S,4'S,7S,7'S,9aS,9a'S)-N,N'-((1S,1'S)-((naphthalene-2,6-diylbis(methylene))bis(oxy))bis(1-phenylethane-2,1-diyl))bis(8,8-dimethyl-4-((S)-2-(methylamino)propionamido)-5-oxooctahydropyrrolo[2,1-b][1,3]thiazepine-7-carboxamide) 63 #timg# (4S,4'S,7S,7'S,9aS,9a'S)-N,N'-((1S,1'S,2R,2'R)-(octane-1,8-diylbis(oxy))bis(2,3-dihydro-1H-indene-2,1-diyl))bis(8,8-dimethyl-4-((S)-2-(methylamino)propionamido)-5-oxooctahydropyrrolo[2,1-b][1,3]thiazepine-7-carboxamide)
[0339] In one aspect, the present invention relates to a compound selected from the group consisting of:
[0340]
[0341]
[0342]
[0343] and pharmaceutically acceptable salts thereof.
[0344] In one aspect, the present invention provides a compound selected from the group consisting of:
[0345]
[0346] and pharmaceutically acceptable salts thereof.
[0347] For all compounds 1-63 described herein, pharmaceutically acceptable salts are also within the scope of the present invention. Most preferably, each of compounds 1-63 can generally exist as a hydrochloride (i.e., HCl salt), for example, more specifically, a dihydrochloride, (2 HCl) salt. Also within the scope of the present invention is any one of compounds 1-63 present as a single species, including its pharmaceutically acceptable salt, and any one of these compounds in the free base form.
[0348] Specific examples of linking groups (L) that can be used according to the present invention include those selected from the group consisting of:
[0349]
[0350]
[0351]
[0352]
[0353] .
[0354] According to one embodiment of the present invention, a pharmaceutical composition is provided, comprising a compound of Formula (I), (Ia), (Ib), (II) or (III), or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable excipient. In another embodiment, the compound is in amorphous form. In a further embodiment, the pharmaceutical composition is in tablet form. In another embodiment, the compound is in the form of a spray-dried dispersion. In another embodiment, the composition is in the form of nanoparticles, e.g., particles having a size between 1 and 100 nanometers.
[0355] According to one embodiment of the present invention, there is provided a method of treating HIV infection in a subject, comprising administering to the subject a compound of Formula (I), (Ia), (Ib), (II) or (III) or a pharmaceutically acceptable salt thereof.
[0356] According to one embodiment of the present invention, there is provided a method of treating HIV infection in a subject, comprising administering to the subject a pharmaceutical composition as described herein.
[0357] In addition, compound of the present invention and linker (L) can exist with specific geometry or stereoisomeric form.The present invention contains all such compounds, including cis and trans isomers, (-)-and (+)-enantiomers, (R)-and (S)-enantiomers, diastereomers, (D)-isomers, (L)-isomers, their racemic mixtures, and their other mixtures, such as mixtures enriched in enantiomers or diastereomers, all fall within the scope of the present invention.Other asymmetric carbon atoms may be present in substituents such as alkyl.All such isomers, and their mixtures, are intended to be included in the present invention.
[0358] Optically active (R)- and (S)-isomers, as well as d and l isomers, can be prepared using chiral synthons or chiral reagents, or resolved using conventional techniques. For example, if a specific enantiomer of a compound of the invention is desired, it can be prepared by asymmetric synthesis or by derivatization with a chiral auxiliary, wherein the resulting diastereomeric mixture is separated and the auxiliary group is cleaved to provide the pure desired enantiomer. Alternatively, when the molecule contains a basic functional group (e.g., amino) or an acidic functional group (e.g., carboxyl), diastereomeric salts can be formed with an appropriate optically active acid or base, and the diastereomers thus formed can then be resolved by fractional crystallization or chromatographic methods known in the art, followed by recovery of the pure enantiomers. Furthermore, separation of enantiomers and diastereomers is often accomplished using chromatography using a chiral stationary phase, optionally combined with chemical derivatization (e.g., formation of carbamates from amines).
[0359] In another embodiment of the present invention, there is provided a compound of Formula I, Ia, Ib, II or III or a pharmaceutically acceptable salt thereof for use in medical therapy.
[0360] In another embodiment of the present invention, there is provided a compound of Formula I, Ia, Ib, II or III or a pharmaceutically acceptable salt thereof for use in treating HIV infection.
[0361] In another embodiment of the present invention, there is provided a compound of Formula I, Ia, Ib, II or III, wherein the compound or a salt of the compound is used in the preparation of a medicament for treating HIV infection in humans.
[0362] In one aspect, the present invention provides a method of curing a subject of HIV infection, comprising administering to the subject a compound of Formulas I, Ia, Ib, II, and III, and any compound of Table 1, and pharmaceutical salts thereof. "Curing" a patient's disease is used to mean eradicating, halting, preventing, or ending the human immunodeficiency virus (HIV) or symptoms, or progression of symptoms or virus, within a defined period of time. For example, in one embodiment, "curing" refers to inducing and maintaining sustained viral control of HIV (e.g., undetectable plasma viremia levels as determined by, for example, polymerase chain reaction (PCR) testing, bDNA (branched DNA) testing, or NASBA (nucleic acid sequence-based amplification) testing) after at least two years of therapeutic administration, alone or in combination with one or more other compounds, without any other therapeutic intervention. The aforementioned PCR, bDNA, and NASBA tests are performed using techniques known and familiar to those skilled in the art. For example, eradication, halting, preventing, or ending of the human immunodeficiency virus or symptoms, or progression of symptoms or virus, can be sustained for at least two years.
[0363] In one aspect, the present invention provides a method of curing an HIV infection in a subject, comprising administering to the subject a pharmaceutical composition comprising a compound of Formula I, Ia, Ib, II, and III, and pharmaceutical salts thereof.
[0364] In one aspect, the present invention provides the use of a compound of Formula I, Ia, Ib, II and III or a pharmaceutically acceptable salt thereof in the preparation of a medicament for curing HIV infection.
[0365] In one aspect, the present invention provides compounds of Formula I, Ia, Ib, II and III or pharmaceutically acceptable salts thereof for use in curing HIV infection.
[0366] Combinations of compounds of Formula I, Ia, Ib, II, and III with one or more agents useful in HIV therapy may also be used in methods of curing HIV infection.
[0367] In one embodiment, the pharmaceutical formulation containing a compound of Formula I, Ia, Ib, II or III, or a salt thereof, is a formulation suitable for parenteral administration. In another embodiment, the formulation is a long-acting parenteral formulation. In a further embodiment, the formulation is a nanoparticle formulation.
[0368] The compounds of the present invention, their salts, solvates, or other pharmaceutically acceptable derivatives thereof, can be used alone or in combination with other therapeutic agents. Thus, in other embodiments, the methods for treating and / or preventing HIV infection in a subject may comprise, in addition to administering a compound of Formula I, Ia, Ib, II, or III, administering one or more additional agents effective against HIV.
[0369] In such embodiments, the one or more additional agents effective against HIV are selected from antiretroviral agents, latency reversing agents, and agents used in eradication therapy.
[0370] In other embodiments, the one or more additional agents effective against HIV are selected from nucleotide reverse transcriptase inhibitors, non-nucleotide reverse transcriptase inhibitors, protease inhibitors, entry inhibitors, attachment and fusion inhibitors, integrase inhibitors, maturation inhibitors, CXCR4 and / or CCR5 inhibitors, histone deacetylase inhibitors, histone crotonyl transferase inhibitors, protein kinase C agonists, proteasome inhibitors, TLR7 agonists, bromodomain inhibitors and neutralizing antibodies, and combinations thereof.
[0371] In certain embodiments, the one or more additional agents effective against HIV are selected from zidovudine, didanosine, lamivudine, zalcitabine, abacavir, stavudine, adefovir, adefovir dipivoxil, fozivudine, todoxil, emtricitabine, alovudine, amdosovir, Elfcitabine, nevirapine, delavirdine, efavirenz, loviride, immunocal, oltipraz, caprovirine, lesvirine, GSK2248761, TMC-278, TMC-125, etravirine, saquinavir, ritonavir, indinavir, nelfinavir, amprenavir, fosamprenavir, becanavir, darunavir, atazanavir, tipranavir, palinavir, rasinavir, enfuvirtide, T-20, T-1249, PRO-542, PRO-140, TNX-355, BMS-806, BMS-663068 and BMS-626529, 5-Helix, raltegravir, elvitegravir, dolutegravir, cabotegravir, bicagvir, vicriviroc (Sch-C), Sch-D, TAK779, maraviroc, TAK449, didanosine, tenofovir, lopinavir, darunavir, vorinostat, panobinostat, romidepsin, valproic acid, mocetinostat, sodium corotonate, bryostatin, ingenol B, disulforam, GS-9620, JQ1, iBET151, bortezomib, epigallocatechin gallate, salinosporamide A, carfilzomib, broadly neutralizing antibodies (bNAbs), eCD4-Ig, CD4-Ig, and dual-affinity retargeting (DART) proteins.
[0372] Thus, the compounds of Formula (I), (Ia), (Ib), (II) or (III) and any other pharmaceutically active agents may be administered together or separately, and when administered separately, administration may occur simultaneously or sequentially in any order. The amounts of the compounds of Formula (I), (Ia), (Ib), (II) or (III) and the other pharmaceutically active agents of the present invention and the relative timing of administration are selected to achieve the desired combined therapeutic effect. The combined administration of the compounds of Formula (I), (Ia), (Ib), (II) or (III) and their salts, solvates or other pharmaceutically acceptable derivatives with the other therapeutic agents may be combined by simultaneous administration in: (1) a single pharmaceutical composition comprising both compounds; or (2) separate pharmaceutical compositions, each comprising one compound. Alternatively, the combination may be administered separately in a sequential manner, wherein one therapeutic agent is administered first and then the other, or vice versa. Such sequential administration may be close in time or distant in time. The amounts of the compound of Formula I, Ia, Ib, II or III, or a salt thereof, and the other pharmaceutically active agent, and the relative times of administration are selected to achieve the desired combined therapeutic effect.
[0373] In addition, the compounds of Formula (I), (Ia), (Ib), (II) or (III) may be used in combination with one or more other agents useful for treating HIV. These agents may include antiretroviral agents, latency reversal agents, and agents used in clearance therapy. Several examples of antiretroviral agents are provided below:
[0374] Nucleotide reverse transcriptase inhibitors, For example, zidovudine, didanosine, lamivudine, zalcitabine, abacavir, stavudine, adefovir, adefovir dipivoxil, fozivudine, todoxil, emtricitabine, alovudine, amdosovir, efavirenz, and similar agents;
[0375] Non-nucleotidic reverse transcriptase inhibitors (including agents with antioxidant activity, such as immunocal, oltipraz, etc.), such as nevirapine, delavirdine, efavirenz, loviride, immunocal, oltipraz, capravirine, lesivirine, GSK2248761, TMC-278, TMC-125, etravirine and similar agents;
[0376] protease inhibitors, For example, saquinavir, ritonavir, indinavir, nelfinavir, amprenavir, fosamprenavir, brenavir, darunavir, atazanavir, tipranavir, palinavir, rasinavir, and similar agents;
[0377] Entry, attachment, and fusion inhibitors,For example, enfuvirtide (T-20), T-1249, PRO-542, PRO-140, TNX-355, BMS-806, BMS-663068 and BMS-626529, 5-Helix, and similar agents;
[0378] Integrase inhibitors, Examples include raltegravir, elvitegravir, dolutegravir, cabotegravir, bicagvir, and similar agents;
[0379] Maturation inhibitors , such as PA-344 and PA-457, and similar agents; and
[0380] CXCR4 and / or CCR5 inhibitors, For example, vicriviroc (Sch-C), Sch-D, TAK779, maraviroc (UK 427,857), TAK449, and those disclosed in WO 02 / 74769, PCT / US03 / 39644, PCT / US03 / 39975, PCT / US03 / 39619, PCT / US03 / 39618, PCT / US03 / 39740 and PCT / US03 / 39732, and similar agents.
[0381] Further examples in which the compounds of the present invention can be used in combination with one or more agents useful for preventing or treating HIV are shown in Table 2.
[0382] Table 2.
[0383] FDA approval Trademark Name Common name Manufacturer 1987 Retrovir Zidovudine, azidothymidine, AZT, ZDV GlaxoSmithKline 1991 Videx Didanosine, dideoxyinosine, ddI Bristol-Myers Squibb 1992 Hivid Zalcitabine, dideoxycytidine, ddC Roche Pharmaceuticals 1994 Zerit Stavudine, d4T Bristol-Myers Squibb 1995 Epivir Lamivudine, 3TC GlaxoSmithKline 1997 Combivir Lamivudine + Zidovudine GlaxoSmithKline 1998 Ziagen Abacavir sulfate, ABC GlaxoSmithKline 2000 Trizivir Abacavir + lamivudine + zidovudine GlaxoSmithKline 2000 Videx EC Enteric-coated didanosine, ddI EC Bristol-Myers Squibb 2001 Viread Tenofovir disoproxil fumarate, TDF Gilead Sciences 2003 Emtriva Emtricitabine, FTC Gilead Sciences 2004 Epzicom Abacavir + lamivudine GlaxoSmithKline 2004 Truvada Emtricitabine + Tenofovir Disoproxil Fumarate Gilead Sciences 1996 Viramune Nevirapine, NVP Boehringer Ingelheim 1997 Rescriptor Delavirdine, DLV Pfizer 1998 Sustiva Efavirenz, EFV Bristol-Myers Squibb 2008 Intelence Etravirine Tibotec Therapeutics 1995 Invirase Saquinavir mesylate, SQV Roche Pharmaceuticals 1996 Norvir Ritonavir, RTV Abbott Laboratories 1996 Crixivan Indinavir, IDV Merck 1997 Viracept Nelfinavir mesylate, NFV Pfizer 1997 Fortovase Saquinavir (no longer sold) Roche Pharmaceuticals 1999 Agenerase Amprenavir, APV GlaxoSmithKline 2000 Kaletra Lopinavir + ritonavir, LPV / RTV Abbott Laboratories 2003 Reyataz Atazanavir sulfate, ATV Bristol-Myers Squibb 2003 Lexiva Fosamprenavir calcium, FOS-APV GlaxoSmithKline 2005 Aptivus tripranavir, TPV Boehringer Ingelheim 2006 Prezista Darunavir Tibotec Therapeutics 2003 Fuzeon Enfuvirtide, T-20 Roche Pharmaceuticals & Trimeris 2007 Selzentry Maravero Pfizer 2007 Isentress Raltegravir Merck 2013 Tivicay Dolutegravir ViiV Healthcare --- --- Cabotegravir
[0384] The present invention can be used in combination with other agents that induce HIV expression, such as latency-reversing agents. Several latency-reversing agents include, but are not limited to, histone deacetylase inhibitors (e.g., vorinostat, panobinostat, romidepsin), histone crotonyltransferase inhibitors (sodium corotonate), protein kinase C agonists (e.g., bryostatin, ingenolB), disulfiram, TLR7 agonists (e.g., GS-9620), and bromodomain inhibitors (e.g., JQ1, iBET151). Many of these agents are described in more detail below.
[0385] The present invention can be used in combination with other agents that induce HIV expression, such as agents used for clearance therapy. Several examples of agents used for clearance therapy or agents used in immune combinations for clearance include, but are not limited to, neutralizing and broadly neutralizing antibodies (bNAbs), eCD4-Ig, CD4-Ig, and dual-affinity retargeting (DART) proteins.
[0386] The scope of combinations of the compounds of the present invention with HIV agents is not limited to those described above, but in principle includes any combination with any pharmaceutical composition useful for treating and / or preventing HIV. As noted, in such combinations, the compounds of the present invention and the other HIV agent may be administered separately or in combination. In addition, one agent may be administered before, simultaneously with, or after the administration of the other agent.
[0387] The present invention can be used in combination with one or more agents that can act as pharmacological enhancers, and with or without additional compounds for the prevention or treatment of HIV. Examples of such pharmacological enhancers (or pharmacokinetic enhancers) include, but are not limited to, ritonavir, GS-9350 (cobicistat), and SPI-452.
[0388] Ritonavir is 10-hydroxy-2-methyl-5-(1-methylethyl)-1-[2-(1-methylethyl)-4-thiazolyl]-3,6-dioxo-8,11-bis(phenylmethyl)-2,4,7,12-tetraazatridecan-13-oic acid, 5-thiazolylmethyl ester, [5S-(5S*,8R*,10R*,11R*)] and is available as Norvir from Abbott Laboratories in Abbott Park, Illinois. Ritonavir is an HIV protease inhibitor used in combination with other antiretroviral agents to treat HIV infection. Ritonavir also inhibits P450-mediated drug metabolism and the P-glycoprotein (Pgp) cellular transport system, resulting in increased concentrations of the active compound in vivo.
[0389] GS-9350 (cobicistat) is a compound being developed by Gilead Sciences of Foster City, California, as a pharmacological enhancer.
[0390] SPI-452 is a compound being developed by Sequoia Pharmaceuticals in Gaithersburg, Maryland, as a pharmacological enhancer.
[0391] In one embodiment of the invention, the compound of Formula I, Ia, Ib, II or III is used in combination with ritonavir. In one embodiment, the combination is an oral fixed dose combination. In another embodiment, the compound of Formula I, Ia, Ib, II or III is formulated into a long-acting parenteral injection, and ritonavir is formulated into an oral composition. In one embodiment, the medicine box containing the compound of Formula I, Ia, Ib, II or III is formulated into a long-acting parenteral injection, and ritonavir is formulated into an oral composition. In another embodiment, the compound of Formula I, Ia, Ib, II or III is formulated into a long-acting parenteral injection, and ritonavir is formulated into an injectable composition. In one embodiment, the medicine box containing the compound of Formula I, Ia, Ib, II or III is formulated into a long-acting parenteral injection, and ritonavir is formulated into an injectable composition.
[0392] In another embodiment of the present invention, a compound of Formula I, Ia, Ib, II or III is used in combination with GS-9350. In one embodiment, the combination is an oral fixed dose combination. In another embodiment, the compound of Formula I, Ia, Ib, II or III is formulated as a long-acting parenteral injection, and GS-9350 is formulated as an oral composition. In one embodiment, a medicine kit is provided, comprising a compound of Formula I, Ia, Ib, II or III formulated as a long-acting parenteral injection and GS-9350 formulated as an oral composition. In another embodiment, a compound of Formula I, Ia, Ib, II or III is formulated as a long-acting parenteral injection, and GS-9350 is formulated as an injectable composition. In one embodiment, a medicine kit is provided, comprising a compound of Formula I, Ia, Ib, II or III formulated as a long-acting parenteral injection and GS-9350 formulated as an injectable composition.
[0393] In one embodiment of the present invention, a compound of Formula I, Ia, Ib, II or III is used in combination with SPI-452. In one embodiment, the combination is an oral fixed dose combination. In another embodiment, the compound of Formula I, Ia, Ib, II or III is formulated as a long-acting parenteral injection, and SPI-452 is formulated as an oral composition. In one embodiment, a kit is provided, comprising a compound of Formula I, Ia, Ib, II or III formulated as a long-acting parenteral injection and SPI-452 formulated as an oral composition. In another embodiment, a compound of Formula I, Ia, Ib, II or III is formulated as a long-acting parenteral injection, and SPI-452 is formulated as an injectable composition. In one embodiment, a kit is provided, comprising a compound of Formula I, Ia, Ib, II or III formulated as a long-acting parenteral injection and SPI-452 formulated as an injectable composition.
[0394] In one embodiment of the present invention, the compound of Formula I, Ia, Ib, II or III is used in combination with compounds found in previously filed PCT / CN2011 / 0013021, which is incorporated herein by reference.
[0395] The aforementioned additional therapeutic agents, when used in combination with the chemical entities described herein, can be used, for example, in amounts such as those indicated in the Physicians' Desk Reference (PDR) or as otherwise determined by one of ordinary skill in the art.
[0396] In another embodiment of the invention, a method of treating a viral infection in a mammal mediated at least in part by a virus of the Retroviridae family is provided, comprising administering to a mammal diagnosed with or at risk of developing said viral infection a compound of Formula I, Ia, Ib, II or III.
[0397] In another embodiment of the present invention, there is provided a method for treating a viral infection in a mammal mediated at least in part by a virus in the retroviral family, the method comprising administering a compound of Formula I, Ia, Ib, II or III to a mammal diagnosed with or at risk of developing said viral infection, wherein said virus is HIV virus. In some embodiments, the HIV virus is HIV-1 virus.
[0398] In another embodiment of the present invention, a method of treating a viral infection in a mammal mediated at least in part by a virus of the Retroviridae family is provided, the method comprising administering to a mammal diagnosed with or at risk of developing said viral infection a compound of Formula I, Ia, Ib, II or III, and further comprising administering a therapeutically effective amount of one or more agents effective against HIV.
[0399] In another embodiment of the present invention, a method for treating a viral infection in a mammal that is mediated at least in part by a virus in the retroviridae family is provided, the method comprising administering to a mammal diagnosed with or at risk of developing the viral infection a compound of Formula I, Ia, Ib, II or III, and further comprising administering a therapeutically effective amount of one or more agents effective against HIV, wherein the agents effective against HIV are selected from the group consisting of nucleotide reverse transcriptase inhibitors; non-nucleotide reverse transcriptase inhibitors; protease inhibitors; entry, attachment and fusion inhibitors; integrase inhibitors; maturation inhibitors; CXCR4 inhibitors; and CCR5 inhibitors.
[0400] In another aspect, the present invention provides a method of depleting latent HIV-infected cells comprising administering to a subject a compound of Formula (I), (Ia), (Ib), (II) or (III) or a pharmaceutically acceptable salt thereof.
[0401] In various embodiments of the above methods, Alk, Alk2, and Alk3 are each represented by the following formula:
[0402] .
[0403] In various embodiments of the above methods, Ar1, Ar2, Ar3, Ar4, Ar5, Ar6, Ar7, Ar8, Ar9, Ar 10 、Ar 11 、Ar 21 、Ar 22 、Ar 23 、Ar 24 、Ar 25 and Ar 26 It is a C6 aryl group.
[0404] In various embodiments of the above invention, Ar 12 、Ar 13 、Ar 14 and Ar 15 、Ar 16 、Ar 17 、Ar 18 and Ar 19 Each is a C9 aryl group.
[0405] In various embodiments of the above invention, Ar 16 、Ar 17 、Ar 18 and Ar 19 Each is C 10 Aryl.
[0406] In various embodiments of the above invention, the linker (L) is selected from the following:
[0407]
[0408]
[0409]
[0410]
[0411] .
[0412] In various embodiments of the above invention, the compound is selected from:
[0413] #timg# (S,4S,4'S,7S,7'S,9aS,9a'S)-N,N'-(methylenebis(4,1-phenylene))bis(8,8-dimethyl-4-((S)-2-(methylamino)propionamido)-5-oxooctahedralpyrrolo[2,1-b][1,3]thiazepine-7-carboxamide) #timg# (S,4S,4'S,7S,7'S,9aS,9a'S)-N,N'-(methylenebis(4,1-phenylene))bis(8,8-dimethyl-4-((S)-2-(methylamino)propanethioamido)-5-oxooctahydropyrrolo[2,1-b][1,3]thiazepine-7-carboxamide) #timg# (S,4S,4'S,7S,7'S,9aS,9a'S)-N,N'-(ethane-1,2-diylbis(2,1-phenylene))bis(8,8-dimethyl-4-((S)-2-(methylamino)propionamido)-5-oxooctahydropyrrolo[2,1-b][1,3]thiazepine-7-carboxamide) #timg# (S,4S,4'S,7S,7'S,9aS,9a'S)-N,N'-(ethane-1,2-diylbis(2,1-phenylene))bis(8,8-dimethyl-4-((S)-2-(methylamino)propanethioamido)-5-oxooctahydropyrrolo[2,1-b][1,3]thiazepine-7-carboxamide) #timg# (S,4S,4'S,7S,7'S,9aS,9a'S)-N,N'-(ethane-1,2-diylbis(4,1-phenylene))bis(8,8-dimethyl-4-((S)-2-(methylamino)propionamido)-5-oxooctahydropyrrolo[2,1-b][1,3]thiazepine-7-carboxamide) #timg# (S,4S,4'S,7S,7'S,9aS,9a'S)-N,N'-(ethane-1,2-diylbis(4,1-phenylene))bis(8,8-dimethyl-4-((S)-2-(methylamino)propanethioamido)-5-oxooctahydropyrrolo[2,1-b][1,3]thiazepine-7-carboxamide) #timg# (S,4S,4'S,7S,7'S,9aS,9a'S)-N,N'-((1R,1'R,2R,2'R)-(piperazine-1,4-dicarbonyl)bis(1,2,3,4-tetrahydronaphthalene-2,1-diyl))bis(8,8-dimethyl-4-((S)-2-(methylamino)propionamido)-5-oxooctahydropyrrolo[2,1-b][1,3]thiazepine-7-carboxamide) #timg# (S,4S,4'S,7S,7'S,9aS,9a'S)-N,N'-((1R,1'R,2R,2'R)-(piperazine-1,4-dicarbonyl)bis(1,2,3,4-tetrahydronaphthalene-2,1-diyl))bis(8,8-dimethyl-4-((S)-2-(methylamino)propanethioamido)-5-oxooctahydropyrrolo[2,1-b][1,3]thiazepine-7-carboxamide) #timg# (S,4S,4'S,7S,7'S,9aS,9a'S)-N,N'-((1R,1'R,2R,2'R)-(((1,4-phenylenebis(methylene))bis(azanediyl))bis(carbonyl))bis(1,2,3,4-tetrahydronaphthalene-2,1-diyl))bis(8,8-dimethyl-4-((S)-2-(methylamino)propionamido)-5-oxooctahydropyrrolo[2,1-b][1,3]thiazepine-7-carboxamide) #timg# (S,4S,4'S,7S,7'S,9aS,9a'S)-N,N'-((1R,1'R,2R,2'R)-(((1,4-phenylenebis(methylene))bis(azanediyl))bis(carbonyl))bis(1,2,3,4-tetrahydronaphthalene-2,1-diyl))bis(8,8-dimethyl-4-((S)-2-(methylamino)propanethioamido)-5-oxooctahydropyrrolo[2,1-b][1,3]thiazepine-7-carboxamide) #timg# (S,4S,4'S,7S,7'S,9aS,9a'S)-N,N'-((1R,1'R,2R,2'R)-(((1R,4R)-cyclohexane-1,4-diylbis(azanediyl))bis(carbonyl))bis(1,2,3,4-tetrahydronaphthalene-2,1-diyl))bis(8,8-dimethyl-4-((S)-2-(methylamino)propionamido)-5-oxooctahydropyrrolo[2,1-b][1,3]thiazepine-7-carboxamide) #timg# (S,4S,4'S,7S,7'S,9aS,9a'S)-N,N'-((1R,1'R,2R,2'R)-(((1R,4R)-cyclohexane-1,4-diylbis(azanediyl))bis(carbonyl))bis(1,2,3,4-tetrahydronaphthalene-2,1-diyl))bis(8,8-dimethyl-4-((S)-2-(methylamino)propanethioamido)-5-oxooctahydropyrrolo[2,1-b][1,3]thiazepine-7-carboxamide) #timg# (S,4S,4'S,7S,7'S,9aS,9a'S)-N,N'-((1S,1'S,2R,2'R)-(hexane-2,4-diyn-1,6-diylbis(oxy))bis(2,3-dihydro-1H-indene-2,1-diyl))bis(8,8-dimethyl-4-((S)-2-(methylamino)propionamido)-5-oxooctahydropyrrolo[2,1-b][1,3]thiazepine-7-carboxamide) #timg# (4S,7S,9aS)-N-((1S,2R)-2-((6-(((1S,2R)-1-((4S,7S,9aS)-8,8-dimethyl-4-((S)-2-(methylamino)propionamido)-5-oxooctahydropyrrolo[2,1-b][1,3]thiazepin-7-carboxamido)-2,3-dihydro-1H-inden-2-yl)oxy)hexa-2,4-diyn-1-yl)oxy)-2,3-dihydro-1H-inden-1-yl)-8,8-dimethyl-4-((S)-2-(methylamino)propanethioamido)-5-oxooctahydropyrrolo[2,1-b][1,3]thiazepin-7-carboxamide #timg# (S,4S,4'S,7S,7'S,9aS,9a'S)-N,N'-((1S,1'S,2R,2'R)-(hexane-2,4-diyn-1,6-diylbis(oxy))bis(2,3-dihydro-1H-indene-2,1-diyl))bis(8,8-dimethyl-4-((S)-2-(methylamino)propanethioamido)-5-oxooctahydropyrrolo[2,1-b][1,3]thiazepine-7-carboxamide) #timg# (S,4S,4'S,7S,7'S,9aS,9a'S)-N,N'-((1S,1'S,2R,2'R)-(butane-1,4-diylbis(oxy))bis(2,3-dihydro-1H-indene-2,1-diyl))bis(8,8-dimethyl-4-((S)-2-(methylamino)propionamido)-5-oxooctahydropyrrolo[2,1-b][1,3]thiazepine-7-carboxamide) #timg# (S,4S,4'S,7S,7'S,9aS,9a'S)-N,N'-((1S,1'S,2R,2'R)-(butane-1,4-diylbis(oxy))bis(2,3-dihydro-1H-indene-2,1-diyl))bis(8,8-dimethyl-4-((S)-2-(methylamino)propanethioamido)-5-oxooctahydropyrrolo[2,1-b][1,3]thiazepine-7-carboxamide) #timg# (S,4S,4'S,7S,7'S,9aS,9a'S)-N,N'-((1S,1'S,2R,2'R)-((oxybis(ethane-2,1-diyl))bis(oxy))bis(2,3-dihydro-1H-indene-2,1-diyl))bis(8,8-dimethyl-4-((S)-2-(methylamino)propionamido)-5-oxooctahydropyrrolo[2,1-b][1,3]thiazepine-7-carboxamide) #timg# (S,4S,4'S,7S,7'S,9aS,9a'S)-N,N'-((1S,1'S,2R,2'R)-((oxybis(ethane-2,1-diyl))bis(oxy))bis(2,3-dihydro-1H-indene-2,1-diyl))bis(8,8-dimethyl-4-((S)-2-(methylamino)propanethioamido)-5-oxooctahydropyrrolo[2,1-b][1,3]thiazepine-7-carboxamide) #timg# (S,4S,4'S,7S,7'S,9aS,9a'S)-N,N'-((1S,1'S,2R,2'R)-(hexane-1,6-diylbis(oxy))bis(2,3-dihydro-1H-indene-2,1-diyl))bis(8,8-dimethyl-4-((S)-2-(methylamino)propionamido)-5-oxooctahydropyrrolo[2,1-b][1,3]thiazepine-7-carboxamide) #timg# (S,4S,4'S,7S,7'S,9aS,9a'S)-N,N'-((1S,1'S,2R,2'R)-(hexane-1,6-diylbis(oxy))bis(2,3-dihydro-1H-indene-2,1-diyl))bis(8,8-dimethyl-4-((S)-2-(methylamino)propanethioamido)-5-oxooctahydropyrrolo[2,1-b][1,3]thiazepine-7-carboxamide) #timg# (S,4S,4'S,7S,7'S,9aS,9a'S)-N,N'-((1S,1'S,2R,2'R)-((1,4-phenylenebis(methylene))bis(oxy))bis(2,3-dihydro-1H-indene-2,1-diyl))bis(8,8-dimethyl-4-((S)-2-(methylamino)propionamido)-5-oxooctahydropyrrolo[2,1-b][1,3]thiazepine-7-carboxamide) #timg# (S,4S,4'S,7S,7'S,9aS,9a'S)-N,N'-((1S,1'S,2R,2'R)-((1,4-phenylenebis(methylene))bis(oxy))bis(2,3-dihydro-1H-indene-2,1-diyl))bis(8,8-dimethyl-4-((S)-2-(methylamino)propanethioamido)-5-oxooctahydropyrrolo[2,1-b][1,3]thiazepine-7-carboxamide) #timg# (S,4S,4'S,7S,7'S,9aS,9a'S)-N,N'-((1S,1'S)-((1,4-phenylenebis(methylene))bis(azanediyl))bis(2-oxo-1-phenylethane-2,1-diyl))bis(8,8-dimethyl-4-((S)-2-(methylamino)propionamido)-5-oxooctahedralpyrrolo[2,1-b][1,3]thiazepine-7-carboxamide) #timg# (S,4S,4'S,7S,7'S,9aS,9a'S)-N,N'-((1S,1'S)-((1,4-phenylenebis(methylene))bis(azanediyl))bis(2-oxo-1-phenylethane-2,1-diyl))bis(8,8-dimethyl-4-((S)-2-(methylamino)propanethioamido)-5-oxooctahedralpyrrolo[2,1-b][1,3]thiazepine-7-carboxamide) #timg# (S,4S,4'S,7S,7'S,9aS,9a'S)-N,N'-((1S,1'S)-piperazine-1,4-diylbis(2-oxo-1-phenylethane-2,1-diyl))bis(8,8-dimethyl-4-((S)-2-(methylamino)propionamido)-5-oxooctahedralpyrrolo[2,1-b][1,3]thiazepine-7-carboxamide) #timg# (S,4S,4'S,7S,7'S,9aS,9a'S)-N,N'-((1S,1'S)-piperazine-1,4-diylbis(2-oxo-1-phenylethane-2,1-diyl))bis(8,8-dimethyl-4-((S)-2-(methylamino)propanethioamido)-5-oxooctahedralpyrrolo[2,1-b][1,3]thiazepine-7-carboxamide) #timg# (S,4S,4'S,7S,7'S,9aS,9a'S)-N,N'-((1S,1'S)-((1S,4S)-cyclohexane-1,4-diylbis(azanediyl))bis(2-oxo-1-phenylethane-2,1-diyl))bis(8,8-dimethyl-4-((S)-2-(methylamino)propionamido)-5-oxooctahedralpyrrolo[2,1-b][1,3]thiazepine-7-carboxamide) #timg# (S,4S,4'S,7S,7'S,9aS,9a'S)-N,N'-((1S,1'S)-((1S,4S)-cyclohexane-1,4-diylbis(azanediyl))bis(2-oxo-1-phenylethane-2,1-diyl))bis(8,8-dimethyl-4-((S)-2-(methylamino)propanethioamido)-5-oxooctahedralpyrrolo[2,1-b][1,3]thiazepine-7-carboxamide) #timg# (S,4S,4'S,7S,7'S,9aS,9a'S)-N,N'-((1S,1'S)-(hexane-2,4-diyn-1,6-diylbis(azanediyl))bis(2-oxo-1-phenylethane-2,1-diyl))bis(8,8-dimethyl-4-((S)-2-(methylamino)propionamido)-5-oxooctahedralpyrrolo[2,1-b][1,3]thiazepine-7-carboxamide) #timg# (4S,7S,9aS)-N-((S)-2-((6-((S)-2-((4S,7S,9aS)-8,8-dimethyl-4-((S)-2-(methylamino)propionamido)-5-oxooctahydropyrrolo[2,1-b][1,3]thiazepine-7-carboxamido)-2-phenylacetamido)hexa-2,4-diyn-1-yl)amino)-2-oxo-1-phenylethyl)-8,8-dimethyl-4-((S)-2-(methylamino)propanethioamido)-5-oxooctahydropyrrolo[2,1-b][1,3]thiazepine-7-carboxamide #timg# (S,4S,4'S,7S,7'S,9aS,9a'S)-N,N'-((1S,1'S)-(hexane-2,4-diyn-1,6-diylbis(azanediyl))bis(2-oxo-1-phenylethane-2,1-diyl))bis(8,8-dimethyl-4-((S)-2-(methylamino)propanethioamido)-5-oxooctahedralpyrrolo[2,1-b][1,3]thiazepine-7-carboxamide) #timg# (S,4S,4'S,7S,7'S,9aS,9a'S)-N,N'-((1S,1'S)-(hexane-2,4-diyn-1,6-diylbis(oxy))bis(1-phenylethane-2,1-diyl))bis(8,8-dimethyl-4-((S)-2-(methylamino)propionamido)-5-oxooctahedralpyrrolo[2,1-b][1,3]thiazepine-7-carboxamide) #timg# (4S,7S,9aS)-N-((S)-2-((6-((S)-2-((4S,7S,9aS)-8,8-dimethyl-4-((S)-2-(methylamino)propionamido)-5-oxooctahydropyrrolo[2,1-b][1,3]thiazepine-7-carboxamido)-2-phenylethoxy)hexa-2,4-diyn-1-yl)oxy)-1-phenylethyl)-8,8-dimethyl-4-((S)-2-(methylamino)propanethioamido)-5-oxooctahydropyrrolo[2,1-b][1,3]thiazepine-7-carboxamide #timg# (S,4S,4'S,7S,7'S,9aS,9a'S)-N,N'-((1S,1'S)-(hexane-2,4-diyn-1,6-diylbis(oxy))bis(1-phenylethane-2,1-diyl))bis(8,8-dimethyl-4-((S)-2-(methylamino)propanethioamido)-5-oxooctahydropyrrolo[2,1-b][1,3]thiazepine-7-carboxamide) #timg# (S,4S,4'S,7S,7'S,9aS,9a'S)-N,N'-((1S,1'S)-(butane-1,4-diylbis(oxy))bis(1-phenylethane-2,1-diyl))bis(8,8-dimethyl-4-((S)-2-(methylamino)propionamido)-5-oxooctahydropyrrolo[2,1-b][1,3]thiazepine-7-carboxamide) #timg# (S,4S,4'S,7S,7'S,9aS,9a'S)-N,N'-((1S,1'S)-(butane-1,4-diylbis(oxy))bis(1-phenylethane-2,1-diyl))bis(8,8-dimethyl-4-((S)-2-(methylamino)propanethioamido)-5-oxooctahydropyrrolo[2,1-b][1,3]thiazepine-7-carboxamide) #timg# (S,4S,4'S,7S,7'S,9aS,9a'S)-N,N'-((1S,1'S)-((oxybis(ethane-2,1-diyl))bis(oxy))bis(1-phenylethane-2,1-diyl))bis(8,8-dimethyl-4-((S)-2-(methylamino)propionamido)-5-oxooctahedralopyrrolo[2,1-b][1,3]thiazepine-7-carboxamide) #timg# (S,4S,4'S,7S,7'S,9aS,9a'S)-N,N'-((1S,1'S)-((oxybis(ethane-2,1-diyl))bis(oxy))bis(1-phenylethane-2,1-diyl))bis(8,8-dimethyl-4-((S)-2-(methylamino)propanethioamido)-5-oxooctahydropyrrolo[2,1-b][1,3]thiazepine-7-carboxamide) #timg# (S,4S,4'S,7S,7'S,9aS,9a'S)-N,N'-((1S,1'S)-(hexane-1,6-diylbis(oxy))bis(1-phenylethane-2,1-diyl))bis(8,8-dimethyl-4-((S)-2-(methylamino)propionamido)-5-oxooctahedralpyrrolo[2,1-b][1,3]thiazepine-7-carboxamide) #timg# (S,4S,4'S,7S,7'S,9aS,9a'S)-N,N'-((1S,1'S)-(hexane-1,6-diylbis(oxy))bis(1-phenylethane-2,1-diyl))bis(8,8-dimethyl-4-((S)-2-(methylamino)propanethioamido)-5-oxooctahydropyrrolo[2,1-b][1,3]thiazepine-7-carboxamide) #timg# (S,4S,4'S,7S,7'S,9aS,9a'S)-N,N'-((1S,1'S)-((1,4-phenylenebis(methylene))bis(oxy))bis(1-phenylethane-2,1-diyl))bis(8,8-dimethyl-4-((S)-2-(methylamino)propionamido)-5-oxooctahydropyrrolo[2,1-b][1,3]thiazepine-7-carboxamide) #timg# (S,4S,4'S,7S,7'S,9aS,9a'S)-N,N'-((1S,1'S)-((1,4-phenylenebis(methylene))bis(oxy))bis(1-phenylethane-2,1-diyl))bis(8,8-dimethyl-4-((S)-2-(methylamino)propanethioamido)-5-oxooctahydropyrrolo[2,1-b][1,3]thiazepine-7-carboxamide)
[0414] In various embodiments of the above methods, X1 and X2 are each O, preferably for formulas (Ia) and (Ib).
[0415] In various embodiments of the above methods, in the linker (L), Ar1, Ar2, Ar3, Ar4, Ar5, Ar6, Ar7, Ar8, Ar9, Ar 10 、Ar 11 、Ar 20 、Ar 21 、Ar 22 、Ar 23 and Ar 24 It is a C6 aryl group.
[0416] In various embodiments of the above methods, the linker (L) is selected from (i) and (v).
[0417] In various embodiments of the above methods, m, n, p and q are each 1 and each (CH2) in formula (v) 0-3 The group is represented by (CH2).
[0418] In various embodiments of the above methods and compounds, the linker (L) is selected from the group consisting of:
[0419] .
[0420] In various embodiments of the above methods, the linker (L) is selected from (vi) and (vii), and Ar 12 、Ar 13 、Ar 14 and Ar 15 Each is a C9 aryl group.
[0421] In various embodiments of the above methods, Ar 12 and Ar 14 Each is ,
[0422] And Ar 13 and Ar 15 Each is , where the wavy lines represent connection points.
[0423] In various embodiments of the above methods, the linker (L) is selected from the group consisting of:
[0424] .
[0425] In one embodiment of the present invention, the present invention relates to a compound of the following formula (Compound 13):
[0426]
[0427] or a pharmaceutically acceptable salt thereof. The present invention also includes pharmaceutical compositions comprising the compound or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable excipient, including, for example, those described herein. The present invention also includes methods of treating HIV infection in a subject, comprising administering the compound or a pharmaceutically acceptable salt thereof, and combinations thereof to the subject. The present invention also includes the compound or a pharmaceutically acceptable salt thereof for use in treating HIV infection. The present invention also includes use of the compound in the preparation of a medicament for treating HIV infection. The present invention also includes methods of depleting latent HIV-infected cells, comprising administering the compound or a pharmaceutically acceptable salt thereof, and combinations thereof to a subject.
[0428] In one embodiment of the present invention, the present invention relates to a compound of the following formula (Compound 20):
[0429]
[0430] or a pharmaceutically acceptable salt thereof. The present invention also includes pharmaceutical compositions comprising the compound or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable excipient, including, for example, those described herein. The present invention also includes methods of treating HIV infection in a subject, comprising administering the compound or a pharmaceutically acceptable salt thereof, and combinations thereof to the subject. The present invention also includes the compound or a pharmaceutically acceptable salt thereof for use in treating HIV infection. The present invention also includes use of the compound in the preparation of a medicament for treating HIV infection. The present invention also includes methods of depleting latent HIV-infected cells, comprising administering the compound or a pharmaceutically acceptable salt thereof, and combinations thereof to a subject.
[0431] In various embodiments, the method of depleting latent HIV infection further comprises administering to the subject one or more additional agents effective against HIV as disclosed above. For example, in various embodiments, the one or more additional agents are selected from nucleotide reverse transcriptase inhibitors, non-nucleotide reverse transcriptase inhibitors, protease inhibitors, entry inhibitors, attachment and fusion inhibitors, integrase inhibitors, maturation inhibitors, CXCR4 and / or CCR5 inhibitors, histone deacetylase inhibitors, histone crotonyl transferase inhibitors, protein kinase C agonists, proteasome inhibitors, TLR7 agonists, bromodomain inhibitors, and antibodies for depletion therapy, and combinations thereof. In various embodiments, the one or more additional agents effective against HIV are selected from zidovudine, didanosine, lamivudine, zalcitabine, abacavir, stavudine, adefovir, adefovir dipivoxil, fozivudine, todoxil, emtricitabine, alovudine, amidosavir, efavirenz, nevirapine, delavirdine, efavirenz, loviride, imipenem, opticraf, caprovirin, lesvirin, GSK2248761, TMC-278, TMC-125, etravirine, Saquinavir, ritonavir, indinavir, nelfinavir, amprenavir, fosamprenavir, becanavir, darunavir, atazanavir, tipranavir, palinavir, lasinavir, enfuvirtide, T-20, T-1249, PRO-542, PRO-140, TNX-355, BMS-806, BMS-663068 and BMS-626529, 5-Helix, raltegravir, elvitegravir, dolutegravir, cabotegravir, bicagvir, vicriviroc (Sch-C), Sch-D, TAK779, maraviroc, TAK449, didanosine, tenofovir, lopinavir, darunavir, vorinostat, panobinostat, romidepsin, valproic acid, mocetinostat, sodium corotonate, bryostatin, ingenol B, disulforam, GS-9620, JQ1, iBET151, bortezomib, epigallocatechin gallate, salinosporamide A, carfilzomib, and neutralizing antibodies, eCD4-Ig, CD4-Ig, bNAb, DARTS, and IgA.
[0432] The compounds according to formula I, Ia, Ib, II and III and their pharmaceutically acceptable salts are useful in the treatment of cancer, precancerous syndromes. Suitably, the present invention relates to a method of treating a cancer selected from the group consisting of brain (glioma), glioblastoma, astrocytoma, glioblastoma multiforme, Bannayan-Zonana syndrome, Cowden disease, Lhermitte-Duclos disease, Wilms' tumor, Ewing's sarcoma, rhabdomyosarcoma, ependymoma, medulloblastoma, head and neck cancer, kidney cancer, liver cancer, melanoma, ovarian cancer, pancreatic cancer, adenocarcinoma, ductal adenocarcinoma, adenosquamous carcinoma, acinar cell carcinoma, glucagonoma, insulinoma, prostate cancer, sarcoma, osteosarcoma, giant cell tumor of bone, thyroid cancer, lymphoblastic T-cell leukemia, chronic myeloid leukemia, chronic lymphocytic leukemia, hairy cell leukemia, acute lymphoblastic leukemia, acute myeloid leukemia, chronic neutrophilic leukemia, acute lymphoblastic T-cell leukemia, plasmacytoma, Immunoblastic large cell leukemia, mantle cell leukemia, multiple myeloma, megakaryoblastic leukemia, multiple myeloma, acute megakaryocytic leukemia, promyelocytic leukemia, erythroleukemia, malignant lymphoma, Hodgkin lymphoma, non-Hodgkin lymphoma, lymphoblastic T-cell lymphoma, Burkitt lymphoma, follicular lymphoma, neuroblastoma, bladder cancer, urothelial cancer, vulvar cancer, cervical cancer, endometrial cancer, kidney cancer, mesothelioma, esophageal cancer, salivary gland cancer, hepatocellular carcinoma, gastric cancer, nasopharyngeal cancer, cheek cancer, oral cancer, GIST (gastrointestinal stromal tumor) and testicular cancer.
[0433] Suitably, the present invention relates to a method for treating a precancerous syndrome in a mammal, including a human, wherein the precancerous syndrome is selected from the group consisting of cervical intraepithelial neoplasia, monoclonal gammopathy of undetermined significance (MGUS), myelodysplastic syndrome, aplastic anemia, cervical lesions, skin nevus (pre-melanoma), prostatic intraepithelial (intraductal) neoplasia (PIN), ductal carcinoma in situ (DCIS), colon polyps and severe hepatitis or cirrhosis.
[0434] The compounds of Formula (I), (Ia), (Ib), (II), (III) and pharmaceutically acceptable salts thereof may be co-administered with at least one other active agent known to be useful in treating cancer or precancerous syndromes.
[0435] As used herein, the term "co-administration" refers to the simultaneous administration or separate sequential administration of a c-MYC inhibitory compound as described herein, and one or more other active agents known to be useful for treating cancer, including chemotherapy and radiation therapy. As used herein, the term one or more other active agents includes any compound or therapeutic agent that is known or exhibits favorable properties when administered to a patient in need of cancer treatment. Preferably, if administration is not simultaneous, the compounds are administered at a time close to each other. In addition, it is not important whether the compounds are administered in the same dosage form, for example, one compound can be administered by injection, while another compound can be administered orally.
[0436] Examples of additional active ingredient(s) (antineoplastic agents) that may be used in combination or co-administered with the combinations of the present invention are listed below. This list is non-limiting. Additional antineoplastic agents are contemplated for use with the compounds of the present invention.
[0437] In general, any anti-tumor agent active against the susceptible tumor being treated can be co-administered in the cancer treatment of the present invention. Examples of such agents can be found in Cancer Principles and Practice of Oncology, VT Devita and S. Hellman (eds.), 6th edition (February 15, 2001), Lippincott Williams & Wilkins Publishers. One of ordinary skill in the art will be able to discern which combinations of agents will be useful based on the specific characteristics of the drugs and cancer involved. Typical anti-tumor agents that can be used in the present invention include, but are not limited to, antimicrotubule agents, such as diterpenoids and vinca alkaloids; platinum complexes; alkylating agents, such as nitrogen mustards, oxazaphosphorines, alkyl sulfonates, nitrosoureas, and triazenes; antibiotic agents, such as anthracyclines, actinomycins, and bleomycins; topoisomerase II inhibitors, such as epipodophyllotoxins; antimetabolites, such as purine and pyrimidine analogs and antifolates; topoisomerase I inhibitors, such as camptothecins; hormones and hormone analogs; signal transduction pathway inhibitors; non-receptor tyrosine kinase angiogenesis inhibitors; immunotherapeutic agents; pro-apoptotic agents; cell cycle signaling inhibitors; proteasome inhibitors; and cancer metabolism inhibitors.
[0438] Examples of additional active ingredients (antineoplastic agents) used in combination or co-administered with the compounds of the present invention are chemotherapeutic agents.
[0439] Anti-microtubule or anti-mitotic agents are cycle-specific agents that are active against the microtubules of tumor cells during the M phase or mitosis of the cell cycle. Examples of anti-microtubule agents include, but are not limited to, diterpenoids and vinca alkaloids.
[0440] Diterpenoids derived from natural sources are cycle-specific anticancer agents that act during the G2 / M phase of the cell cycle. It is believed that diterpenoids stabilize the β-tubulin subunit of microtubules by binding to this protein. Subsequently, protein breakdown appears to be inhibited, mitosis is arrested, and cell death ensues. Examples of diterpenoids include, but are not limited to, paclitaxel and its analog, docetaxel.
[0441] Paclitaxel, also known as 5β,20-epoxy-1,2α,4,7β,10β,13α-hexahydroxytaxane-11-ene-9-one 4,10-diacetate 2-benzoate 13-[(2R,3S)-N-benzoyl-3-phenylisoserine ester], is a hydroxybenzoyl group obtained from the Pacific yew tree Taxus brevifolia ( Taxus brevifolia ) is a natural diterpene product isolated from the plant and is commercially available as TAXOL® injection. It is a member of the taxane family of terpenes. It was first isolated in 1971 by Wani et al. (J. Am. Chem. Soc., 93:2325, 1971), who characterized its structure through chemical and X-ray crystallographic methods. One mechanism of its activity is related to its ability to bind to tubulin, thereby inhibiting cancer cell growth. Schiff et al., Proc. Natl. Acad. Sci. USA, 77:1561-1565 (1980); Schiff et al., Nature, 277:665-667 (1979); Kumar, J. Biol. Chem, 256:10435-10441 (1981). For a review of the synthesis and anticancer activity of some paclitaxel derivatives, see: DGI Kingston et al., Studies in Organic Chemistry vol. 26, entitled "New trends in Natural Products Chemistry 1986", Attaur-Rahman, PW LeQuesne, Eds. (Elsevier, Amsterdam, 1986) pp. 219-235.
[0442] In the United States, paclitaxel has been approved for clinical use in the treatment of refractory ovarian cancer (Markman et al., Yale Journal of Biology and Medicine, 64:583, 1991; McGuire et al., Ann. Intem, Med., 111:273, 1989) and for the treatment of breast cancer (Holmes et al., J. Nat. Cancer Inst., 83:1797, 1991). It is a potential candidate drug for the treatment of skin tumors (Einzig et al., Proc. Am. Soc. Clin. Oncol., 20:46) and head and neck cancer (Forastire et al., Sem. Oncol., 20:56, 1990). The compound has also shown potential for the treatment of polycystic kidney disease (Woo et al., Nature, 368:750, 1994), lung cancer, and malaria. Treatment of patients with paclitaxel results in myelosuppression (multiple cell lineages, Ignoff, RJ et al., Cancer Chemotherapy Pocket Guide) associated with duration of administration above a threshold concentration (50 nM) (Kearns, CM et al., Seminars in Oncology, 3(6) p.16-23, 1995). , 1998).
[0443] Docetaxel, (2R,3S)-N-carboxy-3-phenylisoserine, N-tert-butyl ester, 13-ester with 5β-20-epoxy-1,2α,4,7β,10β,13α-hexahydroxytaxane-11-en-9-one 4-acetate 2-benzoate, trihydrate, is commercially available as an injectable solution as TAXOTERE®. Docetaxel is indicated for the treatment of breast cancer. Docetaxel is a semisynthetic derivative of paclitaxel, prepared using the natural precursor 10-deacetylbaccatin III extracted from the needles of the European yew tree. The dose-limiting toxicity of docetaxel is neutropenia.
[0444] Vinca alkaloids are cycle-specific antitumor agents derived from the periwinkle plant. Vinca alkaloids act during the M phase (mitosis) of the cell cycle by specifically binding to tubulin. As a result, the bound tubulin molecules are unable to polymerize into microtubules. It is believed that mitosis arrests in metaphase, followed by cell death. Examples of vinca alkaloids include, but are not limited to, vinblastine, vincristine, and vinorelbine.
[0445] Vinblastine, also known as vinblastine sulfate, is commercially available as an injectable solution as VELBAN®. While it has potential as a second-line therapy for various solid tumors, it is primarily indicated for the treatment of testicular cancer and various lymphomas, including Hodgkin's disease; and lymphocytic and histiocytic lymphomas. Myelosuppression is a dose-limiting side effect of vinblastine.
[0446] Vincristine, also known as vinblastine, 22-oxo-, sulfate, is commercially available as an injectable solution as ONCOVIN®. Vincristine is indicated for the treatment of acute leukemias and is also used in the treatment of Hodgkin's and non-Hodgkin's lymphomas. Alopecia and neurologic effects are the most common side effects of vincristine; myelosuppression and gastrointestinal mucositis occur to a lesser extent.
[0447] Vinorelbine, also known as 3',4'-didehydro-4'-deoxy-C'-norvincaleukoblastine [R-(R*,R*)-2,3-dihydroxysuccinate (1:2) (salt)], is commercially available as injectable vinorelbine tartrate solution (NAVELBINE®) and is a semisynthetic vinca alkaloid. Vinorelbine is indicated as a single agent or in combination with other chemotherapeutic agents (such as cisplatin) for the treatment of various solid tumors, particularly non-small cell lung cancer, advanced breast cancer, and hormone-refractory prostate cancer. Myelosuppression is the most common dose-limiting side effect of vinorelbine.
[0448] Platinum complexes are non-cyclin-specific anticancer agents that interact with DNA. Platinum complexes enter tumor cells, undergo hydration, and form intra- and inter-strand crosslinks with DNA, resulting in adverse biological effects on tumors. Examples of platinum complexes include, but are not limited to, cisplatin and carboplatin.
[0449] Cisplatin, also known as cis-diaminedichloroplatinum, is commercially available as an injectable solution as PLATINOL®. Cisplatin is primarily indicated for the treatment of metastatic testicular and ovarian cancer, as well as advanced bladder cancer. The main dose-limiting side effects of cisplatin are nephrotoxicity (controllable with hydration and diuresis) and ototoxicity.
[0450] Carboplatin, also known as platinum, diamine[1,1-cyclobutane-dicarboxylate(2-)-O,O'], is commercially available as an injectable solution as PARAPLATIN®. Carboplatin is primarily indicated for the first- and second-line treatment of advanced ovarian cancer. Myelosuppression is the dose-limiting toxicity of carboplatin.
[0451] Alkylating agents are non-pharmacological, specific anticancer agents and strong electrophiles. Typically, alkylating agents form covalent bonds with DNA through alkylation of nucleophilic moieties such as phosphate, amino, sulfhydryl, hydroxyl, carboxyl, and imidazole groups on the DNA molecule. This alkylation disrupts nucleic acid function, leading to cell death. Examples of alkylating agents include, but are not limited to, nitrogen mustards such as cyclophosphamide, melphalan, and chlorambucil; alkyl sulfonates such as busulfan; nitrosoureas such as carmustine; and triazenes such as dacarbazine.
[0452] Cyclophosphamide, 2-[bis(2-chloroethyl)amino]tetrahydro-2H-1,3,2-oxazaphosphorinane monohydrate, is commercially available as an injectable solution or tablets as CYTOXAN®. Cyclophosphamide is indicated as a single agent or in combination with other chemotherapeutic agents for the treatment of malignant lymphomas, multiple myeloma, and leukemias. Alopecia, nausea, vomiting, and leukopenia are the most common dose-limiting side effects of cyclophosphamide.
[0453] Melphalan (4-[bis(2-chloroethyl)amino]-L-phenylalanine) is commercially available as an injectable solution or tablets as ALKERAN®. Melphalan is indicated for the palliative treatment of multiple myeloma and unresectable epithelial ovarian cancer. Myelosuppression is the most common dose-limiting side effect of melphalan.
[0454] Chlorambucil, also known as 4-[bis(2-chloroethyl)amino]phenylbutyric acid, is commercially available as LEUKERAN® tablets. Chlorambucil is indicated for the palliative treatment of chronic lymphocytic leukemia and malignant lymphomas such as lymphosarcoma, giant follicular lymphoma, and Hodgkin's disease. Myelosuppression is the most common dose-limiting side effect of chlorambucil.
[0455] Busulfan, 1,4-butanediol dimethanesulfonate, is commercially available as MYLERAN® tablets. Busulfan is indicated for the palliative treatment of chronic myeloid leukemia. Myelosuppression is the most common dose-limiting side effect of busulfan.
[0456] Carmustine, also known as 1,3-bis(2-chloroethyl)-1-nitrosourea, is commercially available as a single vial of lyophilized material as BiCNU®. Carmustine is indicated as a single agent or in combination with other agents for the palliative treatment of brain tumors, multiple myeloma, Hodgkin's disease, and non-Hodgkin's lymphoma. Delayed myelosuppression is the most common dose-limiting side effect of carmustine.
[0457] Dacarbazine, also known as 5-(3,3-dimethyl-1-triazene)-imidazole-4-carboxamide, is commercially available as a single vial as DTIC-Dome®. Dacarbazine is indicated for the treatment of metastatic malignant melanoma and, in combination with other agents, for the second-line treatment of Hodgkin's disease. Nausea, vomiting, and anorexia are the most common dose-limiting side effects of dacarbazine.
[0458] Antibiotic antitumor agents are non-cyclin-specific agents that bind to or intercalate with DNA. Typically, this interaction results in stable DNA complexes or strand breaks, disrupting the normal function of nucleic acids and leading to cell death. Examples of antibiotic antitumor agents include, but are not limited to, actinomycins such as dactinomycin, anthracyclines such as daunorubicin and doxorubicin, and bleomycin.
[0459] Dactinomycin, also known as actinomycin D, is commercially available in injectable form as COSMEGEN®. Dactinomycin is indicated for the treatment of Wilms tumor and rhabdomyosarcoma. Nausea, vomiting, and anorexia are the most common dose-limiting side effects of dactinomycin.
[0460] Daunorubicin, (8S-cis-)-8-acetyl-10-[(3-amino-2,3,6-trideoxy-α-L-lyxo-hexopyranosyl)oxy]-7,8,9,10-tetrahydro-6,8,11-trihydroxy-1-methoxy-5,12-naphthalenedione hydrochloride, is commercially available as a liposomal injectable form as DAUNOXOME® or as an injectable formulation as CERUBIDINE®. Daunorubicin is indicated for remission induction in the treatment of acute nonlymphocytic leukemia and advanced HIV-associated Kaposi's sarcoma. Myelosuppression is the most common dose-limiting side effect of daunorubicin.
[0461] Doxorubicin, (8S,10S)-10-[(3-amino-2,3,6-trideoxy-α-L-lyxo-hexopyranosyl)oxy]-8-hydroxyacetyl, 7,8,9,10-tetrahydro-6,8,11-trihydroxy-1-methoxy-5,12-naphthalenedione hydrochloride, is commercially available as an injectable form as RUBEX® or ADRIAMYCIN RDF®. Doxorubicin is primarily indicated for the treatment of acute lymphoblastic leukemia and acute myeloid leukemia, but is also a useful agent in the treatment of certain solid tumors and lymphomas. Myelosuppression is the most common dose-limiting side effect of doxorubicin.
[0462] Bleomycin, a fungus isolated from Streptomyces verticillium Streptomyces verticillus ) strain, commercially available as BLENOXANE®. Bleomycin is indicated for the palliative treatment of squamous cell carcinoma, lymphoma, and testicular cancer as a single agent or in combination with other agents. Pulmonary and skin toxicities are the most common dose-limiting side effects of bleomycin.
[0463] Topoisomerase II inhibitors include, but are not limited to, epipodophyllotoxins.
[0464] Epipodophyllotoxins are cycle-specific antitumor agents derived from the mandrake plant. Epipodophyllotoxins typically affect cells in the S and G2 phases of the cell cycle by forming a ternary complex with topoisomerase II and DNA, leading to DNA strand breaks. Strand breaks accumulate, followed by cell death. Examples of epipodophyllotoxins include, but are not limited to, etoposide and teniposide.
[0465] Etoposide, also known as 4'-demethyl-epipodophyllotoxin 9[4,6-0-(R)-ethylidene-β-D-glucopyranoside], is commercially available as an injectable solution or capsule as VePESID® and is commonly referred to as VP-16. Etoposide is indicated as a single agent or in combination with other chemotherapy agents for the treatment of testicular cancer and non-small cell lung cancer. Myelosuppression is the most common side effect of etoposide. Leukopenia is often more severe than thrombocytopenia.
[0466] Teniposide, also known as 4'-demethylepipodophyllotoxin 9[4,6-0-(R)-thienylidene-β-D-glucopyranoside], is commercially available as an injectable solution as VUMON® and is commonly referred to as VM-26. Teniposide is indicated for the treatment of childhood acute leukemia as a single agent or in combination with other chemotherapeutic agents. Myelosuppression is the most common dose-limiting side effect of teniposide. Teniposide can induce leukopenia and thrombocytopenia.
[0467] Antimetabolite tumor agents are cycle-specific antitumor agents that act in the S phase (DNA synthesis) of the cell cycle by inhibiting DNA synthesis or by inhibiting purine or pyrimidine base synthesis to limit DNA synthesis. Therefore, the S phase does not proceed and the cells subsequently die. Examples of antimetabolite antitumor agents include, but are not limited to, fluorouracil, methotrexate, cytarabine, mercaptopurine, thioguanine, and gemcitabine.
[0468] 5-Fluorouracil, also known as 5-fluoro-2,4-(1H,3H)pyrimidinedione, is commercially available as fluorouracil. Administration of 5-fluorouracil inhibits the synthesis of thymidylate and is also incorporated into RNA and DNA. Cell death is often the result. 5-Fluorouracil is indicated as a single agent or in combination with other chemotherapeutic agents for the treatment of breast, colon, rectal, gastric, and pancreatic cancers. Myelosuppression and mucositis are dose-limiting side effects of 5-fluorouracil. Other fluoropyrimidine analogs include 5-fluorodeoxyuridine (floxuridine) and 5-fluorodeoxyuridine monophosphate.
[0469] Cytarabine, 4-amino-1-β-D-arabinofuranosyl-2(1H)-pyrimidinone, is commercially available as CYTOSAR-U® and is commonly referred to as Ara-C. Cytarabine is believed to inhibit DNA chain elongation by terminally incorporating cytarabine into growing DNA chains, thereby exhibiting cell cycle specificity during S phase. Cytarabine is indicated for the treatment of acute leukemias as a single agent or in combination with other chemotherapeutic agents. Other cytidine analogs include 5-azacytidine and 2',2'-difluorodeoxycytidine (gemcitabine). Cytarabine causes leukopenia, thrombocytopenia, and mucositis.
[0470] Mercaptopurine, 1,7-dihydro-6H-purine-6-thione monohydrate, is commercially available as PURINETHOL®. Mercaptopurine inhibits DNA synthesis through an as yet unidentified mechanism, exhibiting cell cycle specificity at S phase. Mercaptopurine is suitable for the treatment of acute leukemias as a single agent or in combination with other chemotherapeutic agents. Myelosuppression and gastrointestinal mucositis are expected side effects of high-dose mercaptopurine. A useful mercaptopurine analog is azathioprine.
[0471] Thioguanine, 2-amino-1,7-dihydro-6H-purine-6-thione, is commercially available as TABLOID®. Thioguanine inhibits DNA synthesis by an as yet unidentified mechanism, exhibiting cell cycle specificity at S phase. Thioguanine is indicated for the treatment of acute leukemias as a single agent or in combination with other chemotherapeutic agents. Myelosuppression, including leukopenia, thrombocytopenia, and anemia, is the most common dose-limiting side effect of thioguanine administration. However, gastrointestinal side effects occur and may be dose-limiting. Other purine analogs include pentostatin, erythrohydroxynonyl adenine, fludarabine phosphate, and cladribine.
[0472] Gemcitabine, 2'-deoxy-2',2'-difluorocytidine monohydrochloride (β-isomer), is commercially available as GEMZAR®. Gemcitabine exhibits cell cycle specificity at the S phase and blocks cell progression through the G1 / S boundary. Gemcitabine is indicated for the treatment of locally advanced non-small cell lung cancer in combination with cisplatin and for the treatment of locally advanced pancreatic cancer alone. Myelosuppression, including leukopenia, thrombocytopenia, and anemia, is the most common dose-limiting side effect of gemcitabine administration.
[0473] Methotrexate, N-[4[[(2,4-diamino-6-pterinyl)methyl]methylamino]benzoyl]-L-glutamic acid, is commercially available as methotrexate sodium. Methotrexate inhibits DNA synthesis, repair, and / or replication by inhibiting dihydrofolate reductase, which is required for the synthesis of purine nucleotides and thymidylate, thereby exhibiting cell cycle effects specifically during the S phase. Methotrexate is indicated as a single agent or in combination with other chemotherapeutic agents for the treatment of choriocarcinoma, meningeal leukemia, non-Hodgkin's lymphoma, and cancers of the breast, head, neck, ovary, and bladder. Myelosuppression (leukopenia, thrombocytopenia, and anemia) and mucositis are expected side effects of methotrexate administration.
[0474] Camptothecins, including camptothecin and camptothecin derivatives, are available or under development as topoisomerase I inhibitors. The cytotoxic activity of camptothecins is believed to be related to their topoisomerase I inhibitory activity. Examples of camptothecins include, but are not limited to, irinotecan, topotecan, and the various optical forms of 7-(4-methylpiperazino-methylene)-10,11-ethylenedioxy-20-camptothecin described below.
[0475] Irinotecan hydrochloride, (4S)-4,11-diethyl-4-hydroxy-9-[(4-piperidinopiperidino)carbonyloxy]-1H-pyrano[3',4',6,7]indolizino[1,2-b]quinoline-3,14(4H,12H)-dione hydrochloride, is commercially available as an injectable solution, CAMPTOSAR®.
[0476] Irinotecan is a derivative of camptothecin that, along with its active metabolite, SN-38, binds to the topoisomerase I-DNA complex. Cytotoxicity is believed to result from irreparable double-strand breaks caused by the interaction of the topoisomerase I:DNA:irinotecan or SN-38 ternary complex with the replicase enzyme. Irinotecan is indicated for the treatment of metastatic cancer of the colon or rectum. The dose-limiting side effects of irinotecan hydrochloride are myelosuppression, including neutropenia, and gastrointestinal effects, including diarrhea.
[0477] Topotecan hydrochloride, (S)-10-[(dimethylamino)methyl]-4-ethyl-4,9-dihydroxy-1H-pyrano[3',4',6,7]indolizino[1,2-b]quinoline-3,14-(4H,12H)-dione monohydrochloride, is commercially available as HYCAMTIN® injection. Topotecan is a camptothecin derivative that binds to the topoisomerase I-DNA complex, preventing the reconnection of single-strand breaks induced by topoisomerase I in response to torsional strain on the DNA molecule. Topotecan is indicated for the second-line treatment of metastatic ovarian cancer and small cell lung cancer. The dose-limiting side effect of topotecan hydrochloride is myelosuppression, primarily neutropenia.
[0478] Hormones and hormone analogs are useful compounds for treating cancer where there is a relationship between the hormone and the growth and / or lack of growth of the cancer. Examples of hormones and hormone analogs that can be used for cancer treatment include, but are not limited to, adrenocortical hormones, such as prednisone and prednisolone, which are used to treat childhood malignant lymphoma and acute leukemia; aminoglutethimide and other aromatase inhibitors, such as anastrozole, letrozole, vorozole, and exemestane, which are used to treat adrenocortical carcinoma and hormone-dependent breast cancer containing estrogen receptors; progestins, such as megestrol acetate, which are used to treat hormone-dependent breast cancer and endometrial cancer; estrogens, androgens, and antiandrogens, such as flutamide, nilutamide, bicalutamide, cyproterone acetate, and 5α-reductase inhibitors, such as finasteride and dutasteride, which are used to treat prostate cancer and benign prostatic hyperplasia (BPH). antiestrogens, such as tamoxifen, toremifene, raloxifene, droloxifene, iodoxyfene, and selective estrogen receptor modulators (SERMS), such as those described in U.S. Pat. Nos. 5,681,835, 5,877,219, and 6,207,716, which are useful in treating hormone-dependent breast cancer and other susceptible cancers; and gonadotropin-releasing hormone (GnRH) and its analogs, which stimulate the release of luteinizing hormone (LH) and / or follicle-stimulating hormone (FSH) to treat prostate cancer, e.g., LHRH agonists and antagonists, such as goserelin acetate and luprolide.
[0479] Signal transduction pathway inhibitors are those that block or inhibit the chemical processes that cause changes in cells. As used herein, such changes are cell proliferation or differentiation. Signal transduction inhibitors useful in the present invention include inhibitors of receptor tyrosine kinases, non-receptor tyrosine kinases, SH2 / SH3 domain blockers, serine / threonine kinases, phosphatidylinositol-3 kinases, inositol signaling, and Ras oncogenes.
[0480] Several protein tyrosine kinases catalyze the phosphorylation of specific tyrosyl residues in various proteins involved in cell growth regulation. Such protein tyrosine kinases can be broadly classified as receptor or non-receptor kinases. Receptor tyrosine kinases are transmembrane proteins with an extracellular ligand binding domain, a transmembrane domain, and a tyrosine kinase domain. Receptor tyrosine kinases participate in the regulation of cell growth and are commonly referred to as growth factor receptors. Inappropriate or uncontrolled activation of many of these kinases, i.e., abnormal kinase growth factor receptor activity, such as through overexpression or mutation, has been shown to lead to uncontrolled cell growth. Therefore, abnormal activity of such kinases is associated with the growth of malignant tissues. Therefore, inhibitors of such kinases can provide cancer treatment methods. Growth factor receptors include, for example, epidermal growth factor receptor (EGFr), platelet-derived growth factor receptor (PDGFr), erbB2, erbB4, vascular endothelial growth factor receptor (VEGFr), tyrosine kinase with immunoglobulin-like and epidermal growth factor homology domains (TIE-2), insulin growth factor-I (IGFI) receptor, macrophage colony-stimulating factor (cfms), BTK, ckit, cmet, fibroblast growth factor (FGF) receptor, Trk receptors (TrkA, TrkB and TrkC), ephrin (eph) receptors and RET proto-oncogene. Several growth receptor inhibitors are under development, including ligand antagonists, antibodies, tyrosine kinase inhibitors and antisense oligonucleotides. Growth factor receptors and agents that inhibit growth factor receptor function are described, for example, in Kath, John C., Exp. Opin. Ther. Patents (2000) 10(6):803-818; Shawver et al. DDT Vol 2, No. 2 February 1997; and Lofts, FJ et al., “Growthfactor receptors as targets”, New Molecular Targets for Cancer Chemotherapy, eds. Workman, Paul and Kerr, David, CRC Press, 1994, London.
[0481] Suitably, the pharmaceutically active compound of the invention is used in combination with a VEGFR inhibitor, suitably 5-[[4-[(2,3-dimethyl-2H-indazol-6-yl)methylamino]-2-pyrimidinyl]amino]-2-methylbenzenesulfonamide, or a pharmaceutically acceptable salt thereof, suitably the monohydrochloride salt, which compound is disclosed and claimed in International Application No. PCT / US01 / 49367, having an International Application Date of December 19, 2001, International Publication No. WO02 / 059110, and International Publication Date of August 1, 2002, the entire disclosures of which are incorporated herein by reference, and which compound is the compound of Example 69. 5-[[4-[(2,3-dimethyl-2H-indazol-6-yl)methylamino]-2-pyrimidinyl]amino]-2-methylbenzenesulfonamide may be prepared as described in International Application No. PCT / US01 / 49367.
[0482] Suitably, 5-[[4-[(2,3-dimethyl-2H-indazol-6-yl)methylamino]-2-pyrimidinyl]amino]-2-methylbenzenesulfonamide is in the form of a monohydrochloride salt. This salt form can be prepared by one skilled in the art according to the description in International Application No. PCT / US01 / 49367, filed December 19, 2001.
[0483] 5-[[4-[(2,3-Dimethyl-2H-indazol-6-yl)methylamino]-2-pyrimidinyl]amino]-2-methylbenzenesulfonamide is commercially available as the monohydrochloride salt and under the generic name pazopanib and the trade name Votrient ® Well known.
[0484] Pazopanib is relevant to the treatment of cancer and ocular diseases / angiogenesis. Suitably, the present invention relates to the treatment of cancer and ocular diseases / angiogenesis, suitably age-related macular degeneration, comprising administering a compound of formula (I) alone or in combination with pazopanib.
[0485] Tyrosine kinases that are not growth factor receptor kinases are referred to as non-receptor tyrosine kinases. Non-receptor tyrosine kinases used in the present invention (which serve as targets or potential targets for anticancer drugs) include cSrc, Lck, Fyn, Yes, Jak, cAbl, FAK (focal adhesion kinase), Bruton's tyrosine kinase, and Bcr-Abl. Such non-receptor kinases and agents that inhibit the function of non-receptor tyrosine kinases are described in Sinh, S. and Corey, SJ, (1999) Journal of Hematotherapy and Stem Cell Research 8 (5): 465-80 and Bolen, JB, Brugge, JS, (1997) Annual review of Immunology. 15: 371-404.
[0486] SH2 / SH3 domain blockers are agents that disrupt the binding of SH2 or SH3 domains in various enzymes or adaptor proteins, including the PI3-K p85 subunit, Src family kinases, adaptor molecules (Shc, Crk, Nck, Grb2) and Ras-GAP. The SH2 / SH3 domain as a target for anticancer drugs is discussed in Smithgall, TE (1995), Journal of Pharmacological and Toxicological Methods. 34(3) 125-32.
[0487] Serine / threonine kinase inhibitors, including MAP kinase cascade blockers, including blockers of Raf kinase (rafk), mitogen- or extracellular-regulated kinase (MEK), and extracellular-regulated kinase (ERK); and protein kinase C family member blockers, including blockers of PKC (α, β, γ, ε, μ, λ, ι, ζ), IkB kinase family (IKKa, IKKb), PKB family kinases, Akt kinase family members, PDK1, and TGFβ receptor kinase. Such serine / threonine kinases and their inhibitors are described in Yamamoto, T., Taya, S., Kaibuchi, K., (1999), Journal of Biochemistry. 126 (5) 799-803; Brodt, P, Samani, A., and Navab, R. (2000), Biochemical Pharmacology, 60. 1101-1107; Massague, J., Weis-Garcia, F. (1996) Cancer Surveys. 27:41-64; Philip, PA, and Harris, AL (1995), Cancer Treatment and Research . 78: 3-27, Lackey, K. et al., Bioorganic and Medicinal Chemistry Letters, (10), 2000, 223-226; U.S. Patent No. 6,268,391; Pearce, LR et al., Nature Reviews Molecular Cell Biology (2010) 11, 9-22 and Martinez-Iacaci, L. et al., Int. J. Cancer (2000), 88(1), 44-52.
[0488] Suitably, the pharmaceutically active compounds of the present invention are used in combination with a MEK inhibitor. Suitably, N-{3-[3-cyclopropyl-5-(2-fluoro-4-iodo-phenylamino)-6,8-dimethyl-2,4,7-trioxo-3,4,6,7-tetrahydro-2H-pyrido[4,3-d]pyrimidin-1-yl]phenyl}acetamide or a pharmaceutically acceptable salt or solvate thereof, suitably a dimethyl sulfoxide solvate, as disclosed and claimed in International Application No. WO 2005 / 121142, filed June 10, 2005, and International Application No. PCT / JP2005 / 011082, filed December 22, 2005, the entire disclosures of which are incorporated herein by reference. N-{3-[3-cyclopropyl-5-(2-fluoro-4-iodo-phenylamino)-6,8-dimethyl-2,4,7-trioxo-3,4,6,7-tetrahydro-2H-pyrido[4,3-d]pyrimidin-1-yl]phenyl}acetamide can be prepared as described in U.S. Patent Publication No. US 2006 / 0014768, published on January 19, 2006, the entire disclosure of which is incorporated herein by reference.
[0489] Suitably, the pharmaceutically active compounds of the present invention are used in combination with a B-Raf inhibitor. Suitably, N- {3-[5-(2-amino-4-pyrimidinyl)-2-(1,1-dimethylethyl)-1,3-thiazol-4-yl]-2-fluorophenyl}-2,6-difluorobenzenesulfonamide or a pharmaceutically acceptable salt thereof, which is disclosed and claimed in International Application No. PCT / US2009 / 042682, filed May 4, 2009, the entire disclosure of which is incorporated herein by reference. N- {3-[5-(2-amino-4-pyrimidinyl)-2-(1,1-dimethylethyl)-1,3-thiazol-4-yl]-2-fluorophenyl}-2,6-difluorobenzenesulfonamide can be prepared as described in International Application No. PCT / US2009 / 042682.
[0490] Suitably, the pharmaceutically active compounds of the present invention are used in combination with an Akt inhibitor. Suitably, N-{(1S)-2-amino-1-[(3,4-difluorophenyl)methyl]ethyl}-5-chloro-4-(4-chloro-1-methyl-1H-pyrazol-5-yl)-2-furancarboxamide, or a pharmaceutically acceptable salt thereof, is disclosed and claimed in International Application No. PCT / US2008 / 053269, filed February 7, 2008, International Publication No. WO 2008 / 098104, and International Publication No. PCT / US2008 / 053269, filed August 14, 2008, the entire disclosure of which is incorporated herein by reference. N-{(1S)-2-amino-1-[(3,4-difluorophenyl)methyl]ethyl}-5-chloro-4-(4-chloro-1-methyl-1H-pyrazol-5-yl)-2-furancarboxamide is the compound of Example 224 and can be prepared as described in International Application No. PCT / US2008 / 053269.
[0491] Suitably, the pharmaceutically active compounds of the present invention are used in combination with an Akt inhibitor. Suitably, N -{( 1S )-2-amino-1-[(3-fluorophenyl)methyl]ethyl}-5-chloro-4-(4-chloro-1-methyl -1H- The present invention relates to a thiophenecarboxamide or a pharmaceutically acceptable salt thereof, which is disclosed and claimed in International Application No. PCT / US2008 / 053269, with an International Application Date of February 7, 2008, an International Publication No. WO 2008 / 098104, and an International Publication No. PCT / US2008 / 053269, with an International Application Date of August 14, 2008, the entire disclosures of which are hereby incorporated by reference. N -{(1 S )-2-amino-1-[(3-fluorophenyl)methyl]ethyl}-5-chloro-4-(4-chloro-1-methyl-1 H- Pyrazol-5-yl)-2-thiophenecarboxamide is the compound of Example 96 and can be prepared as described in International Application No. PCT / US2008 / 053269. Suitably, N -{( 1S )-2-amino-1-[(3-fluorophenyl)methyl]ethyl}-5-chloro-4-(4-chloro-1-methyl - 1 H- Pyrazol-5-yl)-2-thiophenecarboxamide is in the form of a hydrochloride salt. The salt form can be prepared by a person skilled in the art according to the description in international application No. PCT / US2010 / 022323, with an international application date of January 28, 2010.
[0492] Inhibitors of members of the phosphatidylinositol-3 kinase family (including blockers of PI3-kinase, ATM, DNA-PK and Ku) are also useful in the present invention. Such kinases are described in Abraham, RT (1996), Current Opinion in Immunology. . 8 (3) 412-8; Canman, CE, Lim, DS (1998), Oncogene 17 (25) 3301-3308; Jackson, SP (1997), International Journal of Biochemistry and Cell Biology.29 (7):935-8; and Zhong, H. et al., Cancer res, (2000) 60(6), 1541-1545.
[0493] Also of interest herein are inositol signaling inhibitors, such as phospholipase C blockers and inositol analogs. Such signaling inhibitors are described in Powis, G. and Kozikowski A., (1994) New Molecular Targets for Cancer Chemotherapy, edited by Paul Workman and David Kerr, CRC Press, 1994, London.
[0494] Another group of signal transduction pathway inhibitors are Ras oncogene inhibitors. This class of inhibitors includes inhibitors of farnesyltransferase, geranyl-geranyl transferase, and CAAX proteases, as well as antisense oligonucleotides, ribozymes, and immunotherapies. These inhibitors have been shown to block Ras activation in cells containing wild-type mutant Ras, thereby acting as antiproliferative agents. Scharovsky, OG, Rozados, VR, Gervasoni, SI Matar, P. (2000), Journal of Biomedical Science . Ras oncogene suppression is discussed in Ashby, MN (1998), Current Opinion in Lipidology. 9 (2) 99 – 102; and BioChim. Biophys. Acta, (1989) 1423(3):19-30. 。
[0495] As mentioned above, antibody antagonists of receptor kinase ligand binding can also be used as signal transduction inhibitors. This group of signal transduction pathway inhibitors includes the use of humanized antibodies directed against the extracellular ligand binding domain of receptor tyrosine kinases. For example, Imclone C225 EGFR-specific antibody (see Green, MC et al., Monoclonal Antibody Therapy for Solid Tumors, Cancer Treat. Rev., (2000), 26(4), 269-286); Herceptin® erbB2 antibody (see Tyrosine Kinase Signalling in Breast cancer:erbB Family Receptor Tyrosine Kniases, Breast cancer Res., 2000, 2(3), 176-183); and 2CB VEGFR2-specific antibody (see Brekken, RA et al., Selective Inhibition of VEGFR2 Activity by a monoclonal Anti-VEGF antibody blocks tumor growth in mice, Cancer Res. (2000) 60, 5117-5124).
[0496] Non-receptor kinase angiogenesis inhibitors can also be used in the present invention. Inhibitors of angiogenesis-related VEGFR and TIE2 are discussed above with respect to signal transduction inhibitors (both receptors are receptor tyrosine kinases). Angiogenesis is often associated with erbB2 / EGFR signaling, as inhibitors of erbB2 and EGFR have been shown to inhibit angiogenesis, primarily VEGF expression. Therefore, non-receptor tyrosine kinase inhibitors can be used in combination with the compounds of the present invention. For example, anti-VEGF antibodies, which do not recognize VEGFR (receptor tyrosine kinase) but bind to ligands; integrins (α-TIE2) that inhibit angiogenesis; and v Small molecule inhibitors of β3); endostatin and angiostatin (non-RTK) may also prove useful in combination with the disclosed compounds. (See Bruns CJ et al. (2000), Cancer Res., 60: 2926-2935; Schreiber AB, Winkler ME, and Derynck R. (1986), Science, 232: 1250-1253; Yen L et al. (2000), Oncogene 19: 3460-3469).
[0497] Agents used in immunotherapy regimens can also be used in combination with compounds of formula (I). Numerous immunotherapy strategies exist for generating immune responses. These strategies generally fall within the field of tumor vaccination. The efficacy of immunological approaches can be greatly enhanced by combining small molecule inhibitors to inhibit signaling pathways. Discussions of immunological / tumor vaccine approaches targeting erbB2 / EGFR can be found in Reilly RT et al. (2000), Cancer Res. 60: 3569-3576; and Chen Y, Hu D, Eling DJ, Robbins J, and Kipps TJ. (1998), Cancer Res. 58: 1965-1971.
[0498] Agents used in pro-apoptotic strategies (e.g., bcl-2 antisense oligonucleotides) can also be used in the combinations of the present invention. Members of the Bcl-2 protein family block apoptosis. Therefore, upregulation of bcl-2 is associated with chemoresistance. Studies have shown that epidermal growth factor (EGF) stimulates anti-apoptotic members of the bcl-2 family (i.e., mcl-1). Therefore, strategies aimed at downregulating bcl-2 expression in tumors have demonstrated clinical benefit and are currently in Phase II / III trials, namely Genta's G3139 bcl-2 antisense oligonucleotide. Such pro-apoptotic strategies using bcl-2 antisense oligonucleotides are discussed in Water JS et al. (2000), J. Clin. Oncol. 18: 1812-1823; and Kitada S et al. (1994), Antisense Res. Dev. 4: 71-79.
[0499] Cell cycle signaling inhibitors inhibit molecules involved in cell cycle control. A family of protein kinases called cyclin-dependent kinases (CDKs) and their interactions with a family of proteins called cyclins control progression through the eukaryotic cell cycle. Coordinated activation and inactivation of different cyclin / CDK complexes is essential for normal progression through the cell cycle. Several cell cycle signaling inhibitors are under development. For example, examples of cyclin-dependent kinases (including CDK2, CDK4, and CDK6) and their inhibitors are described in, for example, Rosania et al., Exp. Opin. Ther. Patents (2000) 10(2):215-230. In addition, p21WAF1 / CIP1 has been described as an effective and versatile inhibitor of cyclin-dependent kinases (Cdks) (Ball et al., Progress in Cell Cycle Res., 3: 125 (1997)). Compounds that induce p21WAF1 / CIP1 expression are known to inhibit cell proliferation and have tumor suppressor activity (Richon et al., Proc. Nat Acad. Sci. USA 97(18): 10014-10019 (2000)), and are included as inhibitors of cell cycle signaling. Histone deacetylase (HDAC) inhibitors are associated with transcriptional activation of p21WAF1 / CIP1 (Vigushin et al., Anticancer Drugs, 13(1): 1-13 (January 2002)), and are cell cycle signaling inhibitors suitable for combined use herein.
[0500] Examples of such HDAC inhibitors include:
[0501] 1. Vorinostat, including pharmaceutically acceptable salts thereof. Marks et al., Nature Biotechnology 25, 84 to 90 (2007); Stenger, Community Oncology 4, 384-386 (2007).
[0502] Vorinostat has the following chemical structure and name:
[0503]
[0504] N- Hydroxyl -N'- Phenyl-suberamide.
[0505] 2. Romidepsin, including pharmaceutically acceptable salts thereof.
[0506] Vinodhkumar et al., Biomedicine & Pharmacotherapy 62 (2008) 85-93.
[0507] Romidepsin has the following chemical structure and name:
[0508]
[0509] (1S,4S,7Z,10S,16E,21R)-7-Ethylene-4,21-di(propan-2-yl)-2-oxa-12,13-dithia-5,8,20,23-tetraazabicyclo[8.7.6]tricos-16-ene-3,6,9,19,22-pentaone.
[0510] 3. Panobinostat, including pharmaceutically acceptable salts thereof. Drugs of the Future 32(4): 315-322 (2007)。
[0511] Panobinostat has the following chemical structure and name:
[0512]
[0513] (2 E )- N-Hydroxy-3-[4-({[2-(2-methyl-1 H -indol-3-yl)ethyl]amino}methyl)phenyl]acrylamide.
[0514] 4. Valproic acid, including pharmaceutically acceptable salts thereof. Gottlicher et al., EMBO J. 20(24):6969-6978 (2001).
[0515] Valproic acid has the following chemical structure and name:
[0516]
[0517] 2-propylvaleric acid.
[0518] 5. Mocetinostat (MGCD0103), including pharmaceutically acceptable salts thereof. Balasubramanian et al., Cancer Letters 280: 211-221 (2009).
[0519] Mocetinostat has the following chemical structure and name:
[0520]
[0521] N- (2-Aminophenyl)-4-[[(4-pyridin-3-ylpyrimidin-2-yl)amino]methyl]benzamide.
[0522] Further examples of such HDAC inhibitors are included in Bertrand European Journal of Medicinal Chemistry 45, (2010) 2095-2116, in particular the compounds of Table 3 therein, shown below.
[0523]
[0524] Proteasome inhibitors are drugs that block the action of the proteasome, a cellular complex that breaks down proteins such as p53. Several proteasome inhibitors are marketed or under investigation for the treatment of cancer. Suitable proteasome inhibitors for use in the combinations herein include:
[0525] 1. Bortezomib (Velcade®), including its pharmaceutically acceptable salts. Adams J, Kauffman M (2004), Cancer Invest 22 (2): 304–11.
[0526] Bortezomib has the following chemical structure and name.
[0527]
[0528] [(1 R )-3-methyl-1-({(2 S )-3-phenyl-2-[(pyrazin-2-ylcarbonyl)amino]propanoyl}amino)butyl]boronic acid.
[0529] 2. Disulfiram, including pharmaceutically acceptable salts thereof.
[0530] Bouma et al. (1998). J. Antimicrob. Chemother. 42(6):817–20.
[0531] Disulfiram has the following chemical structure and name.
[0532]
[0533] 1,1',1'',1'''-[Disulfanediylbis(thiocarbonylnitrilo)]tetraethane.
[0534] 3. Epigallocatechin gallate (EGCG), including pharmaceutically acceptable salts thereof. Williamson et al., (December 2006), The Journal of Allergy and Clinical Immunology 118(6):1369–74.
[0535] Epigallocatechin gallate has the following chemical structure and name.
[0536]
[0537] 3,4,5-Trihydroxybenzoic acid [(2 R ,3 R )-5,7-dihydroxy-2-(3,4,5-trihydroxyphenyl)chroman-3-yl] ester.
[0538] 4. Salinosporamide A, including pharmaceutically acceptable salts thereof. Feling et al. (2003), Angew. Chem. Int. Ed. Engl. 42(3): 355–7.
[0539] Salinosporin A has the following chemical structure and name.
[0540]
[0541] (4R,5S)-4-(2-chloroethyl)-1-((1S)-cyclohex-2-enyl(hydroxy)methyl)-5-methyl-6-oxa-2-azabicyclo3.2.0heptane-3,7-dione.
[0542] 5. Carfilzomib, including pharmaceutically acceptable salts thereof. Kuhn DJ et al., Blood, 2007, 110:3281-3290.
[0543] Carfilzomib has the following chemical structure and name.
[0544]
[0545] (S)-4-methyl-N-((S)-1-(((S)-4-methyl-1-((R)-2-methyloxiran-2-yl)-1-oxopentan-2-yl)amino)-1-oxo-3-phenylpropan-2-yl)-2-((S)-2-(2-morpholinoacetamido)-4-phenylbutanamido)pentanamide.
[0546] The 70 kilodalton heat shock proteins (Hsp70s) and 90 kilodalton heat shock proteins (Hsp90s) are a family of ubiquitously expressed heat shock proteins. Hsp70s and Hsp90s are overexpressed in certain cancer types. Several Hsp70s and Hsp90s inhibitors are being studied for the treatment of cancer. Suitable Hsp70s and Hsp90s inhibitors for use in the combinations herein include:
[0547] 1. 17-AAG (geldanamycin), including pharmaceutically acceptable salts thereof. Jia W et al. Blood. 2003 Sep 1;102(5):1824-32.
[0548] 17-AAG (geldanamycin) has the following chemical structure and name.
[0549]
[0550] 17-(Allylamino)-17-demethoxygeldanamycin.
[0551] 2. Radicicol, including pharmaceutically acceptable salts thereof (Lee et al., Mol Cell Endocrinol. 2002, 188, 47-54).
[0552] Radicicol has the following chemical structure and name.
[0553]
[0554] (1aR,2Z,4E,14R,15aR)-8-Chloro-9,11-dihydroxy-14-methyl-15,15a-dihydro-1aH-benzo[c]oxirano[2,3-k][1]oxacyclotetradecene-6,12(7H,14H)-dione.
[0555] Cancer Metabolism Inhibitors - Many tumor cells exhibit distinct metabolisms that differ from normal tissues. For example, the rate of glycolysis (the metabolic process that converts glucose to pyruvate) is increased, and the resulting pyruvate is reduced to lactate rather than further oxidized in the mitochondria via the tricarboxylic acid (TCA) cycle. This effect, often seen even under aerobic conditions, is known as the Warburg effect.
[0556] Lactate dehydrogenase A (LDH-A), an isoform of lactate dehydrogenase expressed in muscle cells, plays a key role in tumor cell metabolism by reducing pyruvate to lactate, which can then be exported out of the cell. This enzyme has been shown to be upregulated in many tumor types. Alterations in glucose metabolism, described in the Warburg effect, are crucial for the growth and proliferation of cancer cells, and knocking down LDH-A using RNAi has been shown to reduce cell proliferation and tumor growth in xenograft models.
[0557] DA Tennant et al., Nature Reviews, 2010, 267.
[0558] P. Leder et al., Cancer Cell, 2006, 9, 425.
[0559] High levels of fatty acid synthase (FAS) are found in cancer precursor lesions. Pharmacological inhibition of FAS affects the expression of key oncogenes involved in cancer development and maintenance.
[0560] Alli et al., Oncogene (2005) 24, 39–46. doi:10.1038.
[0561] Cancer metabolism inhibitors, including LDH-A inhibitors and fatty acid biosynthesis inhibitors (or FAS inhibitors), are suitable for use in combination with the compounds of the present invention.
[0562] In one embodiment, the cancer treatment methods of the claimed invention comprise co-administering a compound of Formula I, Ia, Ib, II or III and / or a pharmaceutically acceptable salt thereof and at least one anti-tumor agent, such as one selected from the group consisting of antimicrotubule agents, platinum complexes, alkylating agents, antibiotic agents, topoisomerase II inhibitors, antimetabolites, topoisomerase I inhibitors, hormones and hormone analogs, signal transduction pathway inhibitors, non-receptor tyrosine kinase angiogenesis inhibitors, immunotherapeutic agents, pro-apoptotic agents, cell cycle signaling inhibitors, proteasome inhibitors, and cancer metabolism inhibitors.
[0563] In one embodiment, compounds of Formula I, Ia, and Ib are used as chemosensitizers to enhance tumor cell killing.
[0564] In one embodiment, the combination of compounds of Formula I, Ia, Ib, II, or III is used as a chemosensitizer to enhance tumor cell killing.
[0565] In one embodiment, the compounds of formula I, Ia, Ib, II or III are used in combination with compounds that inhibit the activity of the protein kinase R (PKR)-like ER kinase PERK (PERK inhibitors).
[0566] Suitably, the compounds of Formula I, Ia, Ib, II, III and pharmaceutically acceptable salts thereof may be co-administered with at least one other active agent known to be an inhibitor of PERK kinase (EIF2K3) to treat or lessen the severity of neurodegenerative diseases / injuries, such as Alzheimer's disease, spinal cord injury, traumatic brain injury, ischemic stroke, stroke, diabetes, Parkinson's disease, Huntington's disease, Creutzfeldt-Jakob disease and related prion diseases, progressive supranuclear palsy, amyotrophic lateral sclerosis, myocardial infarction, cardiovascular disease, inflammation, fibrosis, chronic and acute liver disease, chronic and acute lung disease, chronic and acute kidney disease, chronic traumatic encephalopathy (CTE), neurodegeneration, dementia, traumatic brain injury, cognitive impairment, atherosclerosis, eye diseases, arrhythmias, in organ transplantation and transport of transplanted organs.
[0567] "Chemotherapeutic drug" or "chemotherapeutic agent" is used in its ordinary sense to refer to a chemical composition or compound that has anti-tumor properties or the ability to inhibit cell growth or proliferation.
[0568] In addition, the compounds described herein can be co-administered with conventional immunotherapeutic agents, including but not limited to immunostimulants (e.g., Bacillus Calmette-Guérin (BCG), levamisole, interleukin-2, alpha-interferon, etc.), monoclonal antibodies (e.g., anti-CD20, anti-HER2, anti-CD52, anti-HLA-DR, and anti-VEGF monoclonal antibodies), immunotoxins (e.g., anti-CD33 monoclonal antibody-calicheamicin conjugates, anti-CD22 monoclonal antibody-Pseudomonas exotoxin conjugates, etc.), and radioimmunotherapy (e.g., with 111 In, 90 Y or 131 I etc. conjugated anti-CD20 monoclonal antibodies).
[0569] In another embodiment, the compounds described herein may be co-administered with conventional radiotherapeutic agents including, but not limited to, radionuclides, e.g. 47 Sc, 64 C.67 C. 89 Sr. 86 Y. 87 Y and 212 Bi, optionally conjugated to an antibody against a tumor antigen.
[0570] Another example of one or more active ingredients (anti-tumor agents) used in combination or co-administered with the compound is an anti-PD-L1 agent.
[0571] Anti-PD-L1 antibodies and methods for their preparation are known in the art.
[0572] Such PD-L1 antibodies may be polyclonal or monoclonal, and / or recombinant, and / or humanized.
[0573] Exemplary PD-L1 antibodies are disclosed in:
[0574] U.S. Patent Nos. 8,217,149; 12 / 633,339;
[0575] U.S. Patent Nos. 8,383,796; 13 / 091,936;
[0576] U.S. Patent Nos. 8,552,154; 13 / 120,406;
[0577] U.S. Patent Publication Nos. 20110280877; 13 / 068337;
[0578] U.S. Patent Publication No. 20130309250; 13 / 892671;
[0579] WO2013019906;
[0580] WO2013079174;
[0581] U.S. application No. 13 / 511,538 (filed August 7, 2012), which is a U.S. national phase application of international application No. PCT / US10 / 58007 (filed in 2010);
[0582] and
[0583] U.S. application No. 13 / 478,511 (filed May 23, 2012).
[0584] Additional exemplary PD-L1 antibodies (also known as CD274 or B7-H1) and methods of use are disclosed in U.S. Patent Nos. 7,943,743; US20130034559, WO2014055897, U.S. Patent No. 8,168,179; and U.S. Patent No. 7,595,048. PD-L1 antibodies are being developed as immunomodulatory agents for the treatment of cancer.
[0585] In one embodiment, the PD-L1 antibody is an antibody disclosed in U.S. Patent No. 8,217, 149. In another embodiment, the anti-PD-L1 antibody comprises the CDRs of an antibody disclosed in U.S. Patent No. 8,217,149.
[0586] In another embodiment, the PD-L1 antibody is an antibody disclosed in U.S. Application No. 13 / 511,538. In another embodiment, the anti-PD-L1 antibody comprises the CDRs of an antibody disclosed in U.S. Application No. 13 / 511,538.
[0587] In another embodiment, the PD-L1 antibody is an antibody disclosed in application number 13 / 478,511. In another embodiment, the anti-PD-L1 antibody comprises the CDRs of an antibody disclosed in US application number 13 / 478,511.
[0588] In one embodiment, the anti-PD-L1 antibody is BMS-936559 (MDX-1105). In another embodiment, the anti-PD-L1 antibody is MPDL3280A (RG7446). In another embodiment, the anti-PD-L1 antibody is MEDI4736.
[0589] Another example of one or more active ingredients (anti-tumor agents) used in combination or co-administered with the ATF4 pathway inhibitory compounds of the present invention is a PD-1 antagonist.
[0590] "PD-1 antagonist" refers to any compound or biomolecule that blocks the binding of PD-L1 expressed on cancer cells to PD-1 expressed on immune cells (T cells, B cells, or NKT cells), and preferably also blocks the binding of PD-L2 expressed on cancer cells to PD-1 expressed on immune cells. Alternative names or synonyms for PD-1 and its ligands include: for PD-1, PDCD1, PD1, CD279, and SLEB2; for PD-L1, PDCD1L1, PDL1, B7H1, B7-4, CD274, and B7-H; and for PD-L2, PDCD1L2, PDL2, B7-DC, Btdc, and CD273. In any embodiment of the aspects or embodiments of the invention in which a human subject is to be treated, the PD-1 antagonist blocks the binding of human PD-L1 to human PD-1, and preferably blocks the binding of human PD-L1 and PD-L2 to PD-1. The amino acid sequence of human PD-1 can be found in NCBI Locus No.: NP_005009. The amino acid sequences of human PD-L1 and PD-L2 can be found in NCBI Locus No.: NP_054862 and NP_079515, respectively.
[0591] PD-1 antagonists useful in any aspect of the present invention include monoclonal antibodies (mAbs) or antigen-binding fragments thereof that specifically bind to PD-1 or PD-L1, preferably specifically bind to human PD-1 or human PD-L1. mAbs can be human, humanized, or chimeric antibodies and can include a human constant region. In some embodiments, the human constant region is selected from IgG1, IgG2, IgG3, and IgG4 constant regions, and in preferred embodiments, the human constant region is an IgG1 or IgG4 constant region. In some embodiments, the antigen-binding fragment is selected from Fab, Fab'-SH, F(ab')2, scFv, and Fv fragments.
[0592] Examples of mAbs that bind to human PD-1 and are useful in various aspects and embodiments of the invention are described in US7488802, US7521051, US8008449, US8354509, US8168757, WO2004 / 004771, WO2004 / 072286, WO2004 / 056875, and US2011 / 0271358.
[0593] Specific anti-human PD-1 mAbs useful as PD-1 antagonists in any of the aspects and embodiments of the present invention include: MK-3475, a humanized IgG4 mAb, the structure of which is described in WHO Drug Information, Vol. 27, No. 2, pp. 161-162 (2013), which comprises the heavy and light chain amino acid sequences shown in FIG6 ; nivolumab, a human IgG4 mAb, the structure of which is described in WHO Drug Information , Vol. 27, No. 1, pp. 68-69 (2013), which comprises the heavy and light chain amino acid sequences shown in FIG7 ; the humanized antibodies h409A11, h409A16, and h409A17 described in WO2008 / 156712, and AMP-514 being developed by Medimmune.
[0594] Other PD-1 antagonists useful in any of the aspects and embodiments of the present invention include immunoadhesins that specifically bind to PD-1, and preferably to human PD-1, such as fusion proteins comprising the extracellular or PD-1 binding portion of PD-L1 or PD-L2 fused to a constant region (e.g., the Fc region of an immunoglobulin molecule). Examples of immunoadhesion molecules that specifically bind to PD-1 are described in WO2010 / 027827 and WO2011 / 066342. Specific fusion proteins useful as PD-1 antagonists in the treatment methods, medicaments, and uses of the present invention include AMP-224 (also known as B7-DCIg), which is a PD-L2-Fc fusion protein that binds to human PD-1.
[0595] Other examples of mAbs that bind to human PD-L1 and can be used in the methods of treatment, medicines, and uses of the present invention are described in WO2013 / 019906, WO2010 / 077634 A1, and US 8383796. Specific anti-human PD-L1 mAbs that can be used as PD-1 antagonists in the methods of treatment, medicines, and uses of the present invention include MPDL3280A, BMS-936559, MEDI4736, and MSB0010718C.
[0596] KEYTRUDA / pembrolizumab is an anti-PD-1 antibody marketed by Merck for the treatment of lung cancer. The amino acid sequence and methods of use of pembrolizumab are disclosed in U.S. Patent No. 8,168,757.
[0597] Opdivo / nivolumab is a fully human monoclonal antibody marketed by Bristol-Myers Squibb that targets the negative immunoregulatory human cell surface receptor PD-1 (programmed cell death-1, or PCD-1) with immunopotentiating activity. Nivolumab binds to and blocks activation of PD-1 (an Ig superfamily transmembrane protein) through its ligands PD-L1 and PD-L2, leading to T cell activation and cell-mediated immune responses against tumor cells or pathogens. Activated PD-1 negatively regulates T cell activation and effector function by inhibiting PI3K / Akt pathway activation. Other names for nivolumab include BMS-936558, MDX-1106, and ONO-4538. U.S. Patent No. 8,008,449 discloses the amino acid sequence of nivolumab and methods of use and preparation.
[0598] A further example of one or more active ingredients (antineoplastic agents) used in combination or co-administered with the compounds of the present invention is an immunomodulator.
[0599] As used herein, "immunomodulator" refers to any substance that affects the immune system, including monoclonal antibodies. The ICOS binding protein of the present invention can be considered an immunomodulator. Immunomodulators can be used as anti-tumor agents for the treatment of cancer. For example, immunomodulators include but are not limited to anti-CTLA-4 antibodies, such as ipilimumab (YERVOY) and anti-PD-1 antibodies (Opdivo / nivolumab and Keytruda / pembrolizumab). Other immunomodulators include but are not limited to OX-40 antibodies, PD-L1 antibodies, LAG3 antibodies, TIM-3 antibodies, 41BB antibodies, and GITR antibodies.
[0600] Yervoy (ipilimumab) is a fully human CTLA-4 antibody marketed by Bristol Myers Squibb. The protein structure and methods of use of ipilimumab are described in U.S. Patent Nos. 6,984,720 and 7,605,238.
[0601] In another embodiment, the present invention provides a compound of Table 1 or Formula (I), (Ia), (Ib), (II) or (III) as described herein, or a pharmaceutically acceptable salt or prodrug thereof, for use in treating a hepatitis B virus-related disease, condition or disorder. The present invention provides a compound of Table 1 or a pharmaceutically acceptable salt or prodrug thereof, for use in treating a hepatitis B virus-related disease, condition or disorder, wherein the hepatitis B virus-related disease, condition or disorder can be jaundice, liver cancer, liver inflammation, liver fibrosis, cirrhosis, liver failure, diffuse hepatocellular inflammatory disease, hemophagocytic syndrome, or serum hepatitis.
[0602] In a further embodiment, the compound of the present invention of formula (I), (Ia), (Ib), (II) or (III) or a pharmaceutically acceptable salt thereof is selected from the group of compounds listed in Table 1. In addition, the present invention also includes each of these compounds individually and a pharmaceutically acceptable salt thereof.
[0603] In another embodiment, a pharmaceutical composition is provided comprising a pharmaceutically acceptable diluent and a therapeutically effective amount of a compound of Formula I, Ia, Ib, II, or III, or a pharmaceutically acceptable salt thereof.
[0604] In certain embodiments, the compounds of the present invention, or pharmaceutically acceptable salts thereof, are selected from the compounds listed in Table 1. The compounds of the present invention may be provided in the form of pharmaceutically acceptable salts. The term "pharmaceutically acceptable salts" refers to salts prepared from pharmaceutically acceptable inorganic and organic acids and bases. Therefore, the term "or" in the context of "compound or pharmaceutically acceptable salt thereof" should be understood to refer to the compound or its pharmaceutically acceptable salt (alternatively), or the compound and its pharmaceutically acceptable salt (combination).
[0605] As used herein, the term "pharmaceutically acceptable" refers to those compounds, materials, compositions and dosage forms that are suitable for use in contact with the tissues of humans and animals without excessive toxicity, irritation or other problems or complications, within the scope of sound medical judgment. The skilled artisan will appreciate that pharmaceutically acceptable salts of the compounds of Formula I, Ia, Ib, II or III can be prepared. These pharmaceutically acceptable salts can be prepared in situ during the final isolation and purification of the compound, or by reacting the purified compound in its free acid or free base form with a suitable base or acid, respectively.
[0606] Exemplary pharmaceutically acceptable acid salts of the compounds of the invention can be prepared from acids including, but not limited to, formic, acetic, propionic, benzoic, succinic, glycolic, gluconic, lactic, maleic, malic, tartaric, citric, nitric, ascorbic, glucuronic, maleic, fumaric, pyruvic, aspartic, glutamic, benzoic, hydrochloric, hydrobromic, hydroiodic, isocitric, trifluoroacetic, pamoic, propionic, aminobenzoic, methanesulfonic, oxalacetic, oleic, stearic, salicylic, p-hydroxybenzoic, nicotinic, phenylacetic, mandelic, pamoic (pamoic) acid, methanesulfonic, phosphoric, phosphonic, ethanesulfonic, benzenesulfonic, pantothenic, toluenesulfonic, 2-hydroxyethanesulfonic, sulfanilic, sulfuric, salicylic, cyclohexylaminosulfonic, alginic, -hydroxybutyric, mucic, and galacturonic acids. Preferred pharmaceutically acceptable salts include hydrochloric acid and trifluoroacetic acid salts.
[0607] Exemplary pharmaceutically acceptable inorganic base salts of the compounds of the present invention include metal ions. Preferred metal ions include, but are not limited to, suitable alkali metal salts, alkaline earth metal salts, and other physiologically acceptable metal ions. Salts derived from inorganic bases include aluminum salts, ammonium salts, calcium salts, copper salts, iron salts, ferrous salts, lithium salts, magnesium salts, manganese salts, divalent manganese salts, potassium salts, sodium salts, zinc salts, etc. and with their common valences. Exemplary alkali salts include aluminum salts, calcium salts, lithium salts, magnesium salts, potassium salts, sodium salts, and zinc salts. Other exemplary alkali salts include ammonium salts, calcium salts, magnesium salts, potassium salts, and sodium salts. Still other exemplary alkali salts include, for example, hydroxides, carbonates, hydrides, and alkoxides, including NaOH, KOH, Na2CO3, K2CO3, NaH, and potassium tert-butoxide.
[0608] Salts derived from pharmaceutically acceptable organic non-toxic bases include salts of primary, secondary, and tertiary amines, some of which include trimethylamine, diethylamine, N,N'-dibenzylethylenediamine, chloroprocaine, choline, diethanolamine, ethylenediamine, meglumine (N-methylglucamine), and procaine; substituted amines, including naturally occurring substituted amines; cyclic amines; quaternary ammonium cations; and basic ion exchange resins, such as arginine, betaine, caffeine, choline, N,N-dibenzylethylenediamine, diethylamine, 2-diethylaminoethanol, 2-dimethylaminoethanol, ethanolamine, ethylenediamine, N-ethylmorpholine, N-ethylpiperidine, glucosamine, glucosamine, histidine, hydrabamine, isopropylamine, lysine, methylglucamine, morpholine, piperazine, piperidine, polyamine resins, procaine, purines, theobromine, triethylamine, trimethylamine, tripropylamine, tromethamine, and the like.
[0609] All of the above salts can be prepared by conventional methods by those skilled in the art from the corresponding compounds of the present invention. For example, the pharmaceutically acceptable salts of the present invention can be synthesized from the parent compound containing a basic or acidic moiety by conventional chemical methods. Generally, such salts can be prepared by reacting the free acid or base form of these compounds with a stoichiometric amount of an appropriate base or acid in water or in an organic solvent or in a mixture of the two; generally, non-aqueous media such as ether, ethyl acetate, ethanol, isopropanol or acetonitrile are preferred. The salt can be precipitated from the solution and collected by filtration or can be recovered by evaporating the solvent. The degree of ionization in the salt can range from completely ionized to almost non-ionized. A list of suitable salts can be found in Remington's Pharmaceutical Sciences , 17th ed., Mack Publishing Company, Easton, Pa., 1985, p. 1418 and Berge, J. Pharm. Sci., 1977, 66, 1-19, or P. H. Stahl and C. G. Wermuth, eds., Handbook of Pharmaceutical Salts; Properties, Selection and Use, Second EditionStahl / Wermuth: Wiley-VCH / VHCA, 2011 (see those listed in http: / / www.wiley.com / WileyCDA / WileyTitle / productCd-3906390519.html, the disclosure of which is incorporated herein by reference solely for the purpose of listing suitable salts.
[0610] The compounds of formula (I), (Ia), (Ib), (II) or (III) of the present invention may exist in unsolvated and solvated forms. The term "solvate" is used herein to describe a molecular complex comprising a compound of the present invention and one or more pharmaceutically acceptable solvent molecules, such as ethanol. When the solvent is water, the term "hydrate" is used. Pharmaceutically acceptable solvates include hydrates and other solvates in which the solvent of crystallization may be isotopically substituted, such as D2O, d6-acetone, d6-DMSO.
[0611] Compounds of Formula (I), (Ia), (Ib), (II) or (III) containing one or more asymmetric carbon atoms may exist as two or more stereoisomers. When compounds of Formula (I), (Ia), (Ib), (II) or (III) contain alkenyl or alkenylene groups or cycloalkyl groups, geometric cis / trans (or Z / E) isomers are possible. When compounds contain, for example, keto or oxime groups or aromatic moieties, tautomerism ("tautomerism") may occur. Thus, a single compound may exhibit more than one type of isomerism.
[0612] The scope of the compounds claimed herein includes all stereoisomers, geometric isomers, and tautomeric forms of compounds of Formula I, Ia, Ib, II, or III, including compounds exhibiting more than one type of isomerism, and mixtures of one or more thereof. Also included are acid addition salts or base salts in which the counterion is optically active, such as D-lactate or L-lysine, or racemic, such as DL-tartrate or DL-arginine.
[0613] Cis / trans isomers can be separated by conventional techniques well known to those skilled in the art, such as chromatography and fractional crystallization.
[0614] Conventional techniques for the preparation / isolation of individual enantiomers include chiral synthesis from a suitable optically pure precursor or resolution of the racemate (or the racemate of a salt or derivative) using, for example, chiral high pressure liquid chromatography (HPLC).
[0615] Alternatively, the racemate (or racemic precursor) can be reacted with a suitable optically active compound, such as an alcohol, or, in the case where the compound of Formula I, Ia, Ib, II or III contains an acidic or basic moiety, an acid or base, such as tartaric acid or 1-phenylethylamine. The resulting diastereomeric mixture can be separated by chromatography and / or fractional crystallization, and one or both of the diastereoisomers can be converted to the corresponding pure enantiomer by means well known to those skilled in the art.
[0616] The chiral compounds of the present invention (and chiral precursors thereof) can be obtained in enantiomerically enriched form using chromatography, typically HPLC, on an asymmetric stationary phase and a mobile phase consisting of a hydrocarbon (typically heptane or hexane) containing 0 to 50% isopropanol, typically 2 to 20%, and 0 to 5% alkylamine, typically 0.1% diethylamine. Concentration of the eluate provides an enriched mixture.
[0617] Mixtures of stereoisomers can be separated by conventional techniques known to those skilled in the art [e.g., see EL Eliel, "Stereochemistry of Organic Compounds" (Wiley, New York, 1994)].
[0618] The present invention includes all pharmaceutically acceptable isotopically labeled compounds of Formula (I), (Ia), (Ib), (II) or (III) wherein one or more atoms are replaced by an atom having the same atomic number, but an atomic mass or mass number different from the atomic mass or mass number usually found in nature.
[0619] Examples of suitable isotopes for inclusion in the compounds of the present invention include isotopes of hydrogen, e.g. 2 H and 3 H, isotopes of carbon, e.g. 11 C. 13 C and 14 C, isotopes of chlorine, e.g. 36 Cl, isotopes of fluorine, e.g. 18 F, isotopes of iodine, e.g. 123 I and 125 I, isotopes of nitrogen, e.g. 13 N and 15 N, isotopes of oxygen, e.g. 15 O. 17 O and 18 O, isotopes of phosphorus, e.g. 32 P, and isotopes of sulfur, e.g. 35 S.
[0620] Certain isotopically labeled compounds of Formula (I), (Ia), (Ib), (II) or (III), for example those incorporating radioactive isotopes, are useful in drug and / or substrate tissue distribution studies. 3 H and carbon-14 14 C, are particularly useful for this purpose given their ease of incorporation and convenient means of detection.
[0621] Using heavier isotopes (such as deuterium, 2 H) Substitution may offer certain therapeutic benefits resulting from greater metabolic stability, e.g., increased in vivo half-life or reduced dosage requirements, and therefore may be preferred in certain circumstances.
[0622] Isotopically labeled compounds of Formula (I), (Ia), (Ib), (II) or (III) can generally be prepared by conventional techniques known to those skilled in the art or by processes analogous to those described in the accompanying Examples using an appropriate isotopically labeled reagent in place of the non-labeled reagent previously employed.
[0623] The compounds of the present invention may be administered as prodrugs. Thus, certain derivatives of compounds of Formula (I), (Ia), (Ib), (II) or (III), which themselves may have little or no pharmacological activity, may be converted to compounds of Formula (I), (Ia), (Ib), (II) or (III) as "prodrugs" when administered into or onto the body.
[0624] The administration of the chemical entities described herein can be by any acceptable mode of administration for medicaments with similar efficacies, including but not limited to oral, sublingual, subcutaneous, intravenous, intranasal, topical, transdermal, intraperitoneal, intramuscular, intrapulmonary, vaginal, rectal or intraocular. In some embodiments, oral or parenteral administration is used.
[0625] Pharmaceutical compositions or formulations include solid, semisolid, liquid and aerosol dosage forms, such as tablets, capsules, powders, liquids, suspensions, suppositories, aerosols, and the like. Chemical entities can also be administered in sustained-release or controlled-release dosage forms, including reservoir injections, or implantable formulations, osmotic pumps, pills, transdermal (including electrotransport) patches, and the like, for prolonged and / or timed, pulsed administration at a predetermined rate. In certain embodiments, the composition is provided in a unit dosage form suitable for single administration of precise dosages. The active ingredient can be compressed into a pill or small cylinder and implanted subcutaneously or intramuscularly as a reservoir injection or implant. Implants can be made of inert materials, such as biodegradable polymers or synthetic silicones, such as Silastic or silicone rubber.
[0626] Chemical entities can also be administered in the form of liposome delivery systems, such as small unilamellar vesicles, large unilamellar vesicles, and multilamellar vesicles. Liposomes can be formed from a variety of phospholipids, such as cholesterol, stearylamine, or phosphatidylcholine. Liposomal formulations of tyrosine kinase inhibitors can also be used in the methods of the present invention. Liposomal forms of tyrosine kinase inhibitors can be used to increase tolerance to the inhibitor.
[0627] Chemical entities can also be delivered by using monoclonal antibodies as individual carriers to which the compound molecules are coupled.
[0628] Chemical entities can also be prepared using soluble polymers as targetable drug carriers. Such polymers may include polyvinylpyrrolidone, pyran copolymers, polyhydroxy-propyl-methacrylamide-phenol, polyhydroxyethyl-aspartamide-phenol, or polyethylene oxide-polylysine substituted with palmitoyl residues. In addition, chemical entities can be prepared using biodegradable polymers that can be used to achieve controlled drug release, such as cross-linked or amphiphilic block copolymers of polylactic acid, polyglycolic acid, copolymers of polylactic acid and polyglycolic acid, poly-ε-caprolactone, polyhydroxybutyric acid, polyorthoesters, polyacetals, polydihydropyrans, polycyanoacrylates, and hydrogels.
[0629] The chemical entities described herein can be administered alone or, more typically, in combination with conventional pharmaceutical carriers, excipients, and the like (e.g., mannitol, lactose, starch, magnesium stearate, sodium saccharin, talc, cellulose, cross-linked sodium carboxymethyl cellulose, glucose, gelatin, sucrose, magnesium carbonate, and the like). If desired, the pharmaceutical composition may also contain small amounts of non-toxic auxiliary substances, such as wetting agents, emulsifiers, solubilizers, pH buffers, and the like (e.g., sodium acetate, sodium citrate, cyclodextrin derivatives, sorbitan monolaurate, triethanolamine acetate, triethanolamine oleate, and the like). Typically, depending on the intended mode of administration, the pharmaceutical composition contains from about 0.005% to 95% by weight; in certain embodiments, from about 0.5% to 50% by weight of the chemical entity. The actual methods for preparing such dosage forms are known or apparent to those skilled in the art; for example, see Remington's Pharmaceutical Sciences , Mack Publishing Company, Easton, Pennsylvania.
[0630] In certain embodiments, the composition will be in the form of a pill or tablet, and thus the composition will contain, together with the active ingredient, a diluent such as lactose, sucrose, dicalcium phosphate, etc.; a lubricant such as magnesium stearate, etc.; and a binder such as starch, gum arabic, polyvinyl pyrrolidine, gelatin, cellulose, cellulose derivatives, etc. In another solid dosage form, the powder, pill (marume), solution or suspension (for example, in propylene carbonate, vegetable oil or triglyceride) is enclosed in a gelatin capsule.
[0631] Liquid pharmaceutically administrable compositions can be prepared, for example, by dissolving, dispersing, or the like at least one chemical entity and optional pharmaceutical adjuvants in a carrier (e.g., water, saline, aqueous dextrose, glycerol, glycols, ethanol, etc.) to form a solution or suspension. Injections can be prepared in conventional forms, either as liquid solutions or suspensions, as emulsions, or in solid forms suitable for dissolution or suspension in a liquid prior to injection. The percentage of the chemical entity included in such parenteral compositions is highly dependent on its specific properties, as well as the activity of the chemical entity and the needs of the subject. However, percentages of active ingredient in solution of 0.01% to 10% are useful, and these percentages can be higher if the composition is a solid that is subsequently diluted to the above percentages. In certain embodiments, the composition will contain approximately 0.2% to 2% active agent in solution.
[0632] Pharmaceutical compositions of the chemical entities described herein can also be administered to the respiratory tract as an aerosol or solution for a nebulizer, or as a finely divided powder for insufflation, alone or in combination with an inert carrier such as lactose. In this case, the particles of the pharmaceutical composition have a diameter of less than 50 microns, and in certain embodiments, less than 10 microns.
[0633] In general, the provided chemical entities are administered in therapeutically effective amounts by any of the accepted modes of administration used for pharmaceuticals with similar utilities. The dosing regimen for utilizing the chemical entities described herein can be selected based on a variety of factors, including type, species, age, weight, sex, and type of disease being treated; the severity (i.e., stage) of the disease being treated; the route of administration; the patient's renal and hepatic function; and the specific compound or salt thereof being used. For example, a dosing regimen can be used to prevent, inhibit (completely or partially), or arrest the progression of a disease. The drug can be administered more than once per day, for example, once or twice per day.
[0634] Intravenously or subcutaneously, the patient will receive a therapeutically effective amount of a chemical entity as described herein, the therapeutically effective amount being sufficient to deliver about 0.001 to 200 mg / per kilogram of recipient body weight / day; for example, about 0.005-100 mg / kg / day, for example, about 0.005-1 mg / kg / day. Thus, for administration to a person weighing 70 kg, the dosage range can be about 0.35-70 mg / day. Such an amount can be administered in a variety of suitable ways, such as administering a large amount of low concentrations of the chemical entity over an extended period of time or multiple times a day. The amount can be administered continuously for one or more days per week (7 day cycle), intermittently, or in combination thereof. Alternatively, a low amount of high concentration of the chemical entity over a short period of time, for example, continuously, intermittently, or in combination thereof once a day per week (7 day cycle), for one or more days.
[0635] According to the present invention, the chemical entities described herein can be administered by continuous or intermittent administration. For example, intermittent administration of a chemical entity can be administration 1 to 6 days per week, or can refer to administration in cycles (e.g., daily administration for two to eight weeks, followed by a rest period of up to one week without administration), or can refer to administration every other day. The composition can be administered in cycles with rest periods between cycles (e.g., treatment for 2 to 8 weeks with a rest period of up to one week between treatments).
[0636] Subcutaneous formulations can be prepared at a pH range of about 5 to about 12, including appropriate buffers and isotonic agents, according to procedures well known in the art.
[0637] Typically, the chemical entity will be administered as a pharmaceutical composition by any of the following routes: oral, systemic (e.g., transdermal, intranasal, or by suppository), or parenteral (e.g., intramuscular, intravenous, or subcutaneous). In certain embodiments, oral administration may be used with a convenient daily dosing regimen that can be adjusted according to the severity of the affliction. The composition may take the form of a tablet, pill, capsule, semisolid, powder, sustained release formulation, solution, suspension, elixir, aerosol, or any other suitable composition. Another way to administer the provided chemical entity is by inhalation.
[0638] The choice of formulation depends on a variety of factors, such as the route of drug administration and the bioavailability of the drug substance. For delivery by inhalation, the chemical entity can be formulated as a liquid solution, suspension, aerosol propellant, or dry powder and administered in a suitable dispenser. There are several types of inhalation devices: nebulizers, metered-dose inhalers (MDIs), and dry powder inhalers (DPIs). Nebulizer devices generate a high-velocity airflow that sprays the therapeutic agent (formulated in liquid form) into the patient's respiratory tract in the form of an aerosol. MDIs typically package the formulation with compressed gas. Upon actuation, the device releases a measured amount of the therapeutic agent via the compressed gas, providing a reliable method for administering a set dose. DPIs dispense the therapeutic agent as a free-flowing powder that is dispersed into the patient's inspiratory airstream during exhalation. To achieve a free-flowing powder, the therapeutic agent is formulated with an excipient, such as lactose. The measured amount of therapeutic agent is stored in capsules and dispensed upon each actuation.
[0639] Recently, pharmaceutical compositions for drugs with poor bioavailability have been developed based on the principle that bioavailability can be increased by increasing surface area, i.e., reducing particle size. For example, U.S. Patent No. 4,107,288 describes a pharmaceutical formulation having particles ranging in size from 10 to 1,000 nanometers, in which the active material is supported on a cross-linked macromolecular matrix. U.S. Patent No. 5,145,684 describes the production of a pharmaceutical formulation in which a drug substance is pulverized into nanoparticles (average particle size of 400 nm) in the presence of a surface modifier and then dispersed in a liquid medium to produce a pharmaceutical formulation exhibiting very high bioavailability.
[0640] The compositions are generally composed of at least one chemical entity described herein and at least one pharmaceutically acceptable excipient. Acceptable excipients are non-toxic, facilitate administration, and do not adversely affect the therapeutic benefits of the at least one chemical entity described herein. Such excipients can be any solid, liquid, semisolid, or, in the case of aerosol compositions, gaseous excipients generally available to those skilled in the art.
[0641] Solid pharmaceutical excipients include starch, cellulose, talc, glucose, lactose, sucrose, gelatin, malt, rice, flour, chalk, silica gel, magnesium stearate, sodium stearate, glyceryl monostearate, sodium chloride, skim milk powder, etc. Liquid and semi-solid excipients can be selected from glycerol, propylene glycol, water, ethanol and various oils, including those of petroleum, animal, vegetable or synthetic origin, such as peanut oil, soybean oil, mineral oil, sesame oil, etc. Liquid carriers for injectable solutions include water, saline, aqueous dextrose, and ethylene glycol.
[0642] Compressed gases can be used to disperse the chemical entities described herein in aerosol form. Suitable inert gases for this purpose are nitrogen, carbon dioxide, and the like. Other suitable pharmaceutical excipients and their formulations are described in Remington's Pharmaceutical Sciences, edited by E. W. Martin (Mack Publishing Company, 18th edition, 1990).
[0643] The amount of the chemical entity in the composition can vary within the full range employed by those skilled in the art. Typically, the composition will contain, in weight percent (wt%), about 0.01-99.99 wt% of at least one chemical entity described herein, based on the total composition, with the balance being one or more suitable pharmaceutical excipients. In certain embodiments, at least one chemical entity described herein is present at a level of about 1-80 wt%.
[0644] In various embodiments, the pharmaceutical compositions of the present invention include a compound of Formula (I), (Ia), (Ib), (II), or (III), salts thereof, and combinations thereof.
[0645] The various modes of administration, dosages and dosing regimens described herein are merely specific embodiments and should not be construed as limiting the broad scope of the invention. Any permutations, variations and combinations of dosages and dosing regimens are included within the scope of the present invention.
[0646] The compounds of the present invention can be prepared according to the various schemes described below.
[0647] Synthesis method
[0648] The syntheses of the provided chemical entities employ the following general methods and procedures using readily available starting materials. It will be appreciated that where typical or preferred process conditions (i.e., reaction temperatures, times, molar ratios of reactants, solvents, pressures, etc.) are given, other process conditions may also be used unless otherwise indicated. Optimal reaction conditions may vary with the specific reactants or solvents used, but such conditions can be determined by one skilled in the art through routine optimization procedures.
[0649] In addition, method of the present invention can use blocking group, and it prevents some functional group from undesirable reaction.The suitable blocking group of various functional groups and the suitable conditions that are used to protect and deprotect specific functional groups are well known in the art.For example, many blocking groups are described in TW Greene and GM Wuts, Protecting Groups in Organic Synthesis, the 3rd edition, Wiley, New York, 1999 and the references that wherein quote.
[0650] In addition, the provided chemical entities may contain one or more chiral centers, and such compounds can be prepared or isolated as pure stereoisomers, i.e., single enantiomers or diastereomers, or stereoisomer-enriched mixtures. Unless otherwise indicated, all such stereoisomers (and enriched mixtures) are included within the scope of this specification. Pure stereoisomers (or enriched mixtures) can be prepared using, for example, optically active starting materials or stereoselective reagents known in the art. Alternatively, racemic mixtures of such compounds can be separated using, for example, chiral column chromatography, chiral resolving agents, and the like.
[0651] The starting materials for the following reactions are generally known compounds or can be prepared by known procedures or obvious modifications thereof. For example, many starting materials are available from commercial suppliers such as Aldrich Chemical Co. (Milwaukee, Wisconsin, USA), Bachem (Torrance, California, USA), Ernka-Chemce or Sigma (St. Louis, Missouri, USA). Other materials can be prepared by procedures described, for example, in the following standard reference textbooks, or obvious modifications thereof: Fieser and Fieser's Reagents for Organic Synthesis, Volumes 1-15 (John Wiley and Sons, 1991), Rodd's Chemistry of Carbon Compounds, Volumes 1-5 and Supplementals (Elsevier Science Publishers, 1989), Organic Reactions, Volumes 1-40 (John Wiley and Sons, 1991), March's Advanced Organic Chemistry, (John Wiley and Sons, 4th Edition), and Larock's Comprehensive Organic Transformations (VCH Publishers Inc., 1989).
[0652] Unless otherwise specified, the reactions described herein are carried out at atmospheric pressure, typically within a temperature range of -78°C to 200°C. Furthermore, unless used in the examples or otherwise indicated, reaction times and conditions are intended to be approximate, e.g., at a temperature range of about -78°C to about 110°C at about atmospheric pressure for a time of about 1 to about 24 hours; reactions run overnight will require an average of about 16 hours.
[0653] The terms "solvent," "organic solvent," and "inert solvent" each refer to a solvent that is inert under the reaction conditions described in connection therewith, and include, for example, benzene, toluene, acetonitrile, tetrahydrofuran ("THF"), dimethylformamide ("DMF"), chloroform, methylene chloride (or dichloromethane), diethyl ether, methanol, N-methylpyrrolidone ("NMP"), pyridine, and the like.
[0654] If desired, the isolation and purification of the chemical entities and intermediates described herein can be achieved by any suitable separation or purification procedure, such as filtration, extraction, crystallization, column chromatography, thin layer chromatography or thick layer chromatography, or a combination of these procedures. Specific illustrations of suitable separation and isolation procedures can be obtained by reference to the examples below. However, other equivalent separation or isolation procedures may also be used.
[0655] When desired, (R)- and (S)-isomers can be resolved by methods known to those skilled in the art, such as by forming diastereomeric salts or complexes that can be separated, for example, by crystallization; by forming diastereomeric derivatives that can be separated, for example, by crystallization, gas-liquid or liquid chromatography; selective reaction of one enantiomer with an enantiomer-specific reagent, such as enzymatic oxidation or reduction, followed by separation of the modified and unmodified enantiomers; or gas-liquid or liquid chromatography in a chiral environment, such as on a chiral support such as silica with a bound chiral ligand or in the presence of a chiral solvent. Alternatively, a specific enantiomer can be synthesized by asymmetric synthesis using optically active reagents, substrates, catalysts or solvents, or by converting one enantiomer to the other by asymmetric transformation. Example
[0656] The following examples are used to more fully describe the preparation and use of the above invention. It should be understood that these examples are in no way intended to limit the true scope of the present invention, but are presented for illustrative purposes. In the following examples and above synthetic schemes, the following abbreviations have the following meanings. If abbreviations are undefined, they have their generally accepted meanings.
[0657] aq. = Watery µL = Slightly higher µM = micromolar NMR = Nuclear magnetic resonance imaging Boc = tert-Butoxycarbonyl Br = Width Cbz = benzyloxycarbonyl d = Twin Peaks Δ = Chemical shift ℃ = degrees Celsius DCM = dichloromethane dd = Double Twin Peaks DMAP = 4-(Dimethylamino)pyridine DMEM = Dulbeco's modified Eagle's medium DMF = N,N-Dimethylformamide DMP = 2,2-Dimethoxypropane DMSO = dimethyl sulfoxide EtOAc = Ethyl acetate ESI = Electrospray ionization G or g = gram H or hr = Hour HCV = Hepatitis C virus HPLC = High-performance liquid chromatography Hz = hertz IU = International Units <![CDATA[IC 50 ]]> = Inhibitory concentration at 50% inhibition J = Coupling constants (given in Hz unless otherwise stated) LHMDS = Lithium bis(trimethylsilyl)amide M = Multiplets M = Moore's <![CDATA[M+H + ]]> = <![CDATA[Mass spectrometry parent ion peak + H + > Mg or mg = mg Min = minute mL = milliliters mM = millimolar Mmol = millimoles MS = Mass spectrometry Nm = Namor's ppm = parts per million p-TsOH = p-Toluenesulfonic acid qs = sufficient S = Single peak RT = Room temperature sat. = Saturated T = Triple Peak TBS-Cl = tert-Butyldimethylsilyl chloride TFA = Trifluoroacetic acid
[0658] Equipment Description
[0659] 1 H NMR spectra were recorded on a Varian spectrometer. Chemical shifts are expressed in parts per million (ppm). Coupling constants are expressed in Hertz (Hz). Splitting patterns describe the apparent multiplicity and are designated as s (singlet), d (doublet), t (triplet), q (quartet), quint (quintet), m (multiplet), or br (broad).
[0660] Analytical low resolution mass spectra (MS) were recorded on a Waters (Acquity). The following conditions described below were employed.
[0661] Instrument: Agilent 1200-6100
[0662] Scan mode: alternating positive / negative electrospray
[0663] Scan range: 100-1000 amu.
[0664] LC conditions:
[0665] LCMS analysis was performed on a HALO C-18, 4.6*50 mm, 2.7 μm, C18 column at 45°C.
[0666] Inject 1.0 μL of sample.
[0667] The gradient used is:
[0668] Mobile phase A: water + 0.1% v / v formic acid
[0669] Mobile phase B: acetonitrile + 0.1% v / v formic acid
[0670] Time %A %B Flow rate
[0671] 0.00 min 95 5 1.8 ml / min
[0672] 1.0 min 5 95 1.8 ml / min
[0673] 2.0 min 5 95 1.8 ml / min
[0674] 2.5 min 95 5 1.8 ml / min.
[0675] UV detection was provided by the total absorbance signal scanned at 214 nm and 254 nm.
[0676] Instrument: Shimadzu LCMS-2020
[0677] Scan mode: alternating positive / negative electrospray
[0678] Scan range: 100-2000 amu.
[0679] LC conditions:
[0680] LCMS analysis was performed on a HALO C-18, 4.6*50 mm, 2.7 μm, C18 column at 45°C.
[0681] Inject 1.0 μL of sample.
[0682] The gradient used is:
[0683] Mobile phase A: water + 0.1% v / v formic acid
[0684] Mobile phase B: acetonitrile + 0.1% v / v formic acid.
[0685] Time %A %B Flow rate
[0686] 0.00 min 95 5 1.5 ml / min
[0687] 1.0 min 5 95 1.5 ml / min
[0688] 2.0 min 5 95 1.5 ml / min
[0689] 2.5 min 95 5 1.5 ml / min
[0690] 3.0 min 95 5 1.5 ml / min.
[0691] UV detection was provided by the total absorbance signal scanned at 214 nm and 254 nm.
[0692] Protocol and experimental procedures
[0693] The following schemes and procedures illustrate how the compounds of the present invention can be prepared. The specific solvents and reaction conditions indicated are also illustrative and not restrictive. Compounds not described are commercially available or readily prepared by one skilled in the art using available starting materials. The examples disclosed herein are for illustrative purposes only and are not intended to limit the scope of the present invention.
[0694] The additional examples contained herein were determined to have the configurations shown by spectroscopic methods known to those skilled in the art, including, but not limited to, 1D and 2D NMR methods. Compounds of formula (I), (Ia), (Ib), (II) or (III) can be synthesized, for example, according to Schemes 1-6.
[0695] In one embodiment, compounds of Formula 1.12 can be prepared as shown in Scheme 1. The bicyclic ring systems in Formulas 1.5 and 1.6 can be formed using a four-component Ugi reaction of carboxylic acid 1.1, isocyanide 1.2, aldehyde 1.3, and ammonia to give dipeptide 1.4, followed by acid deprotection and cyclization. Compounds of Formulas 1.5 and 1.6 can be synthesized using an asymmetric Ugi synthesis with the addition of a chiral reagent such as a chiral phosphoric acid (Jian Zhang et al., Science, 2018, 361, 1087). Isocyanides (Isocyanide Chemistry: Application in Synthesis and Material Science, edited by V. Nenajdenko, Wiley-VCH, 1st edition) can be synthesized by dehydrating formamide using, for example, phosphorus oxychloride, phosgene, diphosgene, tosyl chloride, etc. Formamides can, in turn, be prepared by formylation of amines with ethyl formate, mixed formic acid-acetic anhydride, formic acid / carbodiimide, or activated formate. Aldehydes of formula 1.3 (M. Vamos et al., ACS Chem. Biol., 2013, 8, 725-732) can be prepared by dimethylation of 4,4-dimethoxybutyronitrile followed by reduction with DIBAL-H. Compounds of formula 1.8 can be prepared by coupling Boc-N-methyl-L-Ala-OH 1.7 with the desired diastereomer 1.5 using standard amide coupling reagents such as T3P, HATU, HBTU, EDC / HOBt, TBTU, and the like in the presence of a base such as Hunig's base, N-methylmorpholine, and the like in an appropriate solvent such as DMF, DCM, and the like. The alkyne in formula 1.8 can be selectively reduced by hydrogenation in the presence of Lindlar's catalyst or alternative methods to give alkenes of formula 1.9. The alkenes of formula 1.9 can be dimerized using the Grubbs olefin metathesis reaction to give compounds of formula 1.10. Olefins of formula 1.10 can be reduced using hydrogenation in the presence of a metal catalyst (eg, palladium on carbon, platinum) to give compounds of formula 1.11, where the Boc protecting group can be removed under acidic conditions such as HCl, TFA, and the like.
[0696]
[0697] In another embodiment, intermediates of formula 2.8 can be prepared according to Scheme 2. Intermediate 2.8 is a universal intermediate for formula I, Ia, Ib, II, or III by coupling with various diamines known to those skilled in the art. Bicyclic compounds of formula 2.5 can be prepared by a four-component Ugi reaction using acid 2.1, isocyanide 2.2, aldehyde 2.3, and ammonia to give dipeptides of formula 2.4. Compounds of formula 2.5 can be prepared by treating dipeptide 2.4 with an acid, which can result in the formation of a bicyclic structure and an indoleamide (O. Kreye et al., SYNLETT, 2007, pp. 3188-3192). Compounds of formula 2.6 and 2.7 can be prepared by coupling Boc-N-methyl-L-Ala-OH 1.7 with compound 2.5 using standard amide coupling reagents such as T3P, HATU, HBTU, EDC / HOBt, TBTU, etc. in the presence of a base such as Hunig's base, N-methylmorpholine, etc. in a suitable solvent such as DMF, DCM, etc. Acids of formula 2.8 can be prepared by basic hydrolysis of indoleamides of formula 2.6 in the presence of sodium hydroxide, etc. in a solvent such as water, methanol.
[0698]
[0699] In another embodiment, intermediates of formula 3.7 can be prepared according to Scheme 3. Intermediate 3.7 is a versatile intermediate to compounds of formula I, Ia, Ib, II, or III by coupling with various diamines known to those skilled in the art.
[0700] Scheme 3. Activated thioamidating reagents of Formula 3.4 can be prepared as follows. Amide coupling of Boc-N-methyl-L-Ala-OH 1.7 with a diamine of Formula 3.1 using mixed anhydride coupling conditions or alternative amide coupling conditions can provide compounds of Formula 3.2. Sulfidation of amide 3.2 using phosphorus pentasulfide in the presence of a base such as sodium carbonate in a solvent such as THF can provide thioamides of Formula 3.3. Nitrobenzotriazole reagents of Formula 3.4 can be prepared by treating thioamide 3.3 with sodium nitrite in acetic acid in a solvent such as THF (M. Ashraf Shalaby et al., J. Org. Chem. 1996, 61, pp. 9045-9048). Compounds of formula 3.5 and 3.6 can be prepared by reacting indoleamide 2.5 with an activated thioacylating agent of formula 3.4 in the presence of a base such as Hunig's base, triethylamine, etc., in a solvent such as DCM, DMF, etc. The separated diastereomers of formula 3.5 can be treated with an aqueous base such as sodium hydroxide in an alcoholic solvent such as methanol to provide intermediates of formula 3.7.
[0701]
[0702] In another embodiment, compounds of Formula 4.3 and 4.5 can be prepared according to Scheme 4. Compounds of Formula 4.2 and 4.4 can be prepared by coupling intermediate 2.8 or 3.7 with diamine 4.1 in the presence of a coupling agent or via an activated ester in the presence of a base such as Hunig's base, triethylamine, and the like, in a solvent such as DMF, THF, DCM, and the like. Coupling agents such as HATU, TBTU, BOP, PyBOP, DEPBT, EDC / HOBt, and EEDQ (but not limited to this list) can be used for the coupling reaction. Compounds of Formula 4.3 and 4.5 can be prepared by Boc deprotection of compounds 4.2 and 4.4 under acidic conditions such as HCl, TFA, and the like.
[0703]
[0704] The diamines used to couple intermediates 2.8 and 3.7 are readily available from commercial suppliers or can be prepared within the skill of the art. Various examples are illustrated in Scheme 5, but are not limited to the type of chemistry or functional group used for the linker. Diamines of formula 5.3 and 5.5 can be prepared by dialkylation of amino alcohol 5.1 or 5.4 in the presence of a base such as sodium hydride in a solvent such as DMF, THF, or the like, where X is a leaving group such as a halogen, tosylate, mesylate, or the like. Compounds of formula 5.8 and 5.10 can be prepared by coupling protected amino acids 5.6 and 5.9 under amide coupling conditions, followed by acid deprotection.
[0705]
[0706] The rectangular box Is a connecting group.
[0707] In another embodiment, dimers of Formulas 6.7, 6.8, 6.9, 6.10, and 6.11 can be prepared according to Scheme 6. Compounds of Formulas 6.3, 6.4, 6.5, and 6.6 can be prepared by amide bond coupling of intermediates 2.8 and 3.7 with amines of Formulas 6.1 and 6.2, where X and Y are linkers with terminal functional groups available for further reaction. Examples of functional groups, but not limited to the following, are protected amines, protected carboxylic acids, protected thiols, alkynes, alkenes, sulfonyl chlorides, azides, hydroxyls, halogens, nitriles, and isocyanates. Monomers of Formulas 6.3 and 6.5 can dimerize to form dimers of Formulas 6.7 and 6.11, for example, when X comprises an alkyne, alkene, amine, or an alternative functional group that can further react to form homodimers via copper-mediated alkyne coupling, olefin metathesis, urea, or sulfonamide formation. Monomers of formula 6.3, 6.4, 6.5, and 6.6 can react with each other to form heterodimers of formula 6.8, 6.9, and 6.10, for example, when X comprises an amine and Y comprises a carboxylic acid, sulfonyl chloride, or isocyanate that can form an amide, sulfonamide, or urea; or when X is an alkyne and Y is an azide that can form a triazole; or when X comprises a hydroxyl group and Y comprises a halogen that can form an ether. The chemistry is not limited to the above list, but other combinations are known to those skilled in the art.
[0708] Intermediate 1:
[0709] (4 S ,7 S ,9a S )-4-(( S )-2-((tert-Butoxycarbonyl)(methyl)amino)propionamido)-8,8-dimethyl- 5-Oxooctahydropyrrolo[2,1-b][1,3]thiazepine-7-carboxylic acid
[0710]
[0711] Step 1: ( E )-1-(2-nitrostyryl)pyrrolidine
[0712] To 1-methyl-2-nitrobenzene (50 g, 365 mmol) N,N- To a solution in dimethylformamide (200 mL) were added pyrrolidine (31.1 g, 438 mmol) and 1,1-dimethoxy -N,N- Dimethylmethylamine (52.2 g, 438 mmol). The resulting mixture was stirred at 60°C. After 5 hours, the temperature was raised to 80°C and stirred for 17 hours. After cooling to room temperature, the mixture was partitioned between methyl tert-butyl ether (500 mL) and water (1 L). The aqueous phase was separated and extracted with methyl tert-butyl ether (500 mL). The combined organic layers were washed with brine, dried over anhydrous sodium sulfate, filtered and concentrated to obtain a dark red oil. (E )-1-(2-nitrostyryl)pyrrolidine (80 g, crude). It was used in the next step without further purification.
[0713] Step 2: 1-(2,2-dimethoxyethyl)-2-nitrobenzene
[0714] Towards( E )-1-(2-nitrostyryl)pyrrolidine (80 g, crude) in methanol (600 mL) was slowly added trimethylchlorosilane (59.5 g, 550 mmol). The mixture was heated at reflux for 24 hours. At this time, the solution was cooled to room temperature and concentrated in vacuo to obtain a residue. It was distributed between ethyl acetate (500 mL) and 5% aqueous citric acid solution (800 mL). The aqueous layer was extracted with ethyl acetate (2×300 mL). The combined organic layers were washed with 5% aqueous sodium bicarbonate solution (300 mL) and then brine. The crude product was dried over anhydrous sodium sulfate, filtered and concentrated to obtain 1-(2,2-dimethoxyethyl)-2-nitrobenzene (79 g, crude) as a dark red oil, which was used in the next step without further purification.
[0715] Step 3: 2-(2,2-Dimethoxyethyl)aniline
[0716] To a solution of 1-(2,2-dimethoxyethyl)-2-nitrobenzene (79 g, 374.4 mmol) in methanol (1 L) was added activated carbon-supported palladium (17.6 g). The mixture was stirred at room temperature under hydrogen at 50 psi for 17 hours. The mixture was filtered through diatomaceous earth and rinsed with methanol. The filtrate was concentrated to give a crude product. The crude product was dissolved in methyl tert-butyl ether (500 mL) and filtered. The filtrate was concentrated to give 2-(2,2-dimethoxyethyl)aniline (60 g, 331.5 mmol, 88.5% yield) as a dark red oil. It was used in the next step without further purification. 1 H NMR (400 MHz, DMSO- d 6 ) δ ppm6.98 – 6.89 (m, 2H), 6.63 (dd, J = 7.9, 1.1 Hz, 1H), 6.51 (td, J = 7.4, 1.2Hz, 1H), 4.80 (s, 2H), 4.55 (t, J = 5.6 Hz, 1H), 3.25 (s, 6H), 2.72 (d, J =5.6 Hz, 2H).
[0717] Step 4: N- (2-(2,2-Dimethoxyethyl)phenyl)formamide
[0718] To a solution of 2-(2,2-dimethoxyethyl)aniline (60 g, 331.5 mmol) and ethyl formate (36.8 g, 497.2 mmol) in anhydrous tetrahydrofuran (400 mL) was slowly added a 1 M solution of lithium bis(trimethylsilyl)amide (597 mL, 597 mmol). The mixture was stirred at room temperature for 12 hours and then refluxed for 18 hours. At this time, saturated ammonium chloride (200 mL) was added and the mixture was extracted with ethyl acetate (3 × 200 mL). The organic phases were combined, dried over anhydrous sodium sulfate, filtered and concentrated. The crude product was purified by silica gel chromatography [petroleum ether / ethyl acetate (6:1 v / v)] to obtain a dark red oil. N- (2-(2,2-Dimethoxyethyl)phenyl)formamide (58 g, 277.5 mmol, 83.7% yield).
[0719] LCMS (2.5 min formic acid): Rt = 1.354 min, m / z: 209.1 [M+1] + ,231.9 [M+Na] + .
[0720] Step 5: 1-(2,2-Dimethoxyethyl)-2-isocyanobenzene
[0721] At 0℃ N To a solution of 1-(2-(2,2-dimethoxyethyl)phenyl)formamide (58 g, 277.5 mmol) in dichloromethane (500 mL) was added triethylamine (143 g, 1415.3 mmol), followed by phosphorus oxychloride (63.9 g, 416.3 mmol). The mixture was warmed to room temperature and stirred for 2 hours. At this time, it was poured into saturated aqueous sodium bicarbonate solution (300 mL) and extracted with dichloromethane (3 × 200 mL). The organic layer was dried over anhydrous sodium sulfate, filtered, and concentrated. The crude product was purified by silica gel chromatography [petroleum ether / ethyl acetate (20:1 v / v)] to give 1-(2,2-dimethoxyethyl)-2-isocyanobenzene (42 g, 218.5 mmol, 79.2% yield) as a light brown oil. 1 H NMR (400 MHz, DMSO- d 6 ) δppm 7.57 – 7.27 (m, 4H), 4.61 (t, J = 5.6 Hz, 1H), 3.27 (s, 6H), 3.00 (d, J=5.6 Hz, 2H). LCMS (2.5 min formic acid): Rt = 1.455 min, m / z: 192.0 (M+1) + .
[0722] Step 6: 4,4-Dimethoxy-2,2-dimethylbutyronitrile
[0723] To a solution of diisopropylamine (89.4 mL, 682 mmol) in tetrahydrofuran (1 L) was added a 2.4 M solution of n-butyllithium in hexane (288 mL, 682 mmol) at -10 ° C under nitrogen. After 30 minutes, the mixture was cooled to -78 ° C and a solution of 4,4-dimethoxybutyronitrile (40 g, 310 mmol) in tetrahydrofuran (30 mL) was added. After 1 hour, methyl iodide (42.4 mL, 682 mmol) was added very slowly. The mixture was allowed to warm to room temperature and stirred overnight. At this time, it was quenched with saturated aqueous ammonium chloride and extracted with ethyl acetate (3 × 400 mL). The organic layer was dried over anhydrous sodium sulfate, filtered and concentrated. The crude product was purified by silica gel chromatography [petroleum ether / ethyl acetate (30:1 v / v)] to give 4,4-dimethoxy-2,2-dimethylbutyronitrile (35 g, 223 mmol, 71.9% yield) as a light yellow oil. 1 H-NMR (400 MHz, CDCl3) δppm 4.60 (t, J = 5.4 Hz, 1H), 3.36 (s, 6H), 1.83 (d, J = 5.4 Hz, 2H), 1.39(s, 6H).
[0724] Step 7: 4,4-Dimethoxy-2,2-dimethylbutanal
[0725] To a solution of 4,4-dimethoxy-2,2-dimethylbutyronitrile (27 g, 172 mmol) in dichloromethane (800 mL) was slowly added a 1 M solution of diisobutylaluminum hydride in hexanes (189 mL, 189 mmol) at -78°C over 3.5 hours. The mixture was allowed to warm to room temperature and quenched with saturated aqueous ammonium chloride (400 mL) and Rochelle's salt (400 mL). The aqueous phase was extracted with dichloromethane (2 × 400 mL). The combined organic layers were washed with brine (400 mL), dried over anhydrous sodium sulfate, filtered, and concentrated. The crude product was purified by silica gel chromatography (petroleum ether / ethyl acetate (30:1 v / v)) to afford 4,4-dimethoxy-2,2-dimethylbutyraldehyde (13 g, 81.1 mmol, 47.1% yield) as a colorless oil. LCMS (2.5 min formic acid): Rt = 1.453 min, m / z: 182.9 (M+Na) + .
[0726] Step 8: (4 S ,9a S )-4-amino-7-(1H-indole-1-carbonyl)-8,8-dimethylhexahydropyrrolo[2,1-b] [1,3]thiazepin-5(2H)-one
[0727] a. N- (tert-Butoxycarbonyl) -S- Trityl -L- A mixture of homocysteine (11.8 g, 24.7 mmol), 1-(2,2-dimethoxyethyl)-2-isocyanobenzene (from Step 5) (4.5 g, 23.5 mmol), 4,4-dimethoxy-2,2-dimethylbutanal (from Step 7) (4.5 g, 28.2 mmol) and 7 M ammonia / methanol (10 mL) in 2,2,2-trifluoroethanol (150 mL) was stirred at 100 °C for 2 hours. At this time, it was quenched with 1 M aqueous sodium hydroxide solution (200 mL) and extracted with ethyl acetate (3 × 150 mL). The combined organic phases were dried over anhydrous sodium sulfate, filtered and concentrated to give crude (( 2S )-tert-Butyl 1-((1-((2-(2,2-dimethoxyethyl)phenyl)amino)-5,5-dimethoxy-3,3-dimethyl-1-oxopentan-2-yl)amino)-1-oxo-4-(tritylthio)butan-2-yl)carbamate (26 g, crude) was obtained as a brown solid. It was used in the next step without any further purification.
[0728] b. After step a, the coarse (( 2STo a solution of tert-butyl )-1-((1-((2-(2,2-dimethoxyethyl)phenyl)amino)-5,5-dimethoxy-3,3-dimethyl-1-oxopentan-2-yl)amino)-1-oxo-4-(tritylthio)butan-2-yl)carbamate (26 g, crude) in dichloromethane (200 mL) was slowly added trifluoroacetic acid (20 mL). The mixture was stirred at 40° C. for 2 hours. The solvent was concentrated and the crude product was purified by silica gel chromatography [dichloromethane / methanol (25:1 v / v)] to provide (4 S ,9a S )-4-amino-7-(1H-indole-1-carbonyl)-8,8-dimethylhexahydropyrrolo[2,1-b][1,3]thiazepin-5(2H)-one (7.5 g, 21.0 mmol) as a sandy solid. LCMS (2.5 min formic acid): Rt = 1.361 min, m / z: 357.9 (M+1) + .
[0729] Step 9: (( S )-1-(((4 S ,7 S ,9a S )-7-(1H-indole-1-carbonyl)-8,8-dimethyl-5-oxooctahydropyridine Tert-butyl pyrolu[2,1-b][1,3]thiazepin-4-yl)amino)-1-oxopropan-2-yl)(methyl)carbamate
[0730] (4S,9aS)-4-amino-7-(1H-indole-1-carbonyl)-8,8-dimethylhexahydropyrrolo[2,1-b][1,3]thiazepin-5(2H)-one (14 g, 39.2 mmol), N- (tert-Butoxycarbonyl)- N- methyl -L- To a solution of alanine (8.76 g, 43.1 mmol), 1-hydroxybenzotriazole (5.82 g, 43.1 mmol) and 4-methylmorpholine (11.88 g, 117.6 mmol) in tetrahydrofuran (400 mL) was added N -(3-Dimethylaminopropyl)- N'-Ethylcarbodiimide hydrochloride (8.27 g, 43.1 mmol). The mixture was stirred at room temperature for 3 hours. At this time, it was quenched with saturated aqueous sodium bicarbonate solution (300 mL) and extracted with ethyl acetate (3 × 150 mL). The combined organic layers were washed with brine (200 mL), dried over anhydrous sodium sulfate, filtered and concentrated. The crude product was purified by silica gel chromatography [petroleum ether / ethyl acetate (2:1 v / v to 1:1 v / v)] to provide ((S)-1-(((4S,7R,9aS)-7-(1H-indole-1-carbonyl)-8,8-dimethyl-5-oxooctahydropyrrolo[2,1-b][1,3]thiazepine-4-yl)amino)-1-oxopropan-2-yl)(methyl)carbamic acid tert-butyl ester (5.2 g, 9.6 mmol, 24.5% yield) as a sandy solid and the desired product as a light yellow solid ((S)-1 Tert-butyl-(((4S,7S,9aS)-7-(1H-indole-1-carbonyl)-8,8-dimethyl-5-oxooctahedralpyrrolo[2,1-b][1,3]thiazepin-4-yl)amino)-1-oxopropan-2-yl)(methyl)carbamate (5.0 g, 9.2 mmol, 23.5% yield). LCMS (2.5 min formic acid): Rt = 1.740 min, m / z: 564.8 (M+1) + .
[0731] Step 10: (4 S ,7 S ,9a S )-4-(( S )-2-(((tert-Butoxycarbonyl)(methyl)amino)propionamido)-8, 8-Dimethyl-5-oxooctahydropyrrolo[2,1-b][1,3]thiazepine-7-carboxylic acid
[0732] Towards(( S )-1-(((4 S ,7 S ,9a S To a solution of tert-butyl 7-(1H-indole-1-carbonyl)-8,8-dimethyl-5-oxooctahydropyrrolo[2,1-b][1,3]thiazepine-4-yl)amino)-1-oxopropan-2-yl)(methyl)carbamate (3.9 g, 7.19 mmol) in methanol (60 mL) was added 1 M aqueous sodium hydroxide solution (60 mL). The mixture was stirred at room temperature for 24 hours. The volatile solvent was removed under reduced pressure. The remaining aqueous phase was washed with ethyl acetate (50 mL), and the pH value of the aqueous phase was adjusted to pH 3 with citric acid. The aqueous phase was extracted with ethyl acetate (3×60 mL). The combined organic phases were washed with brine (100 mL), dried over anhydrous sodium sulfate, filtered and concentrated. The crude product was purified by silica gel chromatography [petroleum ether / ethyl acetate (1:2 v / v)] to give (4 S ,7 S ,9a S )-4-(( S)-2-(((tert-butoxycarbonyl)(methyl)amino)propionamido)-8,8-dimethyl-5-oxooctahedralpyrrolo[2,1-b][1,3]thiazepine-7-carboxylic acid (2 g, 4.51 mmol, 62.7% yield) as a white solid. LCMS (2.5 min formic acid): Rt = 1.493 min, m / z: 443.9 (M+1).
[0733]
[0734] Intermediate II:
[0735] (4S,7S,9aS)-4-((S)-2-((tert-Butoxycarbonyl)(methyl)amino)propanethioamido)-8,8, 9a-Trimethyl-5-oxooctahydropyrrolo[2,1-b][1,3]thiazepine-7-carboxylic acid
[0736]
[0737] Step 1: tert-(S)-(1-((2-amino-5-nitrophenyl)amino)-1-oxopropan-2-yl)(methyl)carbamic acid Butyl ester
[0738] Towards N- (tert-Butoxycarbonyl) -N- To a solution of methyl-L-alanine (20.3 g, 100 mmol) in anhydrous tetrahydrofuran (1.2 L) was added 4-methylmorpholine (20.2 g, 200 mmol). The mixture was stirred at -20°C for 10 minutes, then isobutyl chloroformate (13.6 g, 100 mmol) was added dropwise. The mixture was stirred at -15°C for 2 hours, then warmed to room temperature overnight. The mixture was diluted with ethyl acetate (1.6 L) and washed sequentially with 1M aqueous sodium hydrogen phosphate solution (1 L), 5% aqueous sodium bicarbonate solution (1 L), and brine (1 L). The organic phase was dried over anhydrous sodium sulfate, filtered, and concentrated to yield tert-butyl (S)-(1-((2-amino-5-nitrophenyl)amino)-1-oxopropan-2-yl)(methyl)carbamate (30 g, 88.7 mmol, 88.7% yield) as a dark red oil. LCMS (2.5 min formic acid): Rt = 1.537 min, m / z: 360.9 (M+Na) + .
[0739] Step 2: tert-(S)-(1-((2-amino-5-nitrophenyl)amino)-1-thiopropan-2-yl)(methyl)carbamic acid Butyl ester
[0740] To a solution of phosphorus (V) sulfide (24.4 g, 110 mmol) in anhydrous tetrahydrofuran (1.6 L) was added sodium carbonate (5.8 g, 55 mmol). The mixture was stirred at room temperature for 1 hour and then cooled to 0°C. (S)-tert-butyl (1-((2-amino-5-nitrophenyl)amino)-1-oxopropyl-2-yl)(methyl)carbamate (40 g, 110 mmol) was added to the reaction. The mixture was stirred at room temperature for 3 hours. The solvent was concentrated in vacuo and diluted with ethyl acetate (1 L), which was then washed with 5% aqueous sodium bicarbonate solution (500 mL) and brine (500 mL). The organic layer was dried over anhydrous sodium sulfate, filtered, and concentrated to afford tert-butyl (S)-(1-((2-amino-5-nitrophenyl)amino)-1-thiopropan-2-yl)(methyl)carbamate (33 g, 93.2 mmol, 84.7% yield) as an orange solid. LCMS (2.5 min formic acid): Rt = 1.602 min, m / z: 376.8 (M+Na) + .
[0741] Step 3: (S)-Methyl(1-(6-nitro-1H-benzo[d][1,2,3]triazol-1-yl)-1-thioxopropan-2-yl) tert-Butyl carbamate
[0742] To a solution of tert-butyl (S)-(1-((2-amino-5-nitrophenyl)amino)-1-thioxopropan-2-yl)(methyl)carbamate (30 g, 84.6 mmol) in anhydrous tetrahydrofuran (250 mL) and acetic acid (250 mL) was added sodium nitrite (9 g, 130.4 mmol). The mixture was stirred at 0°C for 1.5 hours. The mixture was washed sequentially with water (3 x 500 mL), 5% aqueous sodium bicarbonate solution (2 x 500 mL), and brine (500 mL). The organic layer was dried over anhydrous sodium sulfate, filtered and concentrated to afford tert-butyl (S)-methyl(1-(6-nitro-1H-benzo[d][1,2,3]triazol-1-yl)-1-thiopropan-2-yl)carbamate (20 g, 54.8 mmol, 64.8% yield) as a brown oil which was used in the next step without further purification.
[0743] Step 4: ((S)-1-(((4S,7S,9aS)-7-(1H-indole-1-carbonyl)-8,8-dimethyl-5-oxooctahydropyridine Tert-butyl pyrolu[2,1-b][1,3]thiazepin-4-yl)amino)-1-thiopropan-2-yl)(methyl)carbamate
[0744] To a solution of (4S,9aS)-4-amino-7-(1H-indole-1-carbonyl)-8,8-dimethylhexahydropyrrolo[2,1-b][1,3]thiazepin-5(2H)-one (15 g, 42 mmol) and (S)-tert-butyl methyl(1-(6-nitro-1H-benzo[d][1,2,3]triazol-1-yl)-1-thioxopropan-2-yl)carbamate (20 g, 54.7 mmol) in dichloromethane (400 mL) was added triethylamine (8.6 g, 84.6 mmol) at 0°C. The mixture was stirred at room temperature overnight. The mixture was concentrated under reduced pressure to obtain the crude product. The crude product was purified by silica gel chromatography (ethyl acetate / petroleum ether = 1 / 15) to give tert-butyl ((S)-1-(((4S,7R,9aS)-7-(1H-indole-1-carbonyl)-8,8-dimethyl-5-oxooctahydroxypyrrolo[2,1-b][1,3]thiazepin-4-yl)amino)-1-thiopropan-2-yl)(methyl)carbamate (3.0 g, 5.37 mmol, 48.8 mmol) as a yellow oil. 25.5% yield) and the desired diastereomer ((S)-tert-butyl 1-(((4S,7S,9aS)-7-(1H-indole-1-carbonyl)-8,8-dimethyl-5-oxooctahydropyrrolo[2,1-b][1,3]thiazepin-4-yl)amino)-1-thioxopropan-2-yl)(methyl)carbamate (3.9 g, 6.98 mmol, 29.4% yield) as a yellow oil. LCMS (2.5 min formic acid): Rt = 1.905 min, m / z: 580.8 (M+Na) + .
[0745] Step 5: (4S,7S,9aS)-4-(2-((tert-Butoxycarbonyl)(methyl)amino)ethanethioamido)-8,8, 9a-Trimethyl-5-oxooctahydropyrrolo[2,1-b][1,3]thiazepine-7-carboxylic acid
[0746] To a solution of tert-butyl (2-(((4S,7S,9aS)-7-(1H-indole-1-carbonyl)-8,8-dimethyl-5-oxooctahedralpyrrolo[2,1-b][1],3]thiazepin-4-yl)amino)-2-thioethyl)(methyl)carbamate (1.5 g, 2.69 mmol) in methanol was slowly added 1 M aqueous sodium hydroxide solution (60 mL). The mixture was stirred at room temperature overnight. The volatile solvent was removed under reduced pressure, and the remaining solution was extracted with ethyl acetate (50 mL). The pH of the aqueous layer was adjusted to pH 4 with 20% aqueous citric acid solution, and then extracted with ethyl acetate (3 x 100 mL). The combined organic layers were washed with brine (100 mL), dried over anhydrous sodium sulfate, filtered, and concentrated to afford (4S,7S,9aS)-4-(2-((tert-butoxycarbonyl)(methyl)amino)ethanethioamido)-8,8,9a-trimethyl-5-oxooctahydroxypyrrolo[2,1-b][1,3]thiazepine-7-carboxylic acid (1 g, 21.8 mmol, 81% yield) as a brown oil. LCMS (2.5 min formic acid): Rt = 1.632 min, m / z: 481.8 (M+Na) + .
[0747] Example 1:
[0748] (4S,4'S,7S,7'S,9aS,9a'S)-N,N'-(methylenebis(4,1-phenylene))bis(8,8-dimethyl-4-((S)-2-(methylamino)propionamido)-5-oxooctahedralpyrrolo[2,1-b][1,3]thiazepine-7-carboxamide) dihydrochloride
[0749]
[0750] Step 1: N,N'-(Methylenebis(4,1-phenylene))dicarbonamide
[0751] To a solution of 4,4'-methylenedianiline (5 g, 25.2 mmol) in toluene (40 mL) was added formic acid (4.64 g, 100.8 mmol). The mixture was stirred at 110 °C for 2 hours. The reaction was concentrated. The crude product was washed with dichloromethane and filtered to obtain the desired product as a white solid. N , N '-(Methylenebis(4,1-phenylene))dicarboxamide (4.7 g, 18.5 mmol, 73.4% yield). LCMS (2.5 min formic acid): Rt = 1.165 min, m / z: 255.1 (M+1) + .
[0752] Step 2: Bis(4-isocyanophenyl)methane
[0753] At 0℃ N , N To a solution of '-(methylenebis(4,1-phenylene))dicarboxamide (4.7 g, 18.5 mmol) in dichloromethane (150 mL) was added triethylamine (19 g, 188.7 mmol), followed by phosphorus oxychloride (8.5 g, 55.4 mmol). The mixture was warmed to room temperature and stirred for 2 hours. The reaction was poured into saturated aqueous sodium bicarbonate (100 mL) and extracted with dichloromethane (3 × 60 mL). The organics were dried over anhydrous sodium sulfate, filtered, and concentrated. The crude product was purified by silica gel chromatography [dichloromethane / methanol (25:1 v / v)] to afford bis(4-isocyanophenyl)methane (1.6 g, 7.3 mmol, 39.6% yield) as a white solid. LCMS (2.5 min formic acid): Rt = 1.715 min, m / z: 218.9 (M+1) + .
[0754] Step 3: (4S,4'S,9aS,9a'S)-N,N'-(methylenebis(4,1-phenylene))bis(4-amino-8,8-dimethyl 5-Oxooctahydropyrrolo[2,1-b][1,3]thiazepine-7-carboxamide
[0755] Will N- (tert-Butoxycarbonyl) -S- Trityl -L-A mixture of homocysteine (2.4 g, 5.04 mmol), bis(4-isocyanophenyl)methane (500 mg, 2.29 mmol), 4,4-dimethoxy-2,2-dimethylbutanal (954 mg, 5.95 mmol), and 7M ammonia / methanol (2 mL, 14 mmol) in 2,2,2-trifluoroethanol (10 mL) was stirred at 80° C. for 30 minutes under microwave conditions. The mixture was quenched with 1M aqueous sodium hydroxide solution (20 mL) and extracted with ethyl acetate (3×15 mL). The organic phases were combined, dried over anhydrous sodium sulfate, filtered, and concentrated to give crude di-tert-butyl ((2S,2'S)-((((methylenebis(4,1-phenylene))bis(azanediyl))bis(5,5-dimethoxy-3,3-dimethyl-1-oxopentan-1,2-diyl))bis(azanediyl))bis(1-oxo-4-(tritylthio)butane-1,2-diyl))dicarbamate (2.0 g, crude) as a brown solid. It was used in the next step without any further purification. To a solution of crude di-tert-butyl ((2S,2'S)-((((methylenebis(4,1-phenylene))bis(azanediyl))bis(5,5-dimethoxy-3,3-dimethyl-1-oxopentane-1,2-diyl))bis(azanediyl))bis(1-oxo-4-(tritylthio)butane-1,2-diyl))dicarbamate (2.0 g, crude) in dichloromethane (20 mL) was slowly added trifluoroacetic acid (5 mL). The mixture was stirred at 40° C. for 2 hours. The reaction was concentrated and purified by silica gel chromatography [dichloromethane / methanol (6:1 v / v)] to afford (4S,4'S,9aS,9a'S)-N,N'-(methylenebis(4,1-phenylene))bis(4-amino-8,8-dimethyl-5-oxooctahydropyrrolo[2,1-b][1,3]thiazepine-7-carboxamide) (500 mg, 0.74 mmol) as a sandy solid. LCMS (2.5 min formic acid): Rt = 1.263 min, m / z: 678.8 (M+1). + .
[0756] Step 4: ((2S,2'S)-(((4S,4'S,7S,7'S,9aS,9a'S)-(((Methylenebis(4,1-phenylene))bis (Azanediyl)bis(carbonyl)bis(8,8-dimethyl-5-oxooctahydropyrrolo[2,1-b][1,3]thiazepine-7,4-dione bis(methylcarbamate)di-tert-butyl bis(azanediyl)bis(1-oxopropane-1,2-diyl)bis(methylcarbamate)
[0757] (4S,4'S,9aS,9a'S)-N,N'-(methylenebis(4,1-phenylene))bis(4-amino-8,8-dimethyl-5-oxooctahedralpyrrolo[2,1-b][1,3]thiazepine-7-carboxamide) (550 mg, 0.810 mmol), N -(tert-Butoxycarbonyl)- N -methyl -LTo a solution of 1-alanine (362 mg, 1.782 mmol), 1-hydroxybenzotriazole (241 mg, 1.782 mmol) and 4-methylmorpholine (491 mg, 4.860 mmol) in tetrahydrofuran (30 mL) was added N -(3-dimethylaminopropyl)- N' -Ethylcarbodiimide hydrochloride (342 mg, 1.782 mmol). The mixture was stirred at room temperature for 3 hours. The mixture was quenched with saturated aqueous sodium bicarbonate (25 mL) and extracted with ethyl acetate (3 × 15 mL). The combined organic phases were washed with brine (20 mL), dried over anhydrous sodium sulfate, filtered, and concentrated. The crude product was purified by silica gel chromatography [dichloromethane / methanol (25:1 v / v)] to afford impure product, which was further purified by chiral-HPLC to afford the desired product, di-tert-butyl ((2S,2'S)-(((4S,4'S,7S,7'S,9aS,9a'S)-(((methylenebis(4,1-phenylene))bis(azanediyl))bis(carbonyl))bis(8,8-dimethyl-5-oxooctahydrolo[2,1-b][1,3]thiazepine-7,4-diyl)bis(azanediyl))bis(1-oxopropane-1,2-diyl))bis(methylcarbamate) ester (55 mg, 0.052 mmol, 6.4% yield) as a white solid. LCMS (2.5 min formic acid): Rt = 1.828 min, m / z: 425 [(M – 2Boc)+2] + / 2.
[0758] Step 5: (4S,4'S,7S,7'S,9aS,9a'S)-N,N'-(methylenebis(4,1-phenylene))bis(8,8-dimethyl 4-((S)-2-(methylamino)propionamido)-5-oxooctahydropyrrolo[2,1-b][1,3]thiazepine-7-carboxylate amine) dihydrochloride
[0759] To a solution of di-tert-butyl ((2S,2'S)-(((4S,4'S,7S,7'S,9aS,9a'S)-(((methylenebis(4,1-phenylene))bis(azanediyl))bis(carbonyl))bis(8,8-dimethyl-5-oxooctahydrolo[2,1-b][1,3]thiazepine-7,4-diyl)bis(azanediyl))bis(1-oxopropane-1,2-diyl))bis(methylcarbamate) (55 mg, 0.052 mmol) in dichloromethane (6 mL) was added 4N hydrogen chloride / 1,4-dioxane (1.5 mL). The mixture was stirred at room temperature for 2 hours. The solvent was removed under reduced pressure and the solid was dried under high vacuum to give (4S,4'S,7S,7'S,9aS,9a'S)-N,N'-(methylenebis(4,1-phenylene))bis(8,8-dimethyl-4-((S)-2-(methylamino)propionamido)-5-oxooctahedralpyrrolo[2,1-b][1,3]thiazepine-7-carboxamide) dihydrochloride (43 mg, 0.046 mmol, 88.5% yield) as a white solid.
[0760]
[0761] LCMS (2.5 min formic acid): Rt = 1.268 min, m / z: 848.9 (M+1) + .
[0762] Example 2:
[0763] (4S,4'S,7S,7'S,9aS,9a'S)-N,N'-(methylenebis(4,1-phenylene))bis(8,8-dimethyl-4-((S)-2-(methylamino)propanethioamido))-5-oxooctahydropyrrolo[2,1-b][1,3]thiazepine-7-carboxamide) dihydrochloride
[0764]
[0765] Step 1: ((2S,2'S)-(((4S,4'S,7S,7'S,9aS,9a'S)-(((Methylenebis(4,1-phenylene)) Bis(azanediyl)bis(carbonyl)bis(8,8-dimethyl-5-oxooctahydropyrrolo[2,1-b][1,3]thiazepine-7,4- di-tert-butyl bis(methylcarbamate)bis(1-thiopropane-1,2-diyl)bis(azanediyl)bis(1-thiopropane-1,2-diyl)bis(methylcarbamate)
[0766] To a solution of (4S,4'S,9aS,9a'S)-N,N'-(methylenebis(4,1-phenylene))bis(4-amino-8,8-dimethyl-5-oxooctahedralpyrrolo[2,1-b][1,3]thiazepine-7-carboxamide) (Example 1, Step 3) (260 mg, 0.38 mmol) in dichloromethane (10 mL) was added triethylamine (116.3 mg, 1.15 mmol) at 0°C. After 10 minutes, a solution of (S)-tert-butyl methyl(1-(6-nitro-1H-benzo[d][1,2,3]triazol-1-yl)-1-thioxopropan-2-yl)carbamate (321.9 mg, 0.88 mmol) in dichloromethane (5 mL) was added. The mixture was stirred at room temperature for an additional 2 hours. The solvent was removed under reduced pressure to yield a yellow syrup. The residue was purified by thin layer chromatography [ethyl acetate / petroleum ether (1:4 v / v)] to give a yellow oil (200 mg, 0.18 mmol), which was further purified by chiral-HPLC to give the title product (45 mg, 0.04 mmol, 10.9% yield). LCMS (2.5 min formic acid): Rt = 1.998 min, m / z: 980.6 (M-Boc+1) + .
[0767] Step 2: (4S,4'S,7S,7'S,9aS,9a'S)-N,N'-(methylenebis(4,1-phenylene))bis(8,8-diphenylene) Methyl-4-((S)-2-(methylamino)propanethioamido)-5-oxooctahydropyrrolo[2,1-b][1,3]thiazepine- 7-formamide) dihydrochloride
[0768] To a solution of di-tert-butyl ((2S,2'S)-(((4S,4'S,7S,7'S,9aS,9a'S)-(((methylenebis(4,1-phenylene))bis(azanediyl))bis(carbonyl))bis(8,8-dimethyl-5-oxooctahydrolo[2,1-b][1,3]thiazepine-7,4-diyl))bis(azanediyl))bis(1-thiopropane-1,2-diyl))bis(methylcarbamate (45 mg, 0.042 mmol) in diethyl ether (2 mL) was added hydrogen chloride (4N in 1,4-dioxane, 1 mL). The reaction was stirred at room temperature for 6 hours. The mixture was concentrated under reduced pressure and dried under high vacuum to give (4S,4'S,7S,7'S,9aS,9a'S)-N,N'-(methylenebis(4,1-phenylene))bis(8,8-dimethyl)-4-((S)-2-(methylamino)propanethioamido)-5-oxooctahhydropyrrolo[2,1-b][1,3]thiazepine-7-carboxamide) dihydrochloride (22 mg, 0.025 mmol, 55% yield) as a light yellow solid.
[0769]
[0770] LCMS (2.5 min formic acid): Rt = 1.298 min, m / z: 880.6 (M+1) + .
[0771] Example 3:
[0772] (4S,4'S,7S,7'S,9aS,9a'S)-N,N'-(ethane-1,2-diylbis(2,1-phenylene))bis(8,8-dimethyl-4-((S)-2-(methylamino)propionamido)-5-oxooctahedralpyrrolo[2,1-b][1,3]thiazepine-7-carboxamide) dihydrochloride
[0773]
[0774] Step 1: 2,2'-(Ethane-1,2-diyl)diphenylamine
[0775] To a solution of 1,2-bis(2-nitrophenyl)ethane (9.5 g, 34.9 mmol) in ethanol (200 mL) was added palladium on activated carbon (1 g). The mixture was stirred at room temperature under hydrogen (1 atm) for 5 hours. The catalyst was filtered and the filtrate was concentrated under reduced pressure. The crude product was purified by silica gel chromatography [petroleum ether / ethyl acetate (1:1 v / v)] to provide 2,2'-(ethane-1,2-diyl)diphenylamine (5 g, 23.6 mmol, 67.6% yield) as a yellow solid. LCMS (2.5 min formic acid): Rt=1.336 min, 212.9 (M+1) + .
[0776] Step 2: N,N'-(Ethane-1,2-diylbis(2,1-phenylene))dicarbonamide
[0777] To a solution of 2,2'-(ethane-1,2-diyl)diphenylamine (5 g, 23.6 mmol) in toluene (100 mL) was added formic acid (4.3 g, 94.4 mmol). The mixture was stirred at reflux overnight. The mixture was concentrated under reduced pressure to afford the crude product, which was washed with petroleum ether to afford N,N'-(ethane-1,2-diylbis(2,1-phenylene))dicarboxamide (5 g, 18.7 mmol, 79.2% yield) as a white solid.
[0778] Step 3: 1,2-Bis(2-isocyanophenyl)ethane
[0779] At 0℃ N , N'To a solution of 1,2-diylbis(2,1-phenylene)dicarboxamide (2 g, 7.46 mmol) in dichloromethane (50 mL) was added triethylamine (7.5 g, 74.6 mmol) followed by phosphorus oxychloride (3.4 g, 22.4 mmol). The mixture was warmed to room temperature and stirred for 4 hours. The reaction was then poured into saturated aqueous sodium bicarbonate solution (50 mL) and extracted with dichloromethane (3 × 30 mL). The combined organic phases were dried over anhydrous sodium sulfate, filtered, and concentrated. The crude product was purified by silica gel chromatography [petroleum ether / ethyl acetate (4:1 v / v)] to provide 1,2-bis(2-isocyanatophenyl)ethane (1.5 g, 6.47 mmol, 86.7% yield) as a white solid. LCMS (2.5 min formic acid): Rt = 1.763 min, m / z: 233.0 (M+1) + .
[0780] Step 4: (4S,4'S,9aS,9a'S)-N,N'-(ethane-1,2-diylbis(2,1-phenylene))bis(4-amino- 8,8-Dimethyl-5-oxooctahydropyrrolo[2,1-b][1,3]thiazepine-7-carboxamide)
[0781] Will N- (tert-Butoxycarbonyl) -S- Trityl -L-A mixture of homocysteine (4.1 g, 8.6 mmol), bis(4-isocyanophenyl)methane (1 g, 4.3 mmol), 4,4-dimethoxy-2,2-dimethylbutanal (1.45 g, 9.0 mmol), and 7M ammonia / methanol (2.4 mL, 16.8 mmol) in 2,2,2-trifluoroethanol (20 mL) was stirred at 80°C under microwave conditions for 30 minutes. The reaction was quenched with 1M sodium hydroxide solution (40 mL) and extracted with ethyl acetate (3 x 30 mL). The combined organic layers were dried over anhydrous sodium sulfate, filtered and concentrated to give crude di-tert-butyl ((2S,2'S)-((((ethane-1,2-diylbis(2,1-phenylene))bis(azanediyl))bis(5,5-dimethoxy-3,3-dimethyl-1-oxopentan-1,2-diyl))bis(azanediyl))bis(1-oxo-4-(tritylthio)butane-1,2-diyl))dicarbamate (4.0 g, crude) as a brown solid. To a solution of di-tert-butyl ((2S,2'S)-((((ethane-1,2-diylbis(2,1-phenylene))bis(azanediyl))bis(5,5-dimethoxy-3,3-dimethyl-1-oxopentan-1,2-diyl))bis(azanediyl))bis(1-oxo-4-(tritylthio)butane-1,2-diyl))dicarbamate (4.0 g, crude) in dichloromethane (50 mL) was slowly added trifluoroacetic acid (10 mL). The mixture was stirred at 40° C. for 2 hours. The reaction was concentrated and purified by silica gel chromatography [dichloromethane / methanol (6:1 v / v)] to afford (4S,4'S,9aS,9a'S)-N,N'-(ethane-1,2-diylbis(2,1-phenylene))bis(4-amino-8,8-dimethyl-5-oxooctahydroxypyrrolo[2,1-b][1,3]thiazepine-7-carboxamide) (2.3 g, 3.32 mmol, 77.2% yield) as a yellow solid. LCMS (2.5 min formic acid): Rt = 1.317 min, m / z: 692.9 (M+1). + .
[0782] Step 5: ((2S,2'S)-(((4S,4'S,7S,7'S,9aS,9a'S)-(((Ethane-1,2-diylbis(2,1- phenyl))bis(azanediyl))bis(carbonyl))bis(8,8-dimethyl-5-oxooctahydropyrrolo[2,1-b][1,3]thiazepine di-tert-butyl bis(1-oxopropane-1,2-diyl)bis(methylcarbamate)
[0783] (4S,4'S,9aS,9a'S)-N,N'-(ethane-1,2-diylbis(2,1-phenylene))bis(4-amino-8,8-dimethyl-5-oxooctahedralpyrrolo[2,1-b][1,3]thiazepine-7-carboxamide) (1 g, 1.44 mmol), N -(tert-Butoxycarbonyl)- N -methyl-L To a solution of 1-alanine (580 mg, 2.88 mmol), 1-hydroxybenzotriazole (430 mg, 3.17 mmol) and 4-methylmorpholine (580 mg, 5.76 mmol) in tetrahydrofuran (30 mL) was added N -(3-dimethylaminopropyl)- N' -Ethylcarbodiimide hydrochloride (580 mg, 3.04 mmol). The mixture was stirred at room temperature for 3 hours. The reaction was quenched with saturated aqueous sodium bicarbonate (25 mL) and extracted with ethyl acetate (3 × 15 mL). The combined organic layers were washed with brine (20 mL), dried over anhydrous sodium sulfate, filtered, and concentrated. The crude product was purified by silica gel chromatography [petroleum ether / ethyl acetate (1:1 v / v)] to give di-tert-butyl ((2S,2'S)-(((4S,4'S,7S,7'S,9aS,9a'S)-(((ethane-1,2-diylbis(2,1-phenylene))bis(azanediyl))bis(carbonyl))bis(8,8-dimethyl-5-oxooctahhydropyrrolo[2,1-b][1,3]thiazepine-7,4-diyl))bis(azanediyl))bis(1-oxopropane-1,2-diyl))bis(methylcarbamate) (1.2 g, 1.13 mmol, 78.5% yield) as a beige solid. LCMS (2.5 min formic acid): Rt = 1.910 min, m / z: 431.9 [(M-2Boc)+2] + / 2.
[0784] Step 6: (4S,4'S,7S,7'S,9aS,9a'S)-N,N'-(ethane-1,2-diylbis(2,1-phenylene))bis (8,8-Dimethyl-4-((S)-2-(methylamino)propionamido)-5-oxooctahydropyrrolo[2,1-b][1,3]thiazepine (methylenediamine) dihydrochloride
[0785] To a solution of di-tert-butyl ((2S,2'S)-(((4S,4'S,7S,7'S,9aS,9a'S)-(((ethane-1,2-diylbis(2,1-phenylene)))bis(azanediyl))bis(carbonyl))bis(8,8-dimethyl-5-oxoocahydropyrrolo[2,1-b][1,3]thiazepine-7,4-diyl))bis(azanediyl))bis(1-oxopropane-1,2-diyl))bis(methylcarbamate (90 mg, 0.085 mmol) in methanol (10 mL) was added 4N hydrogen chloride / 1,4-dioxane (5 mL). The mixture was stirred at room temperature for 4 hours. The mixture was then concentrated and crystallized from diethyl ether and methanol to give (4S,4'S,7S,7'S,9aS,9a'S)-N,N'-(ethane-1,2-diylbis(2,1-phenylene))bis(8,8-dimethyl-4-((S)-2-(methylamino)propionamido)-5-oxooctahhydropyrrolo[2,1-b][1,3]thiazepine-7-carboxamide) dihydrochloride (15 mg, 0.016 mmol, 18.8% yield) as a white solid.
[0786]
[0787] LCMS (2.5 min formic acid): Rt = 1.293 min, m / z: 862.9 (M+1) + .
[0788] Example 4:
[0789] (4S,4'S,7S,7'S,9aS,9a'S)-N,N'-(ethane-1,2-diylbis(2,1-phenylene))bis(8,8-dimethyl-4-((S)-2-(methylamino)propanethioamido)-5-oxooctahydropyrrolo[2,1-b][1,3]thiazepine-7-carboxamide) dihydrochloride
[0790]
[0791] Step 1: ((2S,2'S)-(((4S,4'S,7S,7'S,9aS,9a'S)-(((Ethane-1,2-diylbis(2,1- phenyl))bis(azanediyl))bis(carbonyl))bis(8,8-dimethyl-5-oxooctahydropyrrolo[2,1-b][1,3]thiazepine bis(1-thiopropane-1,2-diyl)bis(methylcarbamate)di-tert-butyl ester
[0792] To a solution of (4S,4'S,9aS,9a'S)-N,N'-(ethane-1,2-diylbis(2,1-phenylene))bis(4-amino-8,8-dimethyl-5-oxooctahedralpyrrolo[2,1-b][1,3]thiazepine-7-carboxamide) (300 mg, 0.44 mmol) in dichloromethane (20 mL) was added triethylamine (132 mg, 1.31 mmol) and (S)-tert-butyl methyl(1-(6-nitro-1H-benzo[d][1,2,3]triazol-1-yl)-1-thioxopropan-2-yl)carbamate (400 mg, 1.09 mmol) at 0°C. The mixture was warmed to room temperature and stirred overnight. The mixture was washed with saturated aqueous sodium bicarbonate solution (15 mL) and brine (15 mL). The organic layer was dried over anhydrous sodium sulfate, filtered, and concentrated. The crude product was purified by preparative HPLC to give di-tert-butyl ((2S,2'S)-(((4S,4'S,7S,7'S,9aS,9a'S)-(((ethane-1,2-diylbis(2,1-phenylene))bis(azanediyl))bis(carbonyl))bis(8,8-dimethyl-5-oxooctahydrolo[2,1-b][1,3]thiazepine-7,4-diyl))bis(azanediyl))bis(1-thiopropane-1,2-diyl))bis(methylcarbamate) (50 mg, 0.046 mmol, 10.5% yield) as a white solid. LCMS (2.5 min formic acid): Rt = 2.173 min, m / z: 1116.6 (M+Na) + .
[0793] Step 2: (4S,4'S,7S,7'S,9aS,9a'S)-N,N'-(ethane-1,2-diylbis(2,1-phenylene))bis (8,8-Dimethyl-4-((S)-2-(methylamino)propanethioamido)-5-oxooctahydropyrrolo[2,1-b][1,3]thio (Azepine-7-carboxamide) dihydrochloride
[0794] To a solution of di-tert-butyl ((2S,2'S)-(((4S,4'S,7S,7'S,9aS,9a'S)-(((ethane-1,2-diylbis(2,1-phenylene))bis(azanediyl))bis(carbonyl))bis(8,8-dimethyl-5-oxooctahydropyrrolo[2,1-b][1,3]thiazepine-7,4-diyl))bis(azanediyl))bis(1-thiopropane-1,2-diyl))bis(methylcarbamate) (50 mg, 0.046 mmol) in dichloromethane (5 mL) was added 4N hydrogen chloride / 1,4-dioxane (4 mL). The mixture was stirred at room temperature for 4 hours. The mixture was concentrated and dried under high vacuum to give (4S,4'S,7S,7'S,9aS,9a'S)-N,N'-(ethane-1,2-diylbis(2,1-phenylene))bis(8,8-dimethyl-4-((S)-2-(methylamino)propanethioamido)-5-oxooctahydrolo[2,1-b][1,3]thiazepine-7-carboxamide) dihydrochloride (35 mg, 0.036 mmol, 78.3 % yield) as a yellow solid.
[0795]
[0796] LCMS (2.5 min formic acid): Rt = 1.389 min, m / z: 894.8 (M+1) + .
[0797] Example 5:
[0798] (4S,4'S,7S,7'S,9aS,9a'S)-N,N'-(ethane-1,2-diylbis(4,1-phenylene))bis(8,8-dimethyl-4-((S)-2-(methylamino)propionamido)-5-oxooctahedralpyrrolo[2,1-b][1,3]thiazepine-7-carboxamide) bistrifluoroacetate
[0799]
[0800] Step 1: ((2S,2'S)-(((4S,4'S,7S,7'S,9aS,9a'S)-(((Ethane-1,2-diylbis(4,1- phenyl))bis(azanediyl))bis(carbonyl))bis(8,8-dimethyl-5-oxooctahydropyrrolo[2,1-b][1,3]thiazepine di-tert-butyl bis(1-oxopropane-1,2-diyl)bis(methylcarbamate)
[0801] To a solution of (4S,7S,9aS)-4-((S)-2-((tert-butoxycarbonyl)(methyl)amino)propionamido)-8,8-dimethyl-5-oxooctahydroxypyrrolo[2,1-b][1,3]thiazepine-7-carboxylic acid (Intermediate I) (230 mg, 0.519 mmol) in 1,2-dichloroethane (20 mL) was added N-Ethoxycarbonyl-2-ethoxy-1,2-dihydroquinoline (EEDQ) (175 mg, 0.709 mmol), N , N- Diisopropylethylamine (120 mg, 0.930 mmol) and 4,4'-(ethane-1,2-diyl)diphenylamine (50 mg, 0.236 mmol) were added and the mixture was stirred at 50°C overnight. The solvent was removed under reduced pressure, and then purified by silica gel chromatography [petroleum ether / ethyl acetate (2:1 v / v)] to give the desired product, ((2S,2'S)-(((4S,4'S,7S,7'S,9aS,9a'S)-(((ethane-1,2-diylbis(4,1-phenylene))bis(azanediyl))bis(carbonyl))bis(8,8-dimethyl-5-oxooctahydrolo[2,1-b][1,3]thiazepine-7,4-diyl))bis(azanediyl))bis(1-oxopropane-1,2-diyl))bis(methylcarbamic acid) di-tert-butyl ester (100 mg, 0.094 mmol, 39.8% yield) as a yellow solid. LCMS (2.5 min formic acid): Rt = 1.828 min, m / z: 432.0 {[(M-2Boc)+2] / 2} + .
[0802] Step 2: (4S,4'S,7S,7'S,9aS,9a'S)-N,N'-(ethane-1,2-diylbis(4,1-phenylene))bis (8,8-Dimethyl-4-((S)-2-(methylamino)propionamido)-5-oxooctahydropyrrolo[2,1-b][1,3]thiazepine (4-(2-( ...nitropropene)carboxamide)bis(trifluoroacetate))
[0803] To a solution of di-tert-butyl ((2S,2'S)-(((4S,4'S,7S,7'S,9aS,9a'S)-(((ethane-1,2-diylbis(4,1-phenylene))bis(azanediyl))bis(carbonyl))bis(8,8-dimethyl-5-oxooctahydropyrrolo[2,1-b][1,3]thiazepine-7,4-diyl))bis(azanediyl))bis(1-oxopropane-1,2-diyl))bis(methylcarbamate) (100 mg, 0.094 mmol) in methanol (5 mL) was added 4N hydrogen chloride / methanol (5 mL). The mixture was stirred at room temperature for 6 hours. The mixture was concentrated and purified by preparative HPLC to give (4S,4'S,7S,7'S,9aS,9a'S)-N,N'-(ethane-1,2-diylbis(4,1-phenylene))bis(8,8-dimethyl-4-((S)-2-(methylamino)propionamido)-5-oxooctahhydropyrrolo[2,1-b][1,3]thiazepine-7-carboxamide) bistrifluoroacetate (64 mg, 0.059 mmol, 62.8% yield) as a white solid.
[0804]
[0805] LCMS (2.5 min formic acid): Rt = 1.284 min, m / z: 862.9 (M+1) + .
[0806] Example 6:
[0807] (4S,4'S,7S,7'S,9aS,9a'S)-N,N'-(ethane-1,2-diylbis(4,1-phenylene))bis(8,8-dimethyl-4-((S)-2-(methylamino)propanethioamido)-5-oxooctahydropyrrolo[2,1-b][1,3]thiazepine-7-carboxamide) dihydrochloride
[0808]
[0809] Step 1: ((2S,2'S)-(((4S,4'S,7S,7'S,9aS,9a'S)-(((Ethane-1,2-diylbis(4,1- phenyl))bis(azanediyl))bis(carbonyl))bis(8,8-dimethyl-5-oxooctahydropyrrolo[2,1-b][1,3]thiazepine Bis(1-thiopropane-1,2-diyl)bis(methylcarbamate)di-tert-butyl ester
[0810] To a solution of (4S,7S,9aS)-4-((S)-2-((tert-butoxycarbonyl)(methyl)amino)propanethioamido)-8,8-dimethyl-5-oxooctahydroxypyrrolo[2,1-b][1,3]thiazepine-7-carboxylic acid (Intermediate II) (141 mg, 0.312 mmol) in 1,2-dichloroethane (20 mL) was added N- Ethoxycarbonyl-2-ethoxy-1,2-dihydroquinoline (EEDQ) (105 mg, 0.423 mmol), N , N- Diisopropylethylamine (72 mg, 0.564 mmol) and 4,4'-(ethane-1,2-diyl)diphenylamine (30 mg, 0.141 mmol) were added. The mixture was stirred at 50°C overnight. The solvent was removed under reduced pressure. The crude product was purified by silica gel chromatography [petroleum ether / ethyl acetate (2:1 v / v)] followed by preparative HPLC to afford di-tert-butyl ((2S,2'S)-(((4S,4'S,7S,7'S,9aS,9a'S)-(((ethane-1,2-diylbis(4,1-phenylene))bis(azanediyl))bis(carbonyl))bis(8,8-dimethyl-5-oxooctahydropyrrolo[2,1-b][1,3]thiazepine-7,4-diyl))bis(azanediyl))bis(1-thiopropane-1,2-diyl))bis(methylcarbamate) (60 mg, 0.055 mmol, 39.0% yield) as a white solid. LCMS (2.5 min formic acid): Rt = 2.059 min.
[0811] Step 2: (4S,4'S,7S,7'S,9aS,9a'S)-N,N'-(ethane-1,2-diylbis(4,1-phenylene))bis (8,8-Dimethyl-4-((S)-2-(methylamino)propanethioamido)-5-oxooctahydropyrrolo[2,1-b][1,3]thio (Azepine-7-carboxamide) dihydrochloride
[0812] To a solution of di-tert-butyl ((2S,2'S)-(((4S,4'S,7S,7'S,9aS,9a'S)-(((ethane-1,2-diylbis(4,1-phenylene))bis(azanediyl))bis(carbonyl))bis(8,8-dimethyl-5-oxooctahydropyrrolo[2,1-b][1,3]thiazepine-7,4-diyl))bis(azanediyl))bis(1-thiopropane-1,2-diyl))bis(methylcarbamate) (70 mg, 0.064 mmol) in methanol (5 mL) was added 4N hydrogen chloride / methanol (3 mL). The mixture was stirred at room temperature overnight. The solvent was removed under reduced pressure to give (4S,4'S,7S,7'S,9aS,9a'S)-N,N'-(ethane-1,2-diylbis(4,1-phenylene))bis(8,8-dimethyl-4-((S)-2-(methylamino)propanethioamido)-5-oxooctahhydropyrrolo[2,1-b][1,3]thiazepine-7-carboxamide) dihydrochloride (43 mg, 0.044 mmol, 68.8% yield) as a yellow solid.
[0813]
[0814] LCMS (2.5 min formic acid): Rt = 1.326 min, m / z: 895.1 (M+1) + .
[0815] Example 7:
[0816] (4S,4'S,7S,7'S,9aS,9a'S)-N,N'-((1R,1'R,2R,2'R)-(piperazine-1,4-dicarbonyl)bis(1,2,3,4-tetrahydronaphthalene-2,1-diyl))bis(8,8-dimethyl-4-((S)-2-(methylamino)propionamido)-5-oxooctahedralopyrrolo[2,1-b][1,3]thiazepine-7-carboxamide) dihydrochloride
[0817]
[0818] Step 1: (1R,2R)-1-((tert-Butoxycarbonyl)amino)-1,2,3,4-tetrahydronaphthalene-2-carboxylic acid
[0819] Sodium carbonate was added to a solution of (1R,2R)-1-amino-1,2,3,4-tetrahydronaphthalene-2-carboxylic acid hydrochloride (1.3 g, 5.71 mmol) in dioxane / water (1:1 v / v, 100 mL) to adjust the pH to 8. Di-tert-butyl dicarbonate (1.62 g, 7.42 mmol) was then added. The mixture was stirred at room temperature overnight. After the reaction was complete, the pH of the mixture was adjusted to pH 4 using 20% citric acid solution. The mixture was extracted with ethyl acetate (3 × 100 mL). The combined organic layers were washed with brine, dried over anhydrous sodium sulfate, filtered, and concentrated. The crude product was purified by silica gel chromatography [petroleum ether / ethyl acetate (3 / 2 v / v)] to give (1R,2R)-1-((tert-butoxycarbonyl)amino)-1,2,3,4-tetrahydronaphthalene-2-carboxylic acid (1.3 g, 4.46 mmol, 78.1% yield) as a white solid. LCMS (2.5 min formic acid): Rt = 1.519 min, m / z: 289.9 (M-1) - .
[0820] Step 2: ((1R,1'R,2R,2'R)-(Piperazine-1,4-dicarbonyl)bis(1,2,3,4-tetrahydronaphthalene-2,1-diyl)) Di-tert-butyl dicarbamate
[0821] To a solution of (1R,2R)-1-((tert-butoxycarbonyl)amino)-1,2,3,4-tetrahydronaphthalene-2-carboxylic acid (270 mg, 0.90 mmol) and piperazine (39.9 mg, 0.46 mmol) in N,N-dimethylformamide (12 mL) was slowly added triethylamine (187.5 mg, 1.85 mmol) and diethyl cyanophosphonate (226.7 mg, 1.38 mmol) at -10°C. The mixture was stirred for 20 minutes. The mixture was allowed to warm to room temperature and stirred for 3 hours. The reaction was quenched with ice water (50 mL) to give a precipitate, which was filtered and dried to afford di-tert-butyl ((1R,1'R,2R,2'R)-(piperazine-1,4-dicarbonyl)bis(1,2,3,4-tetrahydronaphthalene-2,1-diyl))dicarbamate (435 mg, 0.69 mmol, 68.7% yield) as a white solid. LCMS (2.5 min formic acid): Rt = 1.74 min, m / z: 532.7 (M – Boc+1) + .
[0822] Step 3: Piperazine-1,4-diylbis(((1R,2R)-1-amino-1,2,3,4-tetrahydronaphthalen-2-yl)methanone) dihydrochloride Salt
[0823] To a solution of di-tert-butyl ((1R,1'R,2R,2'R)-(piperazine-1,4-dicarbonyl)bis(1,2,3,4-tetrahydronaphthalene-2,1-diyl))dicarbamate (435 mg, 1.0 mmol) in dichloromethane (20 mL) was slowly added 4N hydrogen chloride / 1,4-dioxane (2 mL). The mixture was stirred at room temperature overnight. The solvent was concentrated under reduced pressure to give crude piperazine-1,4-diylbis(((1R,2R)-1-amino-1,2,3,4-tetrahydronaphthalene-2-yl)methanone) dihydrochloride (402 mg) as a white solid. This was used in the reaction without further purification. LCMS (2.5 min formic acid): Rt = 1.07 min, m / z: 432.9 (M+1) + .
[0824] Step 4: ((2S,2'S)-(((4S,4'S,7S,7'S,9aS,9a'S)-((((1R,1'R,2R,2'R)-(piperazine- 1,4-dicarbonyl)bis(1,2,3,4-tetrahydronaphthalene-2,1-diyl))bis(azanediyl))bis(carbonyl))bis(8,8-dimethyl-5- Oxooctahydropyrrolo[2,1-b][1,3]thiazepine-7,4-diyl)bis(azanediyl)bis(1-oxopropane-1,2- di-tert-butyl bis(methylcarbamate)
[0825] Piperazine-1,4-diylbis(((1R,2R)-1-amino-1,2,3,4-tetrahydronaphthalen-2-yl)methanone) dihydrochloride (150 mg, 0.297 mmol), (4S,7S,9aS)-4-((S)-2-((tert-butoxycarbonyl)(methyl)amino)propionamido)-8,8-dimethyl-5-oxooctahedralpyrrolo[2,1-b][1,3]thiazepine-7-carboxylic acid (Intermediate I) (319 mg, 0.68 mmol), 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide iodomethane salt (200 mg, 1.02 mmol), 1-hydroxybenzotriazole (187 mg, 1.36 mmol) and N,N-diisopropylethylamine (269 mg, 2.04 mmol) were stirred in dichloromethane (100 mL). The solution in 4% paraformaldehyde (5% paraformaldehyde) (5% paraformaldehyde) was stirred at room temperature overnight. The reaction was quenched with water (30 mL) and extracted with dichloromethane (3 × 30 mL). The combined organic layers were washed with brine, dried, filtered, and concentrated. The residue was purified by thin layer chromatography [ethyl acetate / petroleum ether (2 / 1 v / v)] to give impure product (93 mg) as a yellow oil. The material was further purified by preparative HPLC to afford di-tert-butyl ((2S,2'S)-(((4S,4'S,7S,7'S,9aS,9a'S)-((((1R,1'R,2R,2'R)-(piperazine-1,4-dicarbonyl)bis(1,2,3,4-tetrahydronaphthalene-2,1-diyl))bis(azanediyl))bis(carbonyl))bis(8,8-dimethyl-5-oxooctahedralopyrrolo[2,1-b][1,3]thiazepine-7,4-diyl))bis(azanediyl))bis(1-oxopropane-1,2-diyl))bis(methylcarbamate (64 mg, 0.05 mmol, 13.9% yield) as a white solid. LCMS (3.0 min formic acid): Rt = 2.51 min, m / z: 1282.6 (M+1) + , 642.5 {[(M-2Boc)+2] / 2} + .
[0826] Step 5: (4S,4'S,7S,7'S,9aS,9a'S)-N,N'-((1R,1'R,2R,2'R)-piperazine-1,4-dicarbonyl) 1-(4-((S)-2-(methylamino)propionamido)-5-(1,2,3,4-tetrahydronaphthalene-2,1-diyl)bis(8,8-dimethyl-4-((S)-2-(methylamino)propionamido)-5- Oxooctahydropyrrolo[2,1-b][1,3]thiazepine-7-carboxamide) dihydrochloride
[0827] To a solution of di-tert-butyl ((2S,2'S)-(((4S,4'S,7S,7'S,9aS,9a'S)-((((1R,1'R,2R,2'R)-(piperazine-1,4-dicarbonyl)bis(1,2,3,4-tetrahydronaphthalene-2,1-diyl))bis(azanediyl))bis(carbonyl))bis(8,8-dimethyl-5-oxoocahydropyrrolo[2,1-b][1,3]thiazepine-7,4-diyl))bis(azanediyl))bis(1-oxopropane-1,2-diyl))bis(methylcarbamate (64 mg, 0.05 mmol) in dichloromethane (5 mL) was added hydrogen chloride (4N in 1,4-dioxane, 1 mL). The reaction was stirred at room temperature overnight. The solvent was removed in vacuo to afford (4S,4'S,7S,7'S,9aS,9a'S)-N,N'-((1R,1'R,2R,2'R)-(piperazine-1,4-dicarbonyl)bis(1,2,3,4-tetrahydronaphthalene-2,1-diyl))bis(8,8-dimethyl-4-((S)-2-(methylamino)propionamido)-5-oxooctahedralopyrrolo[2,1-b][1,3]thiazepine-7-carboxamide) dihydrochloride (50 mg, 0.043 mmol, 84.3% yield) as a white solid.
[0828]
[0829] LCMS (2.5 min formic acid): Rt = 1.407 min, m / z: 1082.8 (M+1) + .
[0830] Example 8:
[0831] (4S,4'S,7S,7'S,9aS,9a'S)-N,N'-((1R,1'R,2R,2'R)-(piperazine-1,4-dicarbonyl)bis(1,2,3,4-tetrahydronaphthalene-2,1-diyl))bis(8,8-dimethyl-4-((S)-2-(methylamino)propanethioamido)-5-oxooctahedralopyrrolo[2,1-b][1,3]thiazepine-7-carboxamide) dihydrochloride
[0832]
[0833] Step 1: ((2S,2'S)-(((4S,4'S,7S,7'S,9aS,9a'S)-((((1R,1'R,2R,2'R)-(piperazine- 1,4-dicarbonyl)bis(1,2,3,4-tetrahydronaphthalene-2,1-diyl))bis(azanediyl))bis(carbonyl))bis(8,8-dimethyl-5- Oxooctahydropyrrolo[2,1-b][1,3]thiazepine-7,4-diyl)bis(azanediyl)bis(1-thiopropane-1,2- di-tert-butyl bis(methylcarbamate)
[0834] Piperazine-1,4-diylbis(((1R,2R)-1-amino-1,2,3,4-tetrahydronaphthalen-2-yl)methanone) dihydrochloride (Example 7, Step 3) (150 mg, 0.297 mmol), (4S,7S,9aS)-4-((S)-2-((tert-butoxycarbonyl)(methyl)amino)propanethioamido)-8,8-dimethyl-5-oxooctahydroxypyrrolo[2,1-b][1,3]thiazepine-7-carboxylic acid (Intermediate II) (272.8 mg, 0.593 mmol), 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide iodomethane salt (170.7 mg, 0.89 mmol), 1-hydroxybenzotriazole (160.5 mg, 1.188 mmol) and N,N-diisopropylethylamine (230.2 A solution of 1,4-dichloro-2-[4-[ ... The material was further purified by preparative HPLC to give di-tert-butyl ((2S,2'S)-(((4S,4'S,7S,7'S,9aS,9a'S)-((((1R,1'R,2R,2'R)-(piperazine-1,4-dicarbonyl)bis(1,2,3,4-tetrahydronaphthalene-2,1-diyl))bis(azanediyl))bis(carbonyl))bis(8,8-dimethyl-5-oxooctahhydropyrrolo[2,1-b][1,3]thiazepine-7,4-diyl))bis(azanediyl))bis(1-thiopropane-1,2-diyl))bis(methylcarbamate) (90 mg, 0.07 mmol, 23.6% yield) as a white solid. LCMS (3.0 min formic acid): Rt = 2.75 min, m / z: 1315.6 (M+1) + .
[0835] Step 2: (4S,4'S,7S,7'S,9aS,9a'S)-N,N'-((1R,1'R,2R,2'R)-piperazine-1,4-dicarbonyl) 1-Diyl)bis(1,2,3,4-tetrahydronaphthalene-2,1-diyl)bis(8,8-dimethyl-4-((S)-2-(methylamino)propanethioamide (2-[(2,1-b][1,3]thiazepine-7-carboxamide) dihydrochloride)
[0836] To a solution of di-tert-butyl ((2S,2'S)-(((4S,4'S,7S,7'S,9aS,9a'S)-((((1R,1'R,2R,2'R)-(piperazine-1,4-dicarbonyl)bis(1,2,3,4-tetrahydronaphthalene-2,1-diyl))bis(azanediyl))bis(carbonyl))bis(8,8-dimethyl-5-oxooctahhydropyrrolo[2,1-b][1,3]thiazepine-7,4-diyl))bis(azanediyl))bis(1-thiopropane-1,2-diyl))bis(methylcarbamate (96 mg, 0.073 mmol) in dichloromethane (10 mL) was added hydrogen chloride (4N in 1,4-dioxane, 1 mL). The mixture was stirred at room temperature overnight. The solvent was removed under reduced pressure to give (4S,4'S,7S,7'S,9aS,9a'S)-N,N'-((1R,1'R,2R,2'R)-(piperazine-1,4-dicarbonyl)bis(1,2,3,4-tetrahydronaphthalene-2,1-diyl))bis(8,8-dimethyl-4-((S)-2-(methylamino)propanethioamido)-5-oxooctahhydropyrrolo[2,1-b][1,3]thiazepine-7-carboxamide) dihydrochloride (60 mg, 0.05 mmol, 68.8% yield) as a white solid.
[0837]
[0838] LCMS (2.5 min formic acid): Rt = 1.246 min, m / z: 1114.4 (M+1) + .
[0839] Example 9:
[0840] (4S,4'S,7S,7'S,9aS,9a'S)-N,N'-((1R,1'R,2R,2'R)-(((1,4-phenylenebis(methylene))bis(azanediyl))bis(carbonyl))bis(1,2,3,4-tetrahydronaphthalene-2,1-diyl))bis(8,8-dimethyl-4-((S)-2-(methylamino)propionamido)-5-oxooctahydropyrrolo[2,1-b][1,3]thiazepine-7-carboxamide) dihydrochloride
[0841]
[0842] Step 1: ((1R,1'R,2R,2'R)-(((1,4-phenylenebis(methylene))bis(azanediyl))bis(carbonyl) Di-tert-butyl bis(1,2,3,4-tetrahydronaphthalene-2,1-diyl)dicarbamate
[0843] To a solution of (1R,2R)-1-((tert-butoxycarbonyl)amino)-1,2,3,4-tetrahydronaphthalene-2-carboxylic acid (114 mg, 0.39 mmol) and 1,4-phenylenediamine (26 mg, 0.19 mmol) in N,N-dimethylformamide (5 mL) was slowly added triethylamine (79 mg, 0.78 mmol) and diethyl cyanophosphonate (96 mg, 0.59 mmol) at -10°C. The mixture was stirred for 20 minutes. The mixture was allowed to warm to room temperature and stirred for 3 hours. The reaction was quenched with ice water (50 mL) to give a precipitate, which was filtered and dried to afford di-tert-butyl ((1R,1'R,2R,2'R)-(((1,4-phenylenebis(methylene))bis(azanediyl))bis(carbonyl))bis(1,2,3,4-tetrahydronaphthalene-2,1-diyl))dicarbamate (180 mg, 0.26 mmol, 67.4% yield) as a white solid. LCMS (2.5 min formic acid): Rt = 1.736 min, m / z: 704.8 (M+Na) + .
[0844] Step 2: (1R,1'R,2R,2'R)-N,N'-(1,4-phenylenebis(methylene))bis(1-amino-1,2,3,4-tetrakis (2-Hydroxynaphthalenecarboxamide) dihydrochloride
[0845] To a solution of di-tert-butyl ((1R,1'R,2R,2'R)-(((1,4-phenylenebis(methylene))bis(azanediyl))bis(carbonyl))bis(1,2,3,4-tetrahydronaphthalene-2,1-diyl))dicarbamate (180 mg, 0.26 mmol) in dichloromethane (10 mL) was slowly added 4N hydrogen chloride / 1,4-dioxane (1 mL). The mixture was stirred at room temperature for 4 hours, and the solvent was removed under reduced pressure to give (1R,1'R,2R,2'R)-N,N'-(1,4-phenylenebis(methylene))bis(1-amino-1,2,3,4-tetrahydronaphthalene-2-carboxamide) dihydrochloride (150 mg) as a white solid. This was used in the next step without further purification. LCMS (2.5 min formic acid): Rt = 1.085 min, m / z: 482.9 (M+1) + .
[0846] Step 3: ((2S,2'S)-(((4S,4'S,7S,7'S,9aS,9a'S)-((((1R,1'R,2R,2'R)-(((1,4- phenylenebis(methylene)bis(azanediyl)bis(carbonyl)bis(1,2,3,4-tetrahydronaphthalene-2,1-diyl)bis(azanediyl) Bis(carbonyl)bis(8,8-dimethyl-5-oxooctahydropyrrolo[2,1-b][1,3]thiazepine-7,4-diyl)bis(methylenebis(1,3-thiazolin-7,4-diyl) ... Di-tert-butyl (azanediyl)bis(1-oxopropane-1,2-diyl)bis(methylcarbamate)
[0847] (1R,1'R,2R,2'R)-N,N'-(1,4-phenylenebis(methylene))bis(1-amino-1,2,3,4-tetrahydronaphthalene-2-carboxamide) dihydrochloride (150 mg, 0.27 mmol), (4S,7S,9aS)-4-((S)-2-((tert-butoxycarbonyl)(methyl)amino)propionamido)-8,8-dimethyl-5-oxooctahedralpyrrolo[2,1-b][1,3]thiazepine-7-carboxylic acid (Intermediate I) (240 mg, 0.54 mmol), 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide iodomethane salt (155.3 mg, 0.81 mmol), 1-hydroxybenzotriazole (146 mg, 1.08 mmol) and N,N-diisopropylethylamine (209.3 A solution of 4-[4-[(2-[(2-[(2-[(2-[(2-[(2-[(2-[(2-[(2-[(2-[(2-[(2-[(2-[(2-[(2-2-[(2-1 ... The material was further purified by preparative HPLC to give di-tert-butyl ((2S,2'S)-(((4S,4'S,7S,7'S,9aS,9a'S)-((((1R,1'R,2R,2'R)-(((1,4-phenylenebis(methylene))bis(azanediyl))bis(carbonyl))bis(1,2,3,4-tetrahydronaphthalene-2,1-diyl))bis(azanediyl))bis(carbonyl))bis(8,8-dimethyl-5-oxoocahydropyrrolo[2,1-b][1,3]thiazepin-7,4-diyl))bis(azanediyl))bis(1-oxopropane-1,2-diyl))bis(methylcarbamate (76 mg, 0.057 mmol, 21.1% yield) as a white solid. LCMS (2.5 min formic acid): Rt = 1.80 min, m / z: 566.9 {[M-2Boc) = 2] / 2} + .
[0848] Step 4: (4S,4'S,7S,7'S,9aS,9a'S)-N,N'-((1R,1'R,2R,2'R)-(((1,4-phenylenebis(1,4-diphenylene) ... (methylene)bis(azanediyl)bis(carbonyl)bis(1,2,3,4-tetrahydronaphthalene-2,1-diyl)bis(8,8-dimethyl-4- ((S)-2-(Methylamino)propionamido)-5-oxooctahydropyrrolo[2,1-b][1,3]thiazepine-7-carboxamide) disalt acid salt
[0849] To a solution of di-tert-butyl ((2S,2'S)-(((4S,4'S,7S,7'S,9aS,9a'S)-((((1R,1'R,2R,2'R)-(((1,4-phenylenebis(methylene))bis(azanediyl))bis(carbonyl))bis(1,2,3,4-tetrahydronaphthalene-2,1-diyl))bis(azanediyl))bis(carbonyl))bis(8,8-dimethyl-5-oxoocahydropyrrolo[2,1-b][1,3]thiazepin-7,4-diyl))bis(azanediyl))bis(1-oxopropane-1,2-diyl))bis(methylcarbamate (80 mg, 0.06 mmol) in dichloromethane (6 mL) was added hydrogen chloride (4N in 1,4-dioxane, 1 mL). The mixture was stirred at room temperature overnight. The mixture was concentrated and dried under high vacuum to give (4S,4'S,7S,7'S,9aS,9a'S)-N,N'-((1R,1'R,2R,2'R)-(((1,4-phenylenebis(methylene))bis(azanediyl))bis(carbonyl))bis(1,2,3,4-tetrahydronaphthalene-2,1-diyl))bis(8,8-dimethyl-4-((S)-2-(methylamino)propionamido)-5-oxooctahedralopyrrolo[2,1-b][1,3]thiazepine-7-carboxamide) dihydrochloride (46.2 mg, 0.038 mmol, 60.5% yield) as a white solid.
[0850]
[0851] LCMS (2.5 min formic acid): Rt = 1.453 min, m / z: 1133.7 (M+1) + ,1155.6 (M+Na) + .
[0852] Example 10:
[0853] (4S,4'S,7S,7'S,9aS,9a'S)-N,N'-((1R,1'R,2R,2'R)-(((1,4-phenylenebis(methylene))bis(azanediyl))bis(carbonyl))bis(1,2,3,4-tetrahydronaphthalene-2,1-diyl))bis(8,8-dimethyl-4-((S)-2-(methylamino)propanethioamido)-5-oxooctahydropyrrolo[2,1-b][1,3]thiazepine-7-carboxamide)
[0854]
[0855] Step 1: ((2S,2'S)-(((4S,4'S,7S,7'S,9aS,9a'S)-((((1R,1'R,2R,2'R)-(((1,4- phenylenebis(methylene)bis(azanediyl)bis(carbonyl)bis(1,2,3,4-tetrahydronaphthalene-2,1-diyl)bis(azanediyl) Bis(carbonyl)bis(8,8-dimethyl-5-oxooctahydropyrrolo[2,1-b][1,3]thiazepine-7,4-diyl)bis(methylenebis(1,3-thiazolin-7,4-diyl) ... Di-tert-butyl (azanediyl)bis(1-thiopropane-1,2-diyl)bis(methylcarbamate)
[0856] (1R,1'R,2R,2'R)-N,N'-(1,4-phenylenebis(methylene))bis(1-amino-1,2,3,4-tetrahydronaphthalene-2-carboxamide) dihydrochloride (Example 9, Step 2) (116 mg, 0.21 mmol), (4S,7S,9aS)-4-((S)-2-((tert-butoxycarbonyl)(methyl)amino)propanethioamido)-8,8-dimethyl-5-oxooctahydroxypyrrolo[2,1-b][1,3]thiazepine-7-carboxylic acid (Intermediate II) (201 mg, 0.44 mmol), 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide iodomethane salt (120 mg, 0.63 mmol), 1-hydroxybenzotriazole (113 mg, 0.84 mmol) and N,N-diisopropylethylamine (279 mg, 2.16 mmol) in dichloromethane (10 mL) were stirred at room temperature overnight. The reaction was quenched with water (30 mL) and extracted with dichloromethane (3×30 mL). The combined organic layers were washed with brine, dried, filtered and concentrated. The residue was purified by thin layer chromatography [ethyl acetate / petroleum ether (2 / 1 v / v)] to give the impure product (110 mg) as a yellow oil.
[0268] The above-mentioned compound was purified by preparative HPLC to give di-tert-butyl ((2S,2'S)-(((4S,4'S,7S,7'S,9aS,9a'S)-((((1R,1'R,2R,2'R)-(((1,4-phenylenebis(methylene))bis(azanediyl))bis(carbonyl))bis(1,2,3,4-tetrahydronaphthalene-2,1-diyl))bis(azanediyl))bis(carbonyl))bis(8,8-dimethyl-5-oxooctahhydropyrrolo[2,1-b][1,3]thiazepin-7,4-diyl))bis(azanediyl))bis(1-thiopropane-1,2-diyl))bis(methylcarbamate (54 mg, 0.039 mmol, 18.9% yield) as a white solid. LCMS (3.0 min formic acid): Rt = 2.614 min, m / z: 1388 (M+Na) + .
[0857] Step 2: (4S,4'S,7S,7'S,9aS,9a'S)-N,N'-((1R,1'R,2R,2'R)-(((1,4-phenylenebis(1,4-diphenylene) ... (methylene)bis(azanediyl)bis(carbonyl)bis(1,2,3,4-tetrahydronaphthalene-2,1-diyl)bis(8,8-dimethyl-4- ((S)-2-(Methylamino)propanethioamido)-5-oxooctahydropyrrolo[2,1-b][1,3]thiazepine-7-carboxylate amine)
[0858] To a solution of di-tert-butyl ((2S,2'S)-(((4S,4'S,7S,7'S,9aS,9a'S)-((((1R,1'R,2R,2'R)-(((1,4-phenylenebis(methylene))bis(azanediyl))bis(carbonyl))bis(1,2,3,4-tetrahydronaphthalene-2,1-diyl))bis(azanediyl))bis(carbonyl))bis(8,8-dimethyl-5-oxooctahhydropyrrolo[2,1-b][1,3]thiazepin-7,4-diyl))bis(azanediyl))bis(1-thiopropane-1,2-diyl))bis(methylcarbamate (54 mg, 0.04 mmol) in dichloromethane (5 mL) was added hydrogen chloride (4N in 1,4-dioxane, 1 mL). The reaction was stirred at room temperature overnight. The solvent was removed under reduced pressure and the mixture was diluted with water. The pH was adjusted to 8-9 with sodium bicarbonate and extracted with dichloromethane (3 x 10 mL). The combined organic layers were washed with brine, dried, filtered, and concentrated under reduced pressure. The residue was purified by thin layer chromatography [dichloromethane / methanol (8 / 1 v / v)] to give (4S,4'S,7S,7'S,9aS,9a'S)-N,N'-((1R,1'R,2R,2'R)-(((1,4-phenylenebis(methylene))bis(azanediyl))bis(carbonyl))bis(1,2,3,4-tetrahydronaphthalene-2,1-diyl))bis(8,8-dimethyl-4-((S)-2-(methylamino)propanethioamido)-5-oxooctahedralopyrrolo[2,1-b][1,3]thiazepine-7-carboxamide) (6 mg, 0.005 mmol, 13 % yield) as a white solid.
[0859]
[0860] LCMS (2.5 min formic acid): Rt = 1.52 min, 1164.7 (M+1) + .
[0861] Example 11:
[0862] (4S,7S,9aS)-8,8-Dimethyl-4-[(2S)-2-(methylamino)propionamido]-5-oxo-N-[(1R,2R)-2-{[(1rs,4rs)-4-[(1R,2R)-1-[(4S,7S,9aS)-8,8-dimethyl-4-[(2S)-2-(methylamino)propionamido]-5-oxo-octahydropyrrolo[2,1-b][1,3]thiazepine-7-amide]-1,2,3,4-tetrahydronaphthalene-2-amide]cyclohexyl]carbamoyl}-1,2,3,4-tetrahydronaphthalene-1-yl]-octahydropyrrolo[2,1-b][1,3]thiazepine-7-carboxamide dihydrochloride
[0863]
[0864] Step 1: ((1R,1'R,2R,2'R)-((((1R,4R)-cyclohexane-1,4-diyl)bis(azanediyl))bis(carbonyl) Di-tert-butyl bis(1,2,3,4-tetrahydronaphthalene-2,1-diyl)dicarbamate
[0865] (1R,2R)-1-((tert-butoxycarbonyl)amino)-1,2,3,4-tetrahydronaphthalene-2-carboxylic acid (250 mg, 0.858 mmol) and (1r,4r)-cyclohexane-1,4-diamine (49 mg, 0.429 mmol) were added to a 1,2,3,4-tetrahydronaphthalene-2-carboxylic acid mixture at -10°C. N , N- Slowly add the solution in dimethylformamide (10 mL) N , N- Diisopropylethylamine (221 mg, 1.716 mmol) and diethyl cyanophosphonate (210 mg, 1.287 mmol) were added. The mixture was stirred for 20 minutes. The mixture was allowed to warm to room temperature and stirred for 3 hours. The reaction was quenched with ice water (100 mL) to obtain a precipitate, which was filtered to obtain di-tert-butyl ((1R,1'R,2R,2'R)-((((1R,4R)-cyclohexane-1,4-diyl)bis(azanediyl))bis(carbonyl))bis(1,2,3,4-tetrahydronaphthalene-2,1-diyl))dicarbamate (240 mg, 0.363 mmol, 84.6% yield) as an orange solid. LCMS (2.5 min formic acid): Rt = 1.724 min, m / z: 628.8 (M+Na) + .
[0866] Step 2: (1R,1'R,2R,2'R)-N,N'-((1R,4R)-cyclohexane-1,4-diyl)bis(1-amino-1,2,3, 4-Tetrahydronaphthalene-2-carboxamide) dihydrochloride
[0867] To a solution of di-tert-butyl ((1R,1'R,2R,2'R)-((((1R,4R)-cyclohexane-1,4-diyl)bis(azanediyl))bis(carbonyl))bis(1,2,3,4-tetrahydronaphthalene-2,1-diyl))dicarbamate (150 mg, 0.23 mmol) in dichloromethane (5 mL) was slowly added 4N hydrogen chloride / 1,4-dioxane (0.5 mL). The mixture was stirred at room temperature overnight. The mixture was concentrated under reduced pressure to give (1R,1'R,2R,2'R)-N,N'-((1R,4R)-cyclohexane-1,4-diyl)bis(1-amino-1,2,3,4-tetrahydronaphthalene-2-carboxamide) dihydrochloride (130 mg, crude) as a yellow syrup. LCMS (2.5 min formic acid): Rt = 1.122 min, m / z: 461.1 (M+1) + .
[0868] Step 3: ((2S,2'S)-(((4S,4'S,7S,7'S,9aS,9a'S)-((((1R,1'R,2R,2'R)-((((1R, 4R)-cyclohexane-1,4-diyl)bis(azanediyl))bis(carbonyl))bis(1,2,3,4-tetrahydronaphthalene-2,1-diyl))bis(azane bis(carbonyl)bis(8,8-dimethyl-5-oxooctahydropyrrolo[2,1-b][1,3]thiazepine-7,4-diyl) Bis(azanediyl)bis(1-oxopropane-1,2-diyl)bis(methylcarbamate) di-tert-butyl ester
[0869] (1R,1'R,2R,2'R)-N,N'-((1R,4R)-cyclohexane-1,4-diyl)bis(1-amino-1,2,3,4-tetrahydronaphthalene-2-carboxamide) dihydrochloride (130 mg, 0.24 mmol), (4S,7S,9aS)-4-((S)-2-((tert-butoxycarbonyl)(methyl)amino)propionamido)-8,8-dimethyl-5-oxooctahedralpyrrolo[2,1-b][1,3]thiazepine-7-carboxylic acid (Intermediate I) (216.2 mg, 0.49 mmol), 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide iodomethane salt (140.1 mg, 0.73 mmol), 1-hydroxybenzotriazole (131.7 mg, 0.97 mmol) and N , N- A solution of diisopropylethylamine (189 mg, 1.46 mmol) in dichloromethane (10 mL) was stirred at room temperature overnight. The reaction was quenched with water (50 mL) and extracted with dichloromethane (3 x 50 mL). The combined organic layers were washed with brine, dried, filtered, and concentrated. The residue was purified by thin-layer chromatography (ethyl acetate / petroleum ether (2 / 1 v / v)) to give the crude product (170 mg) as a yellow oil. The material was further purified by preparative HPLC to afford di-tert-butyl ((2S,2'S)-(((4S,4'S,7S,7'S,9aS,9a'S)-((((1R,1'R,2R,2'R)-((((1R,4R)-cyclohexane-1,4-diyl)bis(azanediyl))bis(carbonyl))bis(1,2,3,4-tetrahydronaphthalene-2,1-diyl))bis(azanediyl))bis(carbonyl))bis(8,8-dimethyl-5-oxoocahydropyrrolo[2,1-b][1,3]thiazepin-7,4-diyl))bis(azanediyl))bis(1-oxopropane-1,2-diyl))bis(methylcarbamate (86 mg, 0.06 mmol, 26.8% yield) as a white solid. LCMS (2.5 min formic acid): Rt = 1.96 min, m / z: 555.9 {[M-2Boc)+2] / 2} + .
[0870] Step 4: (4S,7S,9aS)-8,8-dimethyl-4-[(2S)-2-(methylamino)propionamido]-5-oxo-N- [(1R,2R)-2-{[(1rs,4rs)-4-[(1R,2R)-1-[(4S,7S,9aS)-8,8-dimethyl-4-[(2S)-2-(methylamino [1,3]thiazepine-7-carboxamide]-1,2,3,4-tetrahydronaphthalene- 2-Amino]cyclohexyl]carbamoyl}-1,2,3,4-tetrahydronaphthalen-1-yl]-octahydropyrrolo[2,1-b][1,3]thiazepine Hexamethylenetetramine dihydrochloride
[0871] To di-tert-butyl ((2S,2'S)-(((4S,4'S,7S,7'S,9aS,9a'S)-((((1R,1'R,2R,2'R)-((((1R,4R)-cyclohexane-1,4-diyl)bis(azanediyl))bis(carbonyl))bis(1,2,3,4-tetrahydronaphthalene-2,1-diyl))bis(azanediyl))bis(carbonyl))bis(8,8-dimethyl-5-oxooctahydropyrrolo[2,1-b][1,3]thiazepine-7,4-diyl))bis(azanediyl))bis(1-oxopropane-1,2-diyl))bis(methylcarbamate (80 mg, 0.073 mmol) was added in dichloromethane (10 To a solution of 4-nitropropane (1 mL) in 4% paraformaldehyde (5-nitropropane) was added hydrogen chloride (4 N in 1,4-dioxane, 1 mL). The reaction was stirred at room temperature overnight. The solvent was concentrated under reduced pressure, and the solid was dried under high vacuum to afford the title compound (62 mg, 0.052 mmol, 79.8% yield) as a white solid.
[0872]
[0873] LCMS (2.5 min formic acid): Rt = 1.280 min, m / z: 1110.8 (M+1) + .
[0874] Example 12:
[0875] (4S,7S,9aS)-8,8-Dimethyl-4-[(2S)-2-(methylamino)propanethioamido]-5-oxo-N-[(1R,2R)-2-{[(1rs,4rs))-4-[(1R,2R)-1-[(4S,7S,9aS)-8,8-dimethyl-4-[(2S)-2-(methylamino)propanethioamido]-5-oxo-octahydropyrrolo[2,1-b][1,3]thiazepine-7-carboxamide]-1,2,3,4-tetrahydronaphthalene-2-carboxamide]cyclohexyl]carbamoyl}-1,2,3,4-tetrahydronaphthalene-1-yl]-octahydropyrrolo[2,1-b][1,3]thiazepine-7-carboxamide dihydrochloride
[0876]
[0877] Step 1: ((2S,2'S)-(((4S,4'S,7S,7'S,9aS,9a'S)-((((1R,1'R,2R,2'R)-((((1R, 4R)-cyclohexane-1,4-diyl)bis(azanediyl))bis(carbonyl))bis(1,2,3,4-tetrahydronaphthalene-2,1-diyl))bis(azane bis(carbonyl)bis(8,8-dimethyl-5-oxooctahydropyrrolo[2,1-b][1,3]thiazepine-7,4-diyl) Bis(azanediyl)bis(1-thiopropane-1,2-diyl)bis(methylcarbamate) di-tert-butyl ester
[0878] (1R,1'R,2R,2'R)-N,N'-((1R,4R)-cyclohexane-1,4-diyl)bis(1-amino-1,2,3,4-tetrahydronaphthalene-2-carboxamide) dihydrochloride (Example 11, Step 2) (200 mg, 0.375 mmol), (4S,7S,9aS)-4-((S)-2-((tert-butoxycarbonyl)(methyl)amino)propanethioamido)-8,8-dimethyl-5-oxooctahydrolo[2,1-b][1,3]thiazepine-7-carboxylic acid (Intermediate II) (413 mg, 0.901 mmol), N- (3-Dimethylaminopropyl)- N'- A mixture of ethylcarbodiimide hydrochloride (216 mg, 1.125 mmol), 1-hydroxybenzotriazole (203 mg, 1.5 mmol), and N,N-diisopropylethylamine (290 mg, 2.25 mmol) in dichloromethane (15 mL) was stirred at room temperature for 4 hours. The reaction was poured into water (15 mL) and extracted with dichloromethane (2 × 10 mL). The combined organic phases were dried over anhydrous sodium sulfate, filtered, and concentrated. The crude product was then purified by preparative TLC [petroleum ether / ethyl acetate (1:2 v / v)] followed by preparative HPLC to give di-tert-butyl ((2S,2'S)-(((4S,4'S, 7S,7'S,9aS,9a'S)-((((1R,1'R,2R,2'R)-((((1R,4R)-cyclohexane-1,4-diyl)bis(azanediyl))bis(carbonyl))bis(1,2,3,4-tetrahydronaphthalene-2,1-diyl))bis(azanediyl))bis(carbonyl))bis(8,8-dimethyl-5-oxooctahyropyrrolo[2,1-b][1,3]thiazepine-7,4-diyl))bis(azanediyl))bis(1-thiopropane-1,2-diyl))bis(methylcarbamate (140 mg, 0.104 mmol, 28.0% yield) as a beige solid. LCMS (2.5 min formic acid): Rt = 2.115 min, m / z: 572.1 {[(M-2Boc)+2] / 2} + .
[0879] Step 2: (4S,7S,9aS)-8,8-Dimethyl-4-[(2S)-2-(methylamino)propanethioamido]-5-oxo- Substituted-N-[(1R,2R)-2-{[(1rs,4rs)-4-[(1R,2R)-1-[(4S,7S,9aS)-8,8-dimethyl-4-[(2S)-2- (methylamino)propanethioamido]-5-oxo-octahydropyrrolo[2,1-b][1,3]thiazepine-7-amido]-1, 2,3,4-Tetrahydronaphthalene-2-amido]cyclohexyl]carbamoyl}-1,2,3,4-tetrahydronaphthalene-1-yl]-octahydropyrrolo[2,1- b][1,3]thiazepine-7-carboxamide dihydrochloride
[0880] To the reaction mixture of ((2S,2'S)-(((4S,4'S,7S,7'S,9aS,9a'S)-((((1R,1'R,2R,2'R)-((((1R,4R)-cyclohexane-1,4-diyl)bis(azanediyl))bis(carbonyl))bis(1,2,3,4-tetrahydronaphthalene-2,1-diyl))bis(azanediyl))bis(carbonyl))bis(8,8-dimethyl-5-oxooctahydropyrrolo[2,1-b][1,3]thiazepine-7,4-diyl))bis(azanediyl))bis(1-thiopropane-1,2-diyl))bis(methylcarbamic acid) di-tert-butyl ester (140 mg, 0.104 mmol) in dichloromethane (5 To a solution of 4N hydrogen chloride / 1,4-dioxane (0.5 mL) in 4% paraformaldehyde (5% paraformaldehyde) was added. The mixture was stirred at room temperature overnight. The solvent was removed under reduced pressure and dried under high vacuum to give the title compound (70 mg, 0.058 mmol, 55.3% yield) as a white solid.
[0881]
[0882] LCMS (2.5 min formic acid): Rt = 1.242 min, m / z: 1144.4 (M+1) + , 572.3 [(M+2) / 2] + .
[0883] Example 13:
[0884] (4S,4'S,7S,7'S,9aS,9a'S)-N,N'-((1S,1'S,2R,2'R)-(hexane-2,4-diyn-1,6-diylbis(oxy))bis(2,3-dihydro-1H-indene-2,1-diyl))bis(8,8-dimethyl-4-((S)-2-(methylamino)propionamido)-5-oxooctahedralpyrrolo[2,1-b][1,3]thiazepine-7-carboxamide) dihydrochloride
[0885]
[0886] Step 1: (1S,2R)-2-(Prop-2-yn-1-yloxy)-2,3-dihydro-1H-inden-1-amine
[0887] To a solution of (1S,2R)-1-amino-2,3-dihydro-1H-inden-2-ol (2 g, 13.4 mmol) in tetrahydrofuran (50 mL) was added sodium hydride (60%, dispersion in paraffin liquid) (0.59 g, 14.7 mmol) in portions at 0°C. The mixture was allowed to warm to room temperature. 3-bromoprop-1-yne (1.75 g, 14.7 mmol) was then added and the resulting mixture was heated to 70°C. It was stirred at 70°C overnight. The mixture was quenched with ice water (50 mL) and extracted with ethyl acetate (3 × 30 mL). The combined organic layers were washed with brine (50 mL), dried over anhydrous sodium sulfate, filtered and concentrated. The crude product was purified by silica gel chromatography [petroleum ether / ethyl acetate (3:2 v / v)] to give (1S,2R)-2-(prop-2-yn-1-yloxy)-2,3-dihydro-1H-inden-1-amine (1.2 g, 6.4 mmol, 47.8% yield) as a black oil. LCMS (ES, m / z): 187.1, 188.1 [M+H] + , retention time 0.942 min.
[0888]
[0889] Step 2: ((S)-1-(((4S,7S,9aS)-8,8-dimethyl-5-oxo-7-(((1S,2R)-2-(prop-2-yn- (1-yloxy)-2,3-dihydro-1H-inden-1-yl)carbamoyl)octahydropyrrolo[2,1-b][1,3]thiazepin-4-yl) tert-Butyl amino)-1-oxopropan-2-yl)(methyl)carbamate
[0890] To a solution of (4S,7S,9aS)-4-((S)-2-((tert-butoxycarbonyl)(methyl)amino)propionamido)-8,8-dimethyl-5-oxooctahedralpyrrolo[2,1-b][1,3]thiazepine-7-carboxylic acid (260 mg, 0.587 mmol), 2-(7-azabenzotriazol-1-yl)-N,N,N',N'-tetramethyluronium hexafluorophosphate (305 mg, 0.801 mmol)) and N,N-diisopropylethylamine (138 mg, 1.068 mmol) in 1,2-dichloroethane (10 mL) was added (1S,2R)-2-(prop-2-yn-1-yloxy)-2,3-dihydro-1H-inden-1-amine (100 mg, 0.534 mmol). The mixture was stirred at 50 ° C overnight. The solvent was removed under reduced pressure. The crude product was purified by silica gel chromatography [petroleum ether / ethyl acetate (1: 1 v / v)] and further purified by thin layer chromatography [ethyl acetate / petroleum ether (3 / 2 v / v)] to give tert-butyl ((S)-1-(((4S,7S,9aS)-8,8-dimethyl-5-oxo-7-(((1S,2R)-2-(prop-2-yn-1-yloxy)-2,3-dihydro-1H-inden-1-yl)carbamoyl)octahydropyrrolo[2,1-b][1,3]thiazepine-4-yl)amino)-1-oxopropan-2-yl)(methyl)carbamate (160 mg, 0.261 mmol, 48.9% yield). LCMS (2.5 min formic acid): Rt = 1.662 min, m / z: 634.8 (M+Na) + .
[0891] Step 3: ((2S,2'S)-(((4S,4'S,7S,7'S,9aS,9a'S)-((((1S,1'S,2R,2'R)-(Ha-2, 4-Diyne-1,6-diylbis(oxy)bis(2,3-dihydro-1H-indene-2,1-diyl)bis(azanediyl)bis(carbonyl)bis (8,8-Dimethyl-5-oxooctahydropyrrolo[2,1-b][1,3]thiazepine-7,4-diyl)bis(azanediyl)bis(1- Di-tert-butyl 1,2-dioxypropanebis(methylcarbamate)
[0892] a. To a solution of tert-butyl ((S)-1-(((4S,7S,9aS)-8,8-dimethyl-5-oxo-7-(((1S,2R)-2-(prop-2-yn-1-yloxy)-2,3-dihydro-1H-inden-1-yl)carbamoyl)octahydropyrrolo[2,1-b][1,3]thiazepin-4-yl)amino)-1-oxopropan-2-yl)(methyl)carbamate (160 mg, 0.261 mmol) and pyridine (124 mg, 1.566 mmol) in acetonitrile (7 mL) was added copper acetate (57 mg, 0.313 mmol). The mixture was stirred at 85°C for 1 hour. The mixture was cooled, concentrated, and diluted with ethyl acetate (15 mL). Aqueous ammonia (20-fold dilution, 15 mL) was added. The aqueous phase was extracted with ethyl acetate (2 × 10 mL). The combined organic layers were washed with brine (15 mL), dried over anhydrous sodium sulfate, filtered and concentrated. The crude product was purified by thin layer chromatography [ethyl acetate / petroleum ether (2 / 1 v / v)] followed by preparative HPLC to give di-tert-butyl ((2S,2'S)-(((4S,4'S,7S,7'S,9aS,9a'S)-((((1S,1'S,2R,2'R)-(hexane-2,4-diyn-1,6-diylbis(oxy))bis(2,3-dihydro-1H-indene-2,1-diyl))bis(azanediyl))bis(carbonyl))bis(8,8-dimethyl-5-oxoocahydropyrrolo[2,1-b][1,3]thiazepine-7,4-diyl))bis(azanediyl))bis(1-oxopropane-1,2-diyl))bis(methylcarbamate (80 mg, 0.065 mL) mmol, 50.2% yield) as a white solid. LCMS (2.5 min formic acid): Rt = 1.853 min, m / z: 511.8 {[(M-2Boc)+2] / 2} + .
[0893] b. To a solution of tert-butyl ((S)-1-(((4S,7S,9aS)-8,8-dimethyl-5-oxo-7-(((1S,2R)-2-(prop-2-yn-1-yloxy)-2,3-dihydro-1H-inden-1-yl)carbamoyl)octahydropyrrolo[2,1-b][1,3]thiazepin-4-yl)amino)-1-oxopropan-2-yl)(methyl)carbamate (1.0 g, 1.63 mmol) and pyridine (775 mg, 9.79 mmol) in acetonitrile (20 mL) was added copper acetate (366 mg, 1.96 mmol). The mixture was stirred at 85° C. for 1 hour. The reaction mixture was cooled, concentrated, and diluted with ethyl acetate (100 mL). 20-fold ammonia solution (50 mL) was added. The aqueous phase was extracted with ethyl acetate (2 × 50 mL). The organic layers were combined and washed with brine. Dried over anhydrous sodium sulfate and concentrated to give a crude product. The residue was purified by silica gel column chromatography using ethyl acetate / petroleum ether = 1 / 1 as the eluent to give a crude product. The crude product was then purified by preparative HPLC to afford di-tert-butyl ((2S,2'S)-(((4S,4'S,7S,7'S,9aS,9a'S)-((((1S,1'S,2R,2'R)-(hexane-2,4-diyn-1,6-diylbis(oxy))bis(2,3-dihydro-1H-indene-2,1-diyl))bis(azanediyl))bis(carbonyl)))bis(8,8-dimethyl-5-oxoocahydropyrrolo[2,1-b][1,3]thiazepine-7,4-diyl))bis(azanediyl))bis(1-oxopropane-1,2-diyl))bis(methylcarbamate (800 mg, 0.65 mmol, 80.2% yield) as a white solid. LCMS (ES, m / z): 1222.6, 512.2 [M / 2-Boc+H] + , retention time 1.735 min.
[0894]
[0895] Step 4: (4S,4'S,7S,7'S,9aS,9a'S)-N,N'-((1S,1'S,2R,2'R)-(hexamethylene-2,4-diyne-1, 6-dimethylbis(oxy)bis(2,3-dihydro-1H-indene-2,1-diyl)bis(8,8-dimethyl-4-((S)-2-(methylamino) (Propionamido)-5-oxooctahydropyrrolo[2,1-b][1,3]thiazepine-7-carboxamide) dihydrochloride
[0896] To a solution of di-tert-butyl ((2S,2'S)-(((4S,4'S,7S,7'S,9aS,9a'S)-((((1S,1'S,2R,2'R)-(hexane-2,4-diyn-1,6-diylbis(oxy))bis(2,3-dihydro-1H-indene-2,1-diyl))bis(azanediyl))bis(carbonyl))bis(8,8-dimethyl-5-oxoocahydropyrrolo[2,1-b][1,3]thiazepine-7,4-diyl))bis(azanediyl))bis(1-oxopropane-1,2-diyl))bis(methylcarbamate (80 mg, 0.065 mmol) in dichloromethane (5 mL) was added 4 N hydrogen chloride / 1,4-dioxane (1.5 mL). The mixture was stirred at room temperature overnight. The solvent was removed under reduced pressure and the solid was dried under high vacuum to give (4S,4'S,7S,7'S,9aS,9a'S)-N,N'-((1S,1'S,2R,2'R)-(hexane-2,4-diyn-1,6-diylbis(oxy))bis(2,3-dihydro-1H-indene-2,1-diyl))bis(8,8-dimethyl-4-((S)-2-(methylamino)propionamido)-5-oxooctahedralpyrrolo[2,1-b][1,3]thiazepine-7-carboxamide) dihydrochloride (55 mg, 0.050 mmol, 76.9% yield) as a white solid.
[0897]
[0898] LCMS (2.5 min formic acid): Rt = 1.328 min, m / z: 512.0 [(M+2) / 2] + .
[0899] Example 14:
[0900] (4S,7S,9aS)-N-((1S,2R)-2-((6-(((1S,2R)-1-((4S,7S,9aS)-8,8-dimethyl-4-((S)-2-(methylamino)propionamido)-5-oxooctahydropyrrolo[2,1-b][1,3]thiazepin-7-carboxamido)-2,3-dihydro-1H-inden-2-yl)oxy)hexa-2,4-diyn-1-yl)oxy)-2,3-dihydro-1H-inden-1-yl)-8,8-dimethyl-4-((S)-2-(methylamino)propanethioamido)-5-oxooctahydropyrrolo[2,1-b][1,3]thiazepin-7-carboxamide
[0901]
[0902] Step 1: ((S)-1-(((4S,7S,9aS)-8,8-dimethyl-5-oxo-7-(((1S,2R)-2-(prop-2-yn- (1-yloxy)-2,3-dihydro-1H-inden-1-yl)carbamoyl)octahydropyrrolo[2,1-b][1,3]thiazepin-4-yl) tert-Butyl amino)-1-thiopropan-2-yl)(methyl)carbamate
[0903] To a solution of (4S,7S,9aS)-4-((S)-2-((tert-butoxycarbonyl)(methyl)amino)propanethioamido)-8,8-dimethyl-5-oxooctahedralpyrrolo[2,1-b][1,3]thiazepine-7-carboxylic acid (500 mg, 1.088 mmol), 2-(7-azabenzotriazol-1-yl)-N,N,N',N'-tetramethyluronium hexafluorophosphate (621 mg, 1.632 mmol) and N,N-diisopropylethylamine (309 mg, 2.393 mmol) in 1,2-dichloroethane (15 mL) was added (1S,2R)-2-(prop-2-yn-1-yloxy)-2,3-dihydro-1H-inden-1-amine (224 mg, 1.197 mmol). The mixture was stirred at 50 ° C overnight. The mixture was concentrated and purified by silica gel chromatography [petroleum ether / ethyl acetate (3: 2 v / v)], followed by preparative TLC [petroleum ether / ethyl acetate (2: 3 v / v)] to give tert-butyl ((S) -1- (((4S,7S,9aS) -8,8-dimethyl-5-oxo-7- (((1S,2R) -2- (prop-2-yn-1-yloxy) -2,3-dihydro-1H-inden-1-yl) carbamoyl) octahydropyrrolo [2,1-b] [1,3] thiazepin-4-yl) amino) -1-thiopropan-2-yl) (methyl) carbamate (400 mg, 0.636 mmol, 58.5% yield). LCMS (2.5 min formic acid): Rt = 1.812 min, m / z: 650.8 (M + Na) + .
[0904] Step 2: ((S)-1-(((4S,7S,9aS)-7-(((1S,2R)-2-((6-(((1S,2R)-1-((4S,7S, 9aS)-4-((S)-2-((tert-Butoxycarbonyl)(methyl)amino)propanethioamido)-8,8-dimethyl-5-oxooctahydro Pyrrolo[2,1-b][1,3]thiazepine-7-carboxamido)-2,3-dihydro-1H-inden-2-yl)oxy)hexane-2,4-diyn- 1-yl)oxy)-2,3-dihydro-1H-inden-1-yl)carbamoyl)-8,8-dimethyl-5-oxooctahydropyrrolo[2,1-b] tert-Butyl (1,3-thiazepin-4-yl)amino)-1-oxopropan-2-yl)(methyl)carbamate
[0905] To tert-butyl ((S)-1-(((4S,7S,9aS)-8,8-dimethyl-5-oxo-7-(((1S,2R)-2-(prop-2-yn-1-yloxy)-2,3-dihydro-1H-inden-1-yl)carbamoyl)octahydropyrrolo[2,1-b][1,3]thiazepin-4-yl)amino)-1-oxopropan-2-yl)(methyl)carbamate (390 mg, 0.636 To a solution of tert-butyl ((S)-1-(((4S,7S,9aS)-8,8-dimethyl-5-oxo-7-(((1S,2R)-2-(prop-2-yn-1-yloxy)-2,3-dihydro-1H-inden-1-yl)carbamoyl)octahydropyrrolo[2,1-b][1,3]thiazepin-4-yl)amino)-1-thiopropan-2-yl)(methyl)carbamate (400 mg, 0.636 mmol), and pyridine (301 mg, 3.816 mmol) in acetonitrile (15 mL) was added copper acetate (277 mg, 1.526 mmol). The mixture was stirred at 85° C. for 40 minutes. After cooling, the solvent was removed under reduced pressure. The crude product was diluted with ethyl acetate (20 mL) and aqueous ammonia (20-fold dilution, 20 mL). The aqueous phase was extracted with ethyl acetate (2 x 15 mL).The combined organic layers were washed with brine (20 mL), dried over anhydrous sodium sulfate, filtered and concentrated.The crude product was purified by preparative TLC [petroleum ether / ethyl acetate (2:3 v / v)] and preparative HPLC to give ((S)-1-(((4S,7S,9aS)-7-(((1S,2R)-2-((6-(((1S,2R)-1-((4S,7S,9aS)-4-((S)-2-((tert-butoxycarbonyl)(methyl)amino)propanethioamido)-8,8-dimethyl-5-oxooctahydropyrrolo[2,1-b][ tert-Butyl (50 (1,3]thiazepin-7-carboxamido)-2,3-dihydro-1H-inden-2-yl)oxy)hex-2,4-diyn-1-yl)oxy)-2,3-dihydro-1H-inden-1-yl)carbamoyl)-8,8-dimethyl-5-oxooctahy ropyrrolo[2,1-b][1,3]thiazepin-4-yl)amino)-1-oxopropan-2-yl)methyl)carbamate The results were as follows: 1) 4-[[(4-(2-[ ...
[0906] Step 3: (4S,7S,9aS)-N-((1S,2R)-2-((6-(((1S,2R)-1-((4S,7S,9aS)-8,8-dimethyl 4-((S)-2-(methylamino)propionamido)-5-oxooctahydropyrrolo[2,1-b][1,3]thiazepine-7-carboxamide 2,3-dihydro-1H-inden-2-yl)oxy)hexa-2,4-diyn-1-yl)oxy)-2,3-dihydro-1H-inden-1-yl)-8,8- Dimethyl-4-((S)-2-(methylamino)propanethioamido)-5-oxooctahydropyrrolo[2,1-b][1,3]thiazepine Hexamethylenetetramine dihydrochloride
[0907] ((S)-1-(((4S,7S,9aS)-7-(((1S,2R)-2-((6-(((1S,2R)-1-((4S,7S,9aS)-4-((S)-2-((tert-Butoxycarbonyl)(methyl)amino)propanethioamido)-8,8-dimethyl-5-oxooctahydropyrrolo[2,1-b][1,3]thiazepine- To a solution of tert-butyl (5-(7-formamido)-2,3-dihydro-1H-inden-2-yl)oxy)hex-2,4-diyn-1-yl)oxy)-2,3-dihydro-1H-inden-1-yl)carbamoyl)-8,8-dimethyl-5-oxooctahydropyrrolo[2,1-b][1,3]thiazepin-4-yl)amino)-1-oxopropan-2-yl)methyl)carbamate (50 mg, 0.040 mmol) in dichloromethane (5 mL) was added 4N hydrogen chloride / 1.4-dioxane (0.5 mL). The mixture was stirred at room temperature overnight. The mixture was concentrated and dried to give (4S,7S,9aS)-N-((1S,2R)-2-((6-(((1S,2R)-1-((4S,7S,9aS)-8,8-dimethyl-4-((S)-2-(methylamino)propanamido)-5-oxooctahydropyrrolo[2,1-b][1,3]thiazepine-7-carboxamido)-2,3-dihydro-1H-inden-2-yl)oxy)hexa-2,4-diyn-1-yl)oxy)-2,3-dihydro-1H-inden-1-yl)-8,8-dimethyl-4-((S)-2-(methylamino)propanethioamido)-5-oxooctahydropyrrolo[2,1-b][1,3]thiazepine-7-carboxamide dihydrochloride (20 mg, 0.018 mmol, 45% yield) as a white solid.
[0908]
[0909] LCMS (2.5 min formic acid): Rt = 1.643 min, m / z: 520.0 [(M+2) / 2] + .
[0910] Example 15:
[0911] (4S,4'S,7S,7'S,9aS,9a'S)-N,N'-((1S,1'S,2R,2'R)-(hexane-2,4-diyn-1,6-diylbis(oxy))bis(2,3-dihydro-1H-indene-2,1-diyl))bis(8,8-dimethyl-4-((S)-2-(methylamino)propanethioamido)-5-oxooctahydropyrrolo[2,1-b][1,3]thiazepine-7-carboxamide) dihydrochloride
[0912]
[0913] To a solution of di-tert-butyl ((2S,2'S)-(((4S,4'S,7S,7'S,9aS,9a'S)-((((1S,1'S,2R,2'R)-(hexane-2,4-diyn-1,6-diylbis(oxy))bis(2,3-dihydro-1H-indene-2,1-diyl))bis(azanediyl))bis(carbonyl))bis(8,8-dimethyl-5-oxooctahyropyrrolo[2,1-b][1,3]thiazepine-7,4-diyl))bis(azanediyl))bis(1-thiopropane-1,2-diyl))bis(methylcarbamate) (Example 14, Step 2) (35 mg, 0.028 mmol) in dichloromethane (5 mL) was added 4N hydrogen chloride / 1,4-dioxane (0.5 mL) and 4N HCl / 1,4-dioxane (0.5 mL). mL). The mixture was stirred at room temperature overnight. The solvent was removed under reduced pressure and dried under high vacuum to give (4S,4'S,7S,7'S,9aS,9a'S)-N,N'-((1S,1'S,2R,2'R)-(hexane-2,4-diyne-1,6-diylbis(oxy))bis(2,3-dihydro-1H-indene-2,1-diyl))bis(8,8-dimethyl-4-((S)-2-(methylamino)propanethioamido)-5-oxooctahedralpyrrolo[2,1-b][1,3]thiazepine-7-carboxamide) dihydrochloride (12 mg, 0.011 mmol, 39.3% yield) as a white solid.
[0914]
[0915] LCMS (2.5 min formic acid): Rt = 1.505 min, m / z: 1055.6 (M+1) + .
[0916] Example 16:
[0917] (4S,4'S,7S,7'S,9aS,9a'S)-N,N'-((1S,1'S,2R,2'R)-(butane-1,4-diylbis(oxy))bis(2,3-dihydro-1H-indene-2,1-diyl))bis(8,8-dimethyl-4-((S)-2-(methylamino)propionamido)-5-oxooctahydropyrrolo[2,1-b][1,3]thiazepine-7-carboxamide)
[0918]
[0919] Step 1: (1S,2R)-1-Isocyano-2-(prop-2-yn-1-yloxy)-2,3-dihydro-1H-indene
[0920] A suspension of (1S,2R)-2-(prop-2-yn-1-yloxy)-2,3-dihydro-1H-inden-1-amine (3.31 g, 17.68 mmol) and ethyl formate (28.8 mL, 354 mmol) was heated at 70°C for 21 hours. After cooling, the solvent was removed under reduced pressure to yield crude formamide (3.71 g). To a suspension of the crude formamide in dichloromethane (DCM) (35 mL) at 0°C was added Et3N (12.32 mL, 88 mmol) followed by POCl3 (2.471 mL, 26.5 mmol). After 2 hours, the crude product was poured into a mixture of DCM (150 mL) and saturated aqueous NaHCO3 (60 mL). The aqueous phase was separated and extracted with DCM (50 mL). The combined organic layers were washed with brine (40 mL), dried (Na2SO4), filtered, and concentrated. The crude product was adsorbed on Celite ® The product was purified by silica gel chromatography [1-20% EtOAc / hexanes] to afford (1S,2R)-1-isocyano-2-(prop-2-yn-1-yloxy)-2,3-dihydro-1H-indene, 0.15 ethyl acetate (solvate) (1.88 g, 8.93 mmol, 50.5% yield) as a light yellow oil.
[0921]
[0922] LCMS (ESI) m / z: 171.0 (M-(NC)) + .
[0923] Step 2: (4S,7S,9aS)-4-amino-8,8-dimethyl-5-oxo-N-((1S,2R)-2-prop-2-yn-1- (2,3-dihydro-1H-inden-1-yl)octahydropyrrolo[2,1-b][1,3]thiazepine-7-carboxamide) and
[0924] (4S,7R,9aS)-4-amino-8,8-dimethyl-5-oxo-N-((1S,2R)-2-(prop-2-yn-1-yloxy)- 2,3-Dihydro-1H-inden-1-yl)octahydropyrrolo[2,1-b][1,3]thiazepine-7-carboxamide
[0925] A mixture of N-(tert-butoxycarbonyl)-S-trityl-L-homocysteine (2.05 g, 4.29 mmol), (1S,2R)-1-isocyano-2-(prop-2-yn-1-yloxy)-2,3-dihydro-1H-indene, 0.15% ethyl acetate (solvate) (0.903 g, 4.29 mmol), 4,4-dimethoxy-2,2-dimethylbutanal (1.2 g, 7.49 mmol), and 7 M ammonia in methanol (1.226 mL, 8.58 mmol) in trifluoroethanol (16 mL) was heated at 80°C. After 1 hour, the solvent was removed under reduced pressure. The crude product was diluted with DCM (...
Claims
1. Compounds having the following structure: or a pharmaceutically acceptable salt thereof.
2. The salt according to claim 1, wherein the salt is present as a hydrochloride salt.
3. The salt according to claim 2, wherein the hydrochloride salt is a dihydrochloride salt.
4. A pharmaceutical composition comprising the compound according to claim 1 or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable excipient.
5. The composition according to claim 4, wherein the composition is suitable for parenteral administration.
6. Use of the compound of claim 1 or a pharmaceutically acceptable salt thereof in the preparation of a medicament for depleting latent HIV-infected cells.
7. Use of the compound of claim 1 or a pharmaceutically acceptable salt thereof in the preparation of a medicament for treating HIV infection in a subject.
8. Compounds having the following structure:
9. A pharmaceutical composition comprising the compound according to claim 8 and a pharmaceutically acceptable excipient.
10. The composition according to claim 9, wherein the composition is suitable for parenteral administration.
11. Use of a compound according to claim 8 for the preparation of a medicament for depleting latent HIV infected cells.
12. Use of a compound according to claim 8 in the preparation of a medicament for treating HIV infection in a subject.
13. A compound selected from: and pharmaceutically acceptable salts thereof.
